AU2013202605A1 - Bispecific egfr/igfir binding molecules - Google Patents

Abstract

Bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. Also disclosed are cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the proteins. Exemplary bispecific molecules include antibody-like protein timers based on the tenth fibronectin type III domain.

Description

Regulation 3.2 AUSTRALIA PATENTS ACT, 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT DIVISIONAL Name of Applicant: BRISTOL-MYERS SQUIBB COMPANY Actual Inventors: EMANUEL, Stuart; ENGLE, Linda; CAMPHAUSEN, Ray; WRIGHT, Martin C; RAKESTRAW, Ginger Chao; GOTTARDIS, Marco; CARBONI, Joan Address for service AJ PARK, Level 11, 60 Marcus Clarke Street, Canberra ACT in Australia: 2601, Australia Invention Title: Bispecific EGFR/IGFR Binding Molecules Original Application: Australian patent application 2009316271 dated 24 November 2009 The following statement is a full description of this invention, including the best method of performing it known to us. 5374659_.DOC BISPECIFIC EGFR/IGFIR BINDING MOLECULES SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on November 23, 2009, is named COTH52WO.txt, and is 552,529 bytes in size. RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application Nos. 61/200,164, filed November 24, 2008; 61/200,282, filed November 26, 2008; 61/212,966, filed April 17, 2009; 61/178,279, filed May 14, 2009; and 61/227,330, filed July 21, 2009, which applications are hereby incorporated by reference in their entireties. FIELD OF THE INVENTION The present invention relates to EGFR binding domains and bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary EGFR binding domains and bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain. INTRODUCTION Activation of receptor tyrosine kinase signaling is central to cancer development (see e.g., Grimberg A. Cancer Biol Ther. 2003 2(6):630-5 and Mendelsohn J. J Clin Oncol. 2003 21(14):2787-99). Receptor tyrosine kinases have a conserved domain structure including an extracellular domain, a transmembrane domain and an intracellular tyrosine kinase domain. The extracellular domain can bind to a ligand, such as to a polypeptide growth factor or to a cell membrane 1A 24039697 1DOC associated molecule. Typically, either ligand binding or ligand binding induced dimerization of receptor tyrosine kinases activates the intracellular catalytic tyrosine kinase domain of the receptor and subsequent signal transduction. Examples of receptor tyrosine kinases include, but are not limited to ERBB receptors (e.g., EGFR, ERBB2, ERBB3, ERBB4), erythropoietin-producing hepatocellular (EPH) receptors, fibroblast growth factor (FGF) receptors (e.g., FGFR1, FGFR2, FGFR3, FGFR4, FGFR5), platelet-derived growth factor (PDGF) receptors (e.g., PDGFR-A, PDGFR-B), vascular endothelial growth factor (VEGF) receptors (e.g., VEGFR1/FLT1, VEGFR2/FLK1, VEGF3), tyrosine kinase with immunoglobulin-like and EGF-like domains (TIE) receptors , insulin-like growth factor (IGF) receptors (e.g., INS-R, IGFIR, IR-R), Discoidin Domain (DD) receptors , receptor for c-Met (MET), recepteur d'origine nantais (RON); also known as macrophage stimulating 1 receptor, Flt3 fins-related tyrosine kinase 3 (Flt3), colony stimulating factor 1(CSF1) receptor, adhesion related kinase receptor (e.g., Axl), receptor for c-kit (KIT) and insulin receptor related (IRR) receptors. Inhibition of receptor tyrosine kinases has emerged as an effective treatment strategy for certain human malignancies (for a review see Roussidis AE, In Vivo. 2002 16(6):459-69). While targeted monotherapy may initially be effective in treating cancer, therapeutic resistance often follows, possibly as a result of upregulation of other signaling cascades (see e.g., Nahta R et al., Breast Cancer Res. 2006 8(6):215 and Horn L et al., Clin Lung Cancer. 2007 8:S68-73). Accordingly, there exists a need for developing improved cancer therapeutics. SUMMARY OF THE INVENTION In one aspect, the application provides EGFR binding tenth fibronectin type III domains ( Fn3) having novel sequences. EGFR binding 1 0 Fn3 having a consensus sequence are also provided. Such EGFR binding 10Fn3 may be monomeric or may be included as part of a fusion protein. In another aspect, the application provides bispecific molecules that bind EGFR and IGFIR, referred to herein as "E/I binders". E/I binders encompassed by the invention include bispecific antibodies and dimers of ligand binding scaffold 2 24039697_1.DOC proteins (e.g., tendamistat, affibody, fibronectin type III domain, anticalin, tetranectin, and ankyrin). When constructed as a single polypeptide chain, the E/I binders may be constructed in any orientation, e.g., from N-terminus to C-terminus either in the E-I arrangement or the I-E arrangement. In one aspect, antibody-like protein dimers are provided comprising an EGFR binding 1 0 Fn3 covalently or non-covalently linked to an IGFIR binding 10 Fn3. The 10 Fn3 bind their target (EGFR or IGFIR) with a KD of less than 500 nM. Each of the individual 1 0 Fn3 independently has an amino acid sequence at least 70, 80, 85, 90, 95, 98, or 100% identical to SEQ ID NO: 32, wherein n is an integer from 1-20, o is an integer from 1-20, and p is an integer from 1-40. In some embodiments, n is an integer from 8-12, o is an integer from 4-8, and p is an integer from 4-28. In some embodiments, n is 10, o is 6, and p is 12. In some embodiments, the antibody-like protein dimers comprise IGFIR binding Fn3 covalently linked to EGFR binding ' Fn3 via a polypeptide linker or a polyethylene glycol moiety. In some embodiments, the antibody-like protein dimer comprises an amino acid sequence at least 80, 90, 95, or 100% identical to any one of SEQ ID NOs: 20-31, 53-58, 87-92, 98-105, 118-133, 149-154, 164-169, 179-184, 192-197, 205-210 and 211-216. In some embodiments, the E/I binder comprises an amino acid sequence having any one of SEQ ID NOs: 20-31, 53-58, 87-92, 98-105, 118-133, 149-154, 164-169, 179-184, 192-197, 205-210 and 211-216, wherein (i) the EGFR binding 1 0 Fn3 and/or the IGF-IR binding I Fn3 comprises a 1 0 Fn3 scaffold having from has anywhere from 0 to 20, from 0 to 15, from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, conservative substitutions, deletions or additions relative to the corresponding scaffold amino acids of SEQ ID NO: 1, and/or (ii) the EGFR binding ' 0 Fn3 has anywhere from 0 to 15, from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, conservative substitutions, deletions or additions relative to the corresponding loop sequences of any one of SEQ ID NOs: 5-8, 52, 66-68, 106-108, 112-114, 140-142, 155-157, 170-172, 182, 185-187, 198-200, or 219-327 and/or the IGF-IR binding ' 0 Fn3 has anywhere from 0 to 15, from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 3 24039697_I.DOC to 1 substitutions, conservative substitutions, deletions or additions relative to the corresponding loop sequences of SEQ ID NO: 3. In one aspect, pharmaceutically acceptable compositions are provided comprising an antibody-like protein dimer as described herein and a pharmaceutically acceptable carrier, wherein the composition is essentially pyrogen free. In a further aspect, methods for treating hyperproliferative disorders, such as cancer, in a subject are provided comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable composition comprising an antibody-like protein dimer as described herein. In another aspect, the application provides a nucleic acid encoding an antibody-like protein dimer as described herein. Also provided is a vector comprising a nucleic acid encoding an antibody-like dimer as described herein. Suitable vectors include, for example, expression vectors. Also provided are host cells comprising a nucleic, vector, or expression vector, comprising a nucleic acid encoding an antibody-like protein dimer as described herein. Suitable host cells include prokaryotic and eukaryotic host cells. Exemplary prokaryotic cells are bacterial cells, such as E. coli. Exemplary eukaryotic cells are mammalian cells, such as CHO cells. Also provided are methods for producing an antibody-like protein dimer as described herein, comprising culturing a host cell comprising a nucleic, vector, or expression vector, comprising a nucleic acid encoding the antibody-like protein dimer and recovering the expressed antibody-like protein dimer from the culture. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1. SDS-PAGE Analysis of I1-GS1O-E2. Samples from the lysis of HMS174(DE3) bacterial cell pellet from which I1-GS10-E2 was expressed and purified by a HisTrap chromatography column were run on a 4-12% NuPAGE minigel and stained by Sypro-Orange and visualized by STORM imager. Mark 12 molecular weight standards (Lane 1); Lysate-soluble (Lane 2); Lysate- insoluble (Lane 3); HisTrap load (Lane 4); HisTrap non-bound (Lane 5); Pooled HisTrap 4 24039697 i.DOC Eluate (Lane 6); Dialyzed into 50mM NaOAc, 150mM NaCl, pH 4.5 (Lane 7); Dialyzed into PBS (Lane 8); Dialyzed into Tris, 150mM NaCl, pH 8.5 (Lane 9). Figure 2. A. SEC Analysis of midscale purified Il-GS1O-E2. 22 pg of HisTrap purified Il-GS1O-E2 dialyzed into PBS, pH 7.4 was loaded onto a Superdex 200 10/30 SEC Column (GE Healthcare) with a mobile phase of 100 mM NaPO 4 , 100 mM NaSO 4 , 150 mM NaCl, pH 6.8 and measured using A280. I1-GS1O-E2 eluted predominantly as a single monomeric species at a molecular weight range of approximately 24.6 kDa vs. globular Gel Filtration standards (BioRad). B. SEC analysis of E2-GS 10-I1. Figure 3. A. Differential Scanning Calorimetry (DSC) of midscale purified Il-GS1O-E2 in PBS was performed to determine the Tm. A 1 mg/mL solution of Il GS1O-E2 was scanned from 5 'C to 95 'C at a rate of 1 degree per minute under 3 atm pressure. The data was analyzed versus a control run of the PBS buffer. B. DSC of E2-GS10-I1. Figure 4. Inhibition of IGFR activity in H292 cells. Cells were stimulated with 100 ng/mL of IGF-1 and lOOng/mL of EGF and treated with either . Il, o El, or A El-GS1O- Il HTPP preparations. Phosphorylation of IGFIR on tyrosine 1131 was determined by ELISA. Figure 5. Inhibition of EGFR activity in H292 cells. Cells were stimulated with lOOng/mL of IGF-1 and 1OOng/mL of EGF and treated with either e Il, u El, or A El-GS1O-I1 HTPP preparations. Phosphorylation of EGFR on tyrosine 1068 was determined by ELISA. Figure 6. Inhibition of AKT phosphorylation in H292 cells. Cells were stimulated with 1OOng/mL of IGF-1 and 1OOng/mL of EGF and treated with either . Il, o El, or A El-GS1O-I1 HTPP preparations. Phosphorylation of AKT on serine 473 was determined by ELISA. Figure 7. Inhibition of RH41 cell proliferation. Cells were treated with either * Il, o El, or A El-GS1O-I1 HTPP preparations and percent inhibition of proliferation was determined. Figure 8. Inhibition of H292 cell proliferation. Cells were treated with either * Il, o El, or A El-GS1O-I1 HTPP preparations and percent inhibition of proliferation was determined. 5 24039697_ .DOC Figure 9. Summarizes IC50 values in cell based functional assays for isolated EGFR mononectins, E/I 10 Fn3-based binders with serine at the C-terminal position without PEG added and E/I I 0 Fn3-based binders with cysteine at the C terminal position conjugated to a 40 kDa branched PEG. Representative data is shown. Figure 10. Immunoblot analysis of PEGylated E/I 1 0 Fn3-based binder with E2 in the N-terminal and C-terminal positions. Despite both constructs demonstrating comparable activity in the H292 cell assay for inhibiting EGFR, the E/I 10 Fn3-based binder with E2 at the C-terminal position did not degrade EGFR while the E/I 1 0 Fn3-based binder with E2 at the N-tenninal position did. Both constructs show very weak to no IGFR degradation in this cell line. O-actin was included to demonstrate equal loading across all lanes. The phosphorylation state of EGFR, ERK and Shc was also examined. Figure 11. Inhibition of EGF-stimulated EGFR phosphorylation in H292 cells. Both constructs demonstrated comparable activity in the H292 cell assay for inhibiting EGFR. E2-GS10-I1 (with PEG) (o), Il-GS10-E2 (with PEG) (0), panitumumab (----). Figure 12. Results of tumor xenograft studies. Figure 12A: Preclinical anti tumor activity in the H292 human tumor xenograft model. Mean tumor sizes calculated from groups of 8 mice is shown in mg for control animals (i), E3-GS 10 Il (w/ PEG) dosed at 100mg/kg (o), E2-GS10-I1 (with PEG) dosed at 100 mg/kg (o), panitumumab dosed at 1mg/mouse (A) or 0.1mg/mouse (7). The letter a on the x-axis indicates doses of E/I binders administered and the p indicates doses of panitumumab administered. Figure 12B: Average weight change is shown for each group over the course of the study. Symbols are as described in Figure 12A legend. Figure 13. Pharmacodynamic effects in the H292 NSCLC tumor xenograft model. Levels of the indicated analytes were determined in tumor lysates as described in Example 12. (A) phosph-EGFR, (B) phospho-ErbB2, (C) phospho IGFR, and (D) total EGFR. Checkered bars = panitumumab, empty bars = E2 GS10-I1 (with PEG), hatched bats = E3-GS10-I1 (with PEG). Figure 14. Western blot analysis of MCF7r cells compared to MCF7 parental cells. 6 24039697 .DOC Figure 15. MCF7 (Panel A) and MCF7r (Panel B) human tumor xenograft studies in nude mice. Mean tumor size is shown for both studies calculated from 8 mice per group. Figure 16. GEO human tumor xenograft studies in nude mice. Figure 17. H292 human tumor xenograft studies in nude mice. Figure 18. Colony formation assay with H292 NSCLC cells. A. Representative data is shown from a single plate. B. IC50 from one E/I ' 0 Fn3-based binder is shown with error bars calculated from triplicate measurements. Figure 19. Epitope mapping assay. Location of epitope binding for various EGFR binding antibodies are shown in panel A. A description of the antibodies is provided in Example 18, Table 11. The left column of table 11 provides a number for each anti-EGFR antibody which correlates with the numbered antibodies shown in panel A. Panel B shows an exemplany epitope mapping assay as described in Example 18. Figure 20. DSC analysis of the E/I ' 0 Fn3-based binder, I1-GS1O-E5 pegylated, measured with a scan range of 15-95 'C at 1mg/ml protein concentration in PBS, resulted in a Tm measurement of 55.2 'C Figure 21. Evaluation of E/I 1 0 Fn3-based binders for inhibition of AKT phosphorylation in H292 cells as measured by ELISA. I1-GS1O-E5-pegylated (o) was more potent than Il -pegylated alone (m) or E5-pegylated alone (A) for blocking IGF1-stimulated AKT phosphorylation. Figure 22. Evaluation of E/I ' 0 Fn3-based binders for inhibition of cell proliferation in H292 cells. Il-GS10-E5-pegylated (o) was more potent than Il pegylated alone (A) and E5-pegylated alone (e) had only weak effects for inhibiting the growth of H292 cells. Assays were carried out in triplicate. Representative data is shown. Figure 23. Evaluation of E/I 10 Fn3-based binders for inhibition of cell proliferation in RH41 cells. I1-GS1O-E5-pegylated (0) was slightly more potent than Il-pegylated alone (A) and E5-pegylated alone (e) or panitumumab (dashed line) had almost no effect for inhibiting the growth of RH41 cells. Assays were carried out in triplicate. Representative data is shown. 7 24039697_.DOC Figure 24. Inhibition of ligand stimulated signaling by 1 0 Fn3-based binders (pegylated). Effect of E/I 1 0 Fn3-based binder (Il-GS10-E5 pegylated) on receptor activation and cell signaling in DiFi (Panel A), H292 (Panel B) or BxPC3 (Panel C) cells. Cells were serum starved and treated for 2 hours with 1 pM 1 0 Fn3-based binders before stimulation with either EGF, IGF1 or a combination of EGF + IGF1. GAPDH was probed to illustrate equal loading in all lanes. Figure 25. Inhibition of ligand stimulated signaling in H292 cells by ' 0 Fn3 based binders (unpegylated). Effect of E/I 1 0 Fn3-based binder (E2-GS1O-I1) on receptor activation and cell signaling in H292 cells. Cells were serum starved and treated for 2 hours with 1 pM 10 Fn3-based binders before stimulation with either EGF, IGF1 or a combination of EGF + IGFl. GAPDH was probed to illustrate equal loading in all lanes Figure 26. Competition binding studies with E/I ' 0 Fn3-based binders. A. The EGFR '"Fn3-based binder does not compete for binding of EGFR antibodies to EGFR. Initial injection of the EGFR 1 0 Fn3-based binder shows binding to EGFR on the surface of the chip. A second injection of EGFR 1 0 Fn3-based binder mixed with an equal amount of cetuximab, panitumumab, or nimotuzumab shows no competition for binding of antibodies to EGFR by the EGFR 1 0 Fn3-based binder. B. The E/I 1 0 Fn3-based binder can bind EGFR and IGF-IR simultaneously. Initial injection of the E/I ' 0 Fn3-based binder shows binding to EGFR immobilized on the chip surface. A second injection of the E/I 'UFn3-based binder soluble IGF-IR shows binding of sIGF-IR to other end of the immobilized E/I 1 UFn3-based binder. Figure 27. TGFa plasma levels 4 hours after last dose of xenograft studies. Plasma samples taken at the end of treatment from the BxPC3 (Panel A), GEO (Panel B) and H441 (Panel C) xenograft studies described in Table 24 were analyzed for circulating levels of TGFa. Figure 28. TGFa and IGF1 plasma levels in non tumor bearing nude mice after dosing with I1-GS1O-E5 pegylated. Non-tumor bearing mice were given a single dose of I1-GS1O-E5 pegylated '4Fn3-based binder and analyzed for circulating levels of TGFa (Panel A) and IGF1 (Panel B). Figure 29. H292 xenografn study using E/I 1OFn3-based binders as compared to panitumumab. H292 xenografts were either untreated (m) or dosed three times a 8 24039697 1.DOC week with 1 0 Fn3-based binders formulated in PBS with the individual constructs as described in the figure or dosed every three days i.p. with panitumumab at 1 mg/mouse (o) or 0.1 mg/mouse (o). Actual doses of 1 0 Fn3-based binders and panitumumab (A) are indicated on the x-axis with the panitumumab doses closest to the x-axis below the triangles indicating doses of 1 0 Fn3-based binders. Figure 29A shows measurements out to day 43. Figure 29B shows measurements out to day 27. Figure 30. Pharmaokinectic parameters profile of E2-GS10-Il pegylated in mice. Figure 31. Comparison of half-life at 100 mg/kg and 10 mg/kg IP, and 10 mg/kg and 64 mg/kg SC in various E/I 1 0 Fn3-based binders. Figure 32. Antitumor efficacy of E2-GS10-Il pegylated in the RH41 model. Figure 33. Measurement of pharmacodynamic endpoints in tumors. At the end of treatment, tumors were removed 4 hours following the final dose from DiFi xenograft model (panel A) and H292 xenograft model (panel B) and examined for levels of phospho-EGFR, phospho-IGFR, total EGFR and total IGFR. Equal amounts of total protein lysate was loaded into each lane of the gels and blots were also probed with GAPDH to demonstrate equal loading across all lanes. Figure 34. Sequence of anti-EGFR binder 679F09 (SEQ ID NO: 490). Loop residues which were varied are underlined. Figure 35. BC loop Sequence Analysis I. Frequency of amino acids at each position in the BC loop from EGFR binding sequences. Image created using WebLogo (Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: A sequence logo generator. Genome Research, 14:1188-1190, 2004). Figure 36. DE loop Sequence Analysis 1. Frequency of amino acids at each position in the DE loop from EGFR binding sequences (263 unique DE loop sequences analyzed). Figure 37. FG loop (10-aa length) Sequence Analysis I. Frequency of amino acids at each position in the FG loop from EGFR binding sequences with 10-amino acid long FG loops (228 unique 10-amino acid long FG loops analyzed). Figure 38. FG loop (15-aa length) Sequence Analysis I. Frequency of amino acids at each position in the FG loop from EGFR binding sequences with 15 amino acid long FG loops (349 unique 15-amino acid long FG loops analyzed). 9 24039697 I.DOC Figure 39. BC loop Sequence Analysis II. Frequency of amino acids at each position in the BC loop from all "potent" sequences (85 unique BC loop sequences analyzed). Figure 40. DE loop Sequence Analysis II. Frequency of amino acids at each position in the DE loop from all "potent" sequences (60 unique DE loop sequences analyzed). Figure 41. FG loop (10-aa length) Sequence Analysis II. Frequency of amino acids at each position in the FG loop from all "potent" sequences with 10 amino acid long FG loops (6 unique 10-amino acid long FG loops analyzed). Figure 42. FG loop (15-aa length) Sequence Analysis II. Frequency of amino acids at each position in the FG loop from all "potent" sequences with 15 amino acid long FG loops (65 unique 15-amino acid long FG loops analyzed). Figure 43. Table summarizing various characteristics of E/I 1 0 Fn3-based binders as described in Example 22. Figure 44. Table summarizing various pharmacokinetic parameters of E/I

'

0 Fn3-based binders as described in Example 30. Figure 45. Amino acid sequences of E monomers as described in Example 32. The BC, DE and FG loops in each sequence are underlined. Figure 46. Alignment of wild-type core sequence (amino acids 9-94 of SEQ ID NO: 1) with Il core (SEQ ID NO:65), El core (SEQ ID NO:66), E2 core (SEQ ID NO:67), E3 core (SEQ ID NO:68), E4 core (SEQ ID NO:108), E5 core (SEQ ID NO:114), E85 core (SEQ ID NO:141), E90 core (SEQ ID NO:156), E96 core (SEQ ID NO:171), E105 core (SEQ ID NO:186), and E112 core (SEQ ID NO:199). The BC, DE and FG loops in the wild-type sequences are shown in bold and underlined. The amino acid residues actually changed in comparison to wild-type for the I and E cores are shown i bold and underlined. Figure 47. Nucleic acid sequences of E and I monomers. Unless otherwise specified, the nucleotide sequences encode a monomer having an N+10 N-terminal extension, a Ser tail, and a his tag. Figure 48. Nucleic acid sequence of E/I 1 0 Fn3-based binders. All nucleotide sequences encode an E/I 1 0 Fn3-based binder having an N+10 N-terminal extension on the first monomer in the construct and a Cys tail and his tag on the second 10 24039697 .DOC monomer in the construct. GS1O is SEQ ID NO: 11; GSGCGS8 is SEQ ID NO: 218; and GSGC is SEQ ID NO: 489. DETAILED DESCRIPTION OF THE INVENTION Definitions As used herein, the following terms and phrases shall have the meanings set forth below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art. The singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. The terms "comprise" and "comprising" are used in the inclusive, open sense, meaning that additional elements may be included. The term "including" is used to mean "including but not limited to". "Including" and "including but not limited to" are used interchangeably. The term "antibody-like protein" refers to a non-immunoglobulin protein having an "immunoglobulin-like fold", i.e., comprises about 80-150 amino acid residues that are structurally organized into a set of beta or beta-like strands, forming beta sheets, where the beta or beta-like strands are connected by intervening loop portions. The beta sheets form the stable core of the antibody-like protein, while creating two "faces" composed of the loops that connect the beta or beta-like strands. As described herein, these loops can be varied to create customized ligand binding sites, and such variations can be generated without disrupting the overall stability of the protein. An example of such an antibody-like protein is a "fibronectin-based scaffold protein", by which is meant a polypeptide based on a fibronectin type III domain (Fn3). In one aspect, an antibody-like protein is based on a tenth fibronectin type III domain (1 0 Fn3). By a "polypeptide" is meant any sequence of two or more amino acids, regardless of length, post-translation modification, or function. "Polypeptide," "peptide," and "protein" are used interchangeably herein. "Percent (%) amino acid sequence identity" herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a selected sequence, after aligning the sequences and 11 24039697_1.DOC introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are obtained as described below by using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087, and is publicly available through Genentech, Inc., South San Francisco, Calif The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.OD. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. For purposes herein, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X/Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. The term "therapeutically effective amount" refers to an amount of a drug effective to treat a disease or disorder in a mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer 12 24039697 1.DOC cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the disorder. To the extent the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. For cancer therapy, efficacy in vivo can, for example, be measured by assessing the time to disease progression (TTP) and/or determining the response rates (RR). The half-life of an amino acid sequence or compound can generally be defined as the time taken for the serum concentration of the polypeptide to be reduced by 50% in vivo due to, e.g., degradation of the sequence or compound and/or clearance or sequestration of the sequence or compound by natural mechanisms. The half-life can be determined in any manner known in the art, such as by pharmacokinetic analysis. See e.g., M Gibaldi & D Perron "Pharmacokinetics", published by Marcel Dekker, 2nd Rev. edition (1982). The term "E/I binder" refers to a bispecific molecule that comprises an EGFR binding domain and a distinct IGFIR binding domain. The two domains may be covalently or non-covalently linked. An exemplary E/I binder is an antibody-like dimer comprising an EGFR binding 10 Fn3 and an IGFIR binding 1 0 Fn3, i.e., an E/I 1 0 Fn3 based binder. Overview The epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor (IFGR) play key roles in the tumorigenesis of several types of human cancer. Inhibition of either receptor effectively reduces tumor growth in preclinical models as well as clinically. Blocking the EGFR pathway induces switching to the IGFR pathway to drive growth with in vitro tumor models. Therefore, blocking both receptors simultaneously may achieve superior efficacy to blocking either pathway alone by overcoming pathway switching. In exemplary embodiments, the activity of an E/I binder is synergistic in comparison to the monomeric components of the E/I binder. The specification describes, inter alia, bispecific molecules that bind EGFR and IGFIR, referred to herein as "E/I binders". Applicants have discovered that such bispecific molecules inhibit proliferation of a cancer model cell line with greater 13 24039697_.DOC potency than the corresponding. monospecific binders (see e.g., Example 9 and Figure 8). E/I binders will be useful in numerous therapeutic applications, especially in the treatment of cancer. In addition to therapeutic applications, E/I binders may be used in any circumstance where it is desirable to detect EGFR and/or IGFIR. E/I binders have an EGFR binding domain and a distinct IGFIR binding domain. Typical binding domains include antibodies; therefore, bispecific antibodies may be generated to function as E/I binders. Bispecific antibodies comprising complementary pairs of Vj 1 and VL regions are known in the art. These bispecific antibodies comprise two pairs of VH and VL, each VwI/L pair binding to a single antigen. (see e.g., Hu et al., Cancer Res. 1996 56:3055-306; Neri et al., J. Mol. Biol. 1995 246:367-373; Atwell et al., Mol. Immunol. 1996 33:1301-1312; and Carter et al., Protein Sci. 1997 6:781-788). An exemplary bispecific antibody is a diabody, i.e., a small antibody fragment with two antigen-binding sites, which fragments comprise a heavy-chain variable domain connected to a light-chain variable domain in the same polypeptide chain (Hollinger et al., Proc. Natl. Acad. Sci. USA 1993 90: 6444-6448). E/I binders also encompass dimers of ligand binding scaffold proteins. Scaffold proteins are well described in the literature and include, e.g., tendamistat, affibody, fibroncectin type III domain, anticalin, tetranectin, and ankyrin. Additional scaffold proteins that may be used to generate E/I binders are reviewed in Binz et al., Nature Biotech 23:1257-1268 (2005). Scaffold proteins are based on a rigid core structure or 'framework' that is important in determining and stabilizing the three-dimensional structure. In between the fixed or conserved residues of the scaffold lie variable regions such as loops, surfaces or cavities that can be randomized to alter ligand binding. A large diversity of amino acids is provided in the variable regions between the fixed scaffold residues to provide specific binding to a target molecule. An exemplary ligand binding scaffold protein is based on a fibronectin type III domain (Fn3). Fibronectin is a large protein which plays essential roles in the formation of extracellular matrix and cell-cell interactions; it consists of many repeats of three types (types I, II, and III) of small domains. 14 24039697_.DOC Fn3 is small, monomeric, soluble, and stable. It lacks disulfide bonds and, therefore, is stable under reducing conditions. The overall structure of Fn3 resembles the immunoglobulin fold. Fn3 domains comprise, in order from N terminus to C-terminus, a beta or beta-like strand, A; a loop, AB; a beta or beta-like strand, B; a loop, BC; a beta or beta-like strand, C; a loop, CD; a beta or beta-like strand, D; a loop, DE; a beta or beta-like strand, E; a loop, EF; a beta or beta-like strand, F; a loop, FG; and a beta or beta-like strand, G. The seven antiparallel p strands are arranged as two beta sheets that form a stable core, while creating two "faces" composed of the loops that connect the beta or beta-like strands. Loops AB, CD, and EF are located at one face and loops BC, DE, and FG are located on the opposing face. Any or all of loops AB, BC, CD, DE, EF and FG may participate in ligand binding. There are at least 15 different modules of Fn3, and while the sequence homology between the molecules is low, they all share a high similarity in tertiary structure. Adnectins (Adnexus, a Bristol-Myers Squibb R&D Company) are ligand binding scaffold proteins based on the tenth fibronectin type III domain, i.e., the tenth module of Fn3, (1 0 Fn3). The amino acid sequence of a naturally occurring human 1 0 Fn3 is set forth in SEQ ID NO: 1. VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVP GSKST ATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRT (SEQ ID NO:1) (BC, FG, and DE loops are emphasized) In SEQ ID NO:1, the AB loop corresponds to residues 15-16, the BC loop corresponds to residues 21-30, the CD loop corresponds to residues 39-45, the DE loop corresponds to residues 51-56, the EF loop corresponds to residues 60-66, and the FG loop corresponds to residues 76-87. (Xu et al., Chemistry & Biology 2002 9:933-942). The BC, DE and FG loops align along one face of the molecule and the AB, CD and EF loops align along the opposite face of the molecule. In SEQ ID NO: 1, beta strand A corresponds to residues 9-14, beta strand B corresponds to residues 17-20, beta strand C corresponds to residues 31-38, beta strand D corresponds to residues 46-50, beta strand E corresponds to residues 57-59, beta strand F corresponds to residues 67-75, and beta strand G corresponds to residues 88-94. The strands are connected to each other through the corresponding loop, e.g., 15 24039697_.DOC strands A and B are connected via loop AB in the formation strand A, loop AB, strand B, etc. Residues involved in forming the hydrophobic core (the "core amino acid residues") include the amino acids corresponding to the following amino acids of SEQ ID NO: 1: L8, V10, A13, L18, 120, W22, Y32, 134, Y36, F48, V50, A57, 159, L62, Y68, 170, V72, A74, 188, 190 and Y92, wherein the core amino acid residues are represented by the single letter amino acid code followed by the position at which they are located within SEQ ID NO: 1. See e.g., Dickinson et al., J. Mol. Biol. 236: 1079-1092 (1994). As described above, amino acid residues corresponding to residues 21-30, 51-56, and 76-87 of SEQ ID NO: 1 define the BC, DE and FG loops, respectively. However, it should be understood that not every residue within the loop region needs to be modified in order to achieve a I0Fn3 binder having strong affinity for a desired target, such as IGF-IR or EGFR. For example, in many of the examples described herein, only residues corresponding to amino acids 23-30, 52-55 and 77 86 of SEQ ID NO: 1 were modified to produce high affinity 1 0 Fn3 binders (see Figure 46. Accordingly, in certain embodiments, the BC loop may be defined by amino acids corresponding to residues 23-30 of SEQ ID NO: 1, the DE loop may be defined by amino acids corresponding to residues 52-55 of SEQ ID NO: 1, and the FG loop may be defined by amino acids corresponding to residues 77-86 of SEQ ID NO: 1.

'

0 Fn3 are structurally and functionally analogous to antibodies, specifically the variable region of an antibody. While ' 0 Fn3 domains may be described as "antibody mimics" or "antibody-like proteins", they do offer a number of advantages over conventional antibodies. In particular, they exhibit better folding and thermostability properties as compared to antibodies, and they lack disulphide bonds, which are known to impede or prevent proper folding under certain conditions. Exemplary E/I 1 0 Fn3 based binders are predominantly monomeric with Tm's averaging -50 C. The BC, DE, and FG loops of 1 0 Fn3 are analogous to the complementary determining regions (CDRs) from immunoglobulins. Alteration of the amino acid sequence in these loop regions changes the binding specificity of I 0 Fn3. The protein sequences outside of the CDR-like loops are analogous to the framework regions 16 24039697 _DOC from immunoglobulins and play a role in the structural conformation of the 1 0 Fn3. Alterations in the framework-like regions of I 0 Fn3 are permissible to the extent that the structural conformation is not so altered as to disrupt ligand binding. Methods for generating ' 0 Fn3 ligand specific binders have been described in PCT Publication Nos. WO 00/034787, WO 01/64942, and WO 02/032925, disclosing high affinity TNFa binders, PCT Publication No. WO 2008/097497, disclosing high affinity VEGFR2 binders, and PCT Publication No. WO 2008/066752, disclosing high affinity IGFIR binders. Additional references discussing 1 0 Fn3 binders and methods of selecting binders include PCT Publication Nos. WO 98/056915, WO 02/081497, and WO 2008/031098 and U.S. Publication No. 2003186385. Antibody-like proteins based on the ' 0 Fn3 scaffold can be defined generally by the sequence: VSDVPRDLEVVAATPTSLLI(X)nYYRITYGETGGNSPVQEFTV(X)oATISGLKP GVDYTITVYAV(X),ISINYRT (SEQ ID NO: 32), wherein n is an integer from 1 20, o is an integer from 1-20, and p is an integer from 1-40. The BC, DE, and FG loops are represented by (X), (X)o, and (X)p, respectively. 1 0 Fn3 generally begin with the amino acid residue corresponding to number 1 of SEQ ID NO: 1. However, domains with amino acid deletions are also encompassed by the invention. In some embodiments, amino acid residues corresponding to the first eight amino acids of SEQ ID NO: 1 are deleted. Additional sequences may also be added to the N- or C-terminus. For example, an additional MG sequence may be placed at the N-terminus of 1 0 Fn3. The M will usually be cleaved off, leaving a G at the N-terminus. In some embodiments, sequences may be placed at the C-terminus of the 1 0 Fn3 domain, e.g., EIDKPSQ (SEQ ID NO: 9), EIDKPCQ (SEQ ID NO: 10), EGSGS (SEQ ID NO: 96) or EGSGC (SEQ ID NO: 97). The non-ligand binding sequences of 1 0 Fn3, i.e., the "1 0 Fn3 scaffold", may be altered provided that the 1 0 Fn3 retains ligand binding function and/or structural stability. In some embodiments, one or more of Asp 7, Glu 9, and Asp 23 are replaced by another amino acid, such as, for example, a non-negatively charged amino acid residue (e.g., Asn, Lys, etc.). These mutations have been reported to have the effect of promoting greater stability of the mutant 1 0 Fn3 at neutral pH as 17 24039697_.DOC compared to the wild-type form (See, PCT Publication No. WO 02/04523). A variety of additional alterations in the 1 Fn3 scaffold that are either beneficial or neutral have been disclosed. See, for example, Batori et al., Protein Eng. 2002 15(12):1015-20; Koide et al., Biochemistry 2001 40(34):10326-33. The ' 0 Fn3 scaffold may be modified by one or more conservative substitutions. As many as 5%, 10%, 20% or even 30% or more of the amino acids in the 1 0 Fn3 scaffold may be altered by a conservative substitution without substantially altering the affinity of the 10Fn3 for a ligand. For example, the scaffold modification preferably reduces the binding affinity of the 1 0 Fn3 binder for a ligand by less than 100-fold, 50-fold, 25-fold, 10-fold, 5-fold, or 2-fold. It may be that such changes will alter the immunogenicity of the 1 0 Fn3 in vivo, and where the immunogenicity is decreased, such changes will be desirable. As used herein, "conservative substitutions" are residues that are physically or functionally similar to the corresponding reference residues. That is, a conservative substitution and its reference residue have similar size, shape, electric charge, chemical properties including the ability to form covalent or hydrogen bonds, or the like. Preferred conservative substitutions are those fulfilling the criteria defined for an accepted point mutation in Dayhoff et al., Atlas of Protein Sequence and Structure 5:345-352 (1978 & Supp.). Examples of conservative substitutions are substitutions within the following groups: (a) valine, glycine; (b) glycine, alanine; (c) valine, isoleucine, leucine; (d) aspartic acid, glutamic acid; (e) asparagine, glutamine; (f) serine, threonine; (g) lysine, arginine, methionine; and (h) phenylalanine, tyrosine. E Binders In one aspect, the disclosure provides antibody-like proteins comprising an EGFR binding 1 0 Fn3 domain. In certain embodiments, an EGFR binding 10Fn3 may be provided as part of a fusion protein or multimer. For example, an EGFR binding 1 0 Fn3 may be covalently or non-covalently linked to at least a second 1 0 Fn3 binding domain. The second ' 0 Fn3 binding domain may bind to EGFR or to a different target. In an exemplary embodiment, an EGFR binding 1 0 Fn3 may be covalently or non-covalently linked to an IGF-IR binding " 0 Fn3. 18 24039697_I.DOC In exemplary embodiments, the EGFR binding 1 0 Fn3 proteins described herein bind to EGFR with a KD of less than 500 nM, 100 nM, 50 nM, 10 nM, 1 nM, 500 pM, 100 pM. 100 pM, 50 pM or 10 pM. In exemplary embodiments, the BC loop of the EGFR binding 10Fn3 proteins correspond to amino acids 23-30 of SEQ ID NO: 1, the DE loop of the EGFR binding 1 0 Fn3 proteins correspond to amino acids 52-55 of SEQ ID NO: 1, and the FG loop of the EGFR binding ' 0 Fn3 proteins correspond to amino acids 77-86 of SEQ ID NO: 1. In one embodiment, the invention provides an EGFR binding " 0 Fn3 comprising a BC loop having a YQ at the positions corresponding to amino acids 29 and 30 of SEQ ID NO: 1. In another embodiment, the invention provides an EGFR binding 10Fn3 comprising a BC loop having a YQ at the positions corresponding to amino acids 29 and 30 of SEQ ID NO: 1 and an FG loop that is fifteen amino acids in length, e.g., an FG loop that is extended in length by five amino acids due to an insertion of five amino acids between residues corresponding to amino acids 77-86 of SEQ ID NO: 1. In another embodiment, the invention provides an EGFR binding 10Fn3 comprising a BC loop having a YQ at the positions corresponding to amino acids 29 and 30 of SEQ ID NO: 1 and a DE loop having a V, I, L, M or A residue at the position corresponding to amino acid 54 of SEQ ID NO: 1. In another embodiment, the invention provides an EGFR binding ' 0 Fn3 comprising a BC loop having a YQ at the positions corresponding to amino acids 29 and 30 of SEQ ID NO: 1, a DE loop having a V, I, L, M or A residue at the position corresponding to amino acid 54 of SEQ ID NO: 1, and an FG loop that is fifteen amino acids in length, e.g., an FG loop that is extended in length by five amino acids due to an insertion of five amino acids between residues corresponding to amino acids 77-86 of SEQ ID NO: 1. In another embodiment, the invention provides an EGFR binding 1 0 Fn3 comprising a BC loop having a YQ at the positions corresponding to amino acids 29 and 30 of SEQ ID NO: 1 and an FG loop comprising a D or N at the position corresponding to amino acid 77 of SEQ ID NO: 1. 19 24039697_I.DOC In another embodiment, the invention provides an EGFR binding ' 0 Fn3 comprising a BC loop having a YQ at the positions corresponding to amino acids 29 and 30 of SEQ ID NO: 1 and an FG loop (i) that is fifteen amino acids in length, e.g., an FG loop that is extended in length by five amino acids due to an insertion of five amino acids between residues corresponding to amino acids 77-86 of SEQ ID NO: 1 and (ii) comprises a D or N at the position corresponding to amino acid 77 of SEQ ID NO: 1. In another embodiment, the invention provides an EGFR binding ' 0 Fn3 comprising a DE loop comprising a V, I, L, M or A residue at the position corresponding to amino acid 54 of SEQ ID NO: I and an FG loop comprising a D or N at the position corresponding to amino acid 77 of SEQ ID NO: 1. In another embodiment, the invention provides an EGFR binding ' 0 Fn3 comprising a DE loop comprising a V, I, L, M or A residue at the position corresponding to amino acid 54 of SEQ ID NO: 1 and an FG loop (i) that is fifteen amino acids in length, e.g., an FG loop that is extended in length by five amino acids due to an insertion of five amino acids between residues corresponding to amino acids 77-86 of SEQ ID NO: 1 and (ii) comprises a D or N at the position corresponding to amino acid 77 of SEQ ID NO: 1. In another embodiment, the invention provides an EGFR binding " 0 Fn3 comprising a BC loop having a YQ at the positions corresponding to amino acids 29 and 30 of SEQ ID NO: 1, a DE loop comprising a V, I, L, M or A residue at the position corresponding to amino acid 54 of SEQ ID NO: 1, and an FG loop comprising a D or N at the position corresponding to amino acid 77 of SEQ ID NO: 1. In another embodiment, the invention provides an EGFR binding ' 0 Fn3 comprising a BC loop having a YQ at the positions corresponding to amino acids 29 and 30 of SEQ ID NO: 1, a DE loop comprising a V, I, L, M or A residue at the position corresponding to amino acid 54 of SEQ ID NO: 1, and an FG loop (i) that is fifteen amino acids in length, e.g., an FG loop that is extended in length by five amino acids due to an insertion of five amino acids between residues corresponding to amino acids 77-86 of SEQ ID NO: 1 and (ii) comprises a D or N at the position corresponding to amino acid 77 of SEQ ID NO: 1. 20 24039697_1.DOC In another embodiment, the invention provides an EGFR binding ' 0 Fn3 comprising a BC loop comprising the amino acid sequence XXXXXXYQ, a DE loop comprising the amino acid sequence XX(V/I/L/M/A)X, and an FG loop comprising the amino acid sequence (D/N)Xn, wherein X is any amino acid and n is 9-14 amino acids. In an exemplary embodiment, n is 14 amino acids. In another embodiment, the invention provides an EGFR binding 10Fn3 comprising a BC loop corresponding to amino acids 23-30 of SEQ ID NO: 1 comprising the amino acid sequence XXXXXXYQ, a DE loop corresponding to amino acids 52-55 of SEQ ID NO: 1 comprising the amino acid sequence XX(V/I/L/M/A)X, and an FG loop corresponding to amino acids 77-86 of SEQ ID NO: 1 comprising the amino acid sequence (D/N)Xn, wherein X is any amino acid and n is 9-14 amino acids. In an exemplary embodiment, n is 14 amino acids. In another embodiment, the invention provides an EGFR binding 10Fn3 comprising a BC loop comprising the amino acid sequence XXXXXXYQ, a DE loop comprising the amino acid sequence XX(V/I/L/M/A)X, and an FG loop comprising an amino acid sequence selected from: i. (D/N)(Y/M)(Y/A/M)(Y/H/F)(K/Q/V)(E/P/R)(Y/T/K)X(E/Y/Q)(Y/G/H); and ii. D(Y/F/W)(Y/F/K)(N/D/P)(P/H/L)(A/T/V)(T/D/S)(H/Y/G)(E/P/V)(Y/H)(T/K /I)(Y/F)(H/N/Q)(T/Q/E)(T/S/I); wherein X is any amino acid. In another embodiment, the invention provides an EGFR binding " 0 Fn3 comprising a BC loop comprising the amino acid sequence XXXXXXYQ, a DE loop comprising the amino acid sequence (G/Y/H)(D/M/G)(V/L/I)X, and an FG loop comprising an amino acid sequence (D/N)(Y/M)(Y/A/M)(Y/H/F)(K/Q/V)(E/P/R)(Y/T/K)X(E/Y/Q)(Y/G/H), wherein X is any amino acid. In another embodiment, the invention provides an EGFR binding ' 0 Fn3 comprising a BC loop comprising the amino acid sequence XXXXXXYQ, a DE loop comprising the amino acid sequence (G/Y/H)(D/M/G)(V/L/I)X, and an FG loop comprising an amino acid sequence 21 24039697 .DOC D(Y/F/W)(Y/F/K)(N/D/P)(P/H/L)(A/T/V)(T/D/S)(H/Y/G)(E/P/V)(Y/H)(T/K/I)(Y/F )(H/N/Q)(T/Q/E)(T/S/I), wherein X is any amino acid. In another embodiment, the invention provides an EGFR binding ' 0 Fn3 comprising a BC loop comprising the amino acid sequence XXXXXXYQ, a DE loop comprising the amino acid sequence XX(V/I/L/M/A)X, and an FG loop comprising an amino acid sequence selected from: i. DY(A/Y)GKPYXEY (SEQ ID NO: 473); ii. DY(A/Y)Y(K/R/Q/T)PYXEY (SEQ ID NO: 474); iii. (D/N)Y(A/Y)(Y/F)(K/R/Q/T)EYXE(Y/H) (SEQ ID NO: 475); iv. DYY(H/Y)X(R/K)X(E/T)YX (SEQ ID NO: 476); v. DYY(H/Y)(K/H/Q)(R/K)T(E/T)Y(G/P) (SEQ ID NO: 477); vi. (D/N)MMHV(E/D)YXEY (SEQ ID NO: 478); vii. DYMHXXYXEY (SEQ ID NO: 479); and viii. D(M/Y)YHX(K/R)X(V/I/L/M)YG (SEQ ID NO: 480); wherein X is any amino acid. In another embodiment, the invention provides an EGFR binding 1 0 Fn3 comprising a BC loop comprising the amino acid sequence XXXXXXYQ, a DE loop comprising the amino acid sequence XX(V/I/L/M/A)X, and an FG loop comprising an amino acid sequence selected from: i. D(Y/F)(Y/F)NPXTHEYXYXXX (SEQ ID NO: 481); ii. D(Y/F)(Y/F)D(P/L)X(T/S)HXYXYXXX (SEQ ID NO: 482); and iii. D(Y/F)(K/R)PHXDGPH(T/I)YXE(S/Y) (SEQ ID NO: 483); wherein X is any amino acid. In another embodiment, the invention provides an EGFR binding '4Fn3 comprising a BC loop comprising the amino acid sequence XXXXXXYQ, a DE loop comprising the amino acid sequence XX(V/I/L/M/A)X, and an FG loop comprising the amino acid sequence (D/N)(M/Y)(M/A/W)(H/F/Y)(V/K)EY(A/Q/R/S/T)E(Y/H/D), wherein X is any amino acid. In another embodiment, the invention provides an EGFR binding 10Fn3 comprising a BC loop comprising the amino acid sequence XXXXXXYQ, a DE loop comprising the amino acid sequence XX(V/I/L/M/A)X, and an FG loop 22 24039697_1 .DOC comprising the amino acid sequence D(Y/F/W)(Y/F/K)(N/P/D)(P/H/L)X(T/D/S)(H/G/Y)(E/P/Y)(Y/H)XYXXX, wherein X is any amino acid. In various embodiments, the DE loop of the EGFR binding 10Fn3 may comprise the sequence (G/Y/H)(D/M/G)(V/L/I)X. In another embodiment, the invention provides an EGFR binding ' 0 Fn3 comprising an FG loop comprising an amino acid sequence selected from: i. D(Y/F)(Y/F)NPXTHEYXYXXX (SEQ ID NO: 481); ii. D(Y/F)(Y/F)D(P/L)X(T/S)HXYXYXXX (SEQ ID NO: 482); and iii. D(Y/F)(K/R)PHXDGPH(T/I)YXE(S/Y) (SEQ ID NO: 483); wherein X is any amino acid. In certain embodiments, the EGFR binding 1 0 Fn3 comprises any of the consensus sequences provided above, with the proviso that the EGFR binding ' 0 Fn3 does not comprise one or more of the following sequences: i. VSDVPRDLEVVAATPTSLLISWQVPRPMYQRYYRITYGETGGNSPVQ EFTVPGGVRTATISGLKPGVDYTITVYAVTDYMHSEYRQYPISINYRT (SEQ ID NO: 484), and ii. VSDVPRDLEVVAATPTSLLISWQVPRPMYQYYRITYGETGGNSPVQE FTVPGGVRTATISGLKPGVDYTITVYAVTDYMHSEYRQYPISINYRT (SEQ ID NO: 485), and iii. VSDVPRDLEVVAATPTSLLISWQVPRPMYQRYYRITYGETGGNSPVQ EFTVPGGVRTATISGLKPGVDYTITVYAVTDYMHSEYRQYPISINYRTEIDKP CQ (SEQ ID NO: 486). In certain embodiments, an EGFR binding 1 0 Fn3 comprising one of the consensus sequences provided above has at least 40%, 50%, 60%, 70%, 75%, or 80% identity to SEQ ID NO: 1. In certain embodiments, the overall structure of an EGFR binding 1 0 Fn3 comprising one of the consensus sequences provided above resembles the immunoglobulin fold. In certain embodiment, an EGFR binding 1 0 Fn3 comprising one of the consensus sequences provided above further comprises 23 24039697_.DOC the core amino acid residues of the scaffold. In certain embodiments, an EGFR binding 1 0 Fn3 comprising one of the consensus sequences provided above has at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identity to any one of SEQ ID NOs: 5-8, 52, 66-68, 106-108, 112-114, 140-142, 155-157, 170-172, 182, 185-187, 198-200, or 219-327. In certain embodiments, an EGFR binding ' 0 Fn3 comprising one of the consensus sequences provided above has at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identity to the amino acid sequence of amino acid residues corresponding to E9 of SEQ ID NO: 1 through T94 of SEQ ID NO: 1 of any one of SEQ ID NOs: 5-8, 52, 66-68, 106-108, 112-114, 140-142, 155 157, 170-172, 182, 185-187, 198-200, or 219-327. In certain embodiments, the EGFR binding 1 0 Fn3 comprising one of the consensus sequences provided above comprises a 1 0 Fn3 scaffold having from has anywhere from 0 to 20, from 0 to 15, from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, conservative substitutions, deletions or additions relative to the scaffold amino acids residues of SEQ ID NO: 1. In certain embodiments, the invention provides an EGFR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 23 30, a DE loop having the amino acid sequence set forth in amino acids 52-55, and an FG loop having the amino acid sequence set forth in amino acids 77-86 of any one of SEQ ID NOs: 219-327. In certain embodiments, the invention provides an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30, a DE loop having the amino acid sequence set forth in amino acids 51-56, and an FG loop having the amino acid sequence set forth in amino acids 76-87 of any one of SEQ ID NOs: 219-327. In certain embodiments, the invention provides an EGFR binding 1 0 Fn3 comprising an amino acid sequence at least 60%, 75%, 80%, 85%, 90%, 95%, or 98% identical to any one of SEQ ID NOs: 219-327. In one embodiment, an antibody-like protein is provided comprising a tenth fibronectin type III domain ( 1 0 Fn3) that binds EGFR with a KD of less than 500 nM and comprises a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 5, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 5, and an FG loop having the amino acid sequence set forth in amino acids 76-92 of SEQ ID NO: 5. In some embodiments, 24 240396971 .DOC the EGFR binding 1 Fn3 comprises a BC loop having the amino acid sequence XgDSGRGSYQXh (SEQ ID NO: 40), a DE loop having the amino acid sequence XiGPVHXj (SEQ ID NO: 42), and an FG loop having the amino acid sequence XkDHKPHADGPHTYHEX (SEQ ID NO: 44); wherein X is any amino acid and g, h, i, j, k, and 1 are integers independently selected from 0 to 5. In some embodiments, the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence SWDSGRGSYQ (SEQ ID NO: 39), a DE loop having the amino acid sequence PGPVHT (SEQ ID NO: 41), and an FG loop having the amino acid sequence TDHKPHADGPHTYHESP (SEQ ID NO: 43). In some embodiments, the EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, or 100% identical to SEQ ID NOs: 5 or 6. In one embodiment, an antibody-like protein is provided comprising a tenth fibronectin type III domain (10Fn3) that binds EGFR with a KD of less than 500 nM and comprises a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 7, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 7, and an FG loop having the amino acid sequence set forth in amino acids 76-87 of SEQ ID NO: 7. In some embodiments, the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XmVAGAEDYQXn (SEQ ID NO: 34), a DE loop having the amino acid sequence XoHDLVXp (SEQ ID NO: 36), and an FG loop having the amino acid sequence XqDMMHVEYTEHXr (SEQ ID NO: 38); wherein X is any amino acid and m, n, o, p, q, and r are integers independently selected from 0 to 5. In some embodiments, the EGFR binding '0Fn3 comprises a BC loop having the amino acid sequence SWVAGAEDYQ (SEQ ID NO: 33), a DE loop having the amino acid sequence PHDLVT (SEQ ID NO: 35), and an FG loop having the amino acid sequence TDMMHVEYTEHP (SEQ ID NO: 37). In some embodiments, the EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, or 100% identical to SEQ ID NO: 7 or 8. In one embodiment, an antibody-like protein is provided comprising a tenth fibronectin type III domain ( 1 0 Fn3) that binds EGFR with a KD of less than 500 nM and comprises a BC loop having the amino acid sequence set forth in amino acids 23-30 of SEQ ID NO: 82, a DE loop having the amino acid sequence set forth in 25 24039697_.DOC amino acids 51-55 of SEQ ID NO: 82, and an FG loop having the amino acid sequence set forth in amino acids 76-86 of SEQ ID NO: 82. In some embodiments, the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XSLPGKLRYQXt (SEQ ID NO: 60), a DE loop having the amino acid sequence XuHDLRX, (SEQ ID NO: 62), and an FG loop having the amino acid sequence XyNMMHVEYSEYXz (SEQ ID NO: 64); wherein X is any amino acid and s, t, u, w, y and z are integers independently selected from 0 to 5. In some embodiments, the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence LPGKLRYQ (resdiues 3-13 of SEQ ID NO: 59), a DE loop having the amino acid sequence PHDLR (residues 1-5 of SEQ ID NO: 61), and an FG loop having the amino acid sequence TNMMHVEYSEY (residues 1-11 of SEQ ID NO: 63). In some embodiments, the EGFR binding ' 0 Fn3 has an amino acid sequence at least 80, 90, 95, or 100% identical to SEQ ID NO: 52 or 82. In one embodiment, an antibody-like protein is provided comprising a tenth fibronectin type III domain (1 0 Fn3) that binds EGFR with a KD of less than 500 nM and comprises a BC loop having the amino acid sequence set forth in amino acids 23-30 of SEQ ID NO: 106, a DE loop having the amino acid sequence set forth in amino acids 51-55 of SEQ ID NO: 106, and an FG loop having the amino acid sequence set forth in amino acids 76-86 of SEQ ID NO: 106. In some embodiments, the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XgHERDGSRQXh (SEQ ID NO: 134), a DE loop having the amino acid sequence XiGGVRXj (SEQ ID NO: 135), and an FG loop having the amino acid sequence XkDYFNPTTHEYIYQTTXI (SEQ ID NO: 136); wherein X is any amino acid and g, h, i, j, k and 1 are integers independently selected from 0 to 5. In some embodiments, the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence SWHERDGSRQ (SEQ ID NO: 109), a DE loop having the amino acid sequence PGGVRT (SEQ ID NO: 110), and an FG loop having the amino acid sequence TDYFNPTTHEYIYQTTP (SEQ ID NO: 111). In some embodiments, the EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, or 100% identical to any one of SEQ ID NOs: 106-108. In one embodiment, an antibody-like protein is provided comprising a tenth fibronectin type III domain (1 0 Fn3) that binds EGFR with a KD of less than 500 nM 26 24039697_.DOC and comprises a BC loop having the amino acid sequence set forth in amino acids 23-30 of SEQ ID NO: 112, a DE loop having the amino acid sequence set forth in amino acids 51-55 of SEQ ID NO: 112, and an FG loop having the amino acid sequence set forth in amino acids 76-86 of SEQ ID NO: 112. In some embodiments, the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XgWAPVDRYQXh (SEQ ID NO: 137), a DE loop having the amino acid sequence XiRDVYXj (SEQ ID NO: 138), and an FG loop having the amino acid sequence XkDYKPHADGPHTYHESX (SEQ ID NO: 139); wherein X is any amino acid and g, h, i, j, k and 1 are integers independently selected from 0 to 5. In some embodiments, the EGFR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence SWWAPVDRYQ (SEQ ID NO: 115), a DE loop having the amino acid sequence PRDVYT (SEQ ID NO: 116), and an FG loop having the amino acid sequence TDYKPHADGPHTYHESP (SEQ ID NO: 117). In some embodiments, the EGFR binding ' 0 Fn3 has an amino acid sequence at least 80, 90, 95, or 100% identical to any one of SEQ ID NOs: 112-114. In one embodiment, an antibody-like protein is provided comprising a tenth fibronectin type III domain (1 0 Fn3) that binds EGFR with a KD of less than 500 nM and comprises a BC loop having the amino acid sequence set forth in amino acids 13-22 of SEQ ID NO: 141, a DE loop having the amino acid sequence set forth in amino acids 43-48 of SEQ ID NO: 141, and an FG loop having the amino acid sequence set forth in amino acids 68-84 of SEQ ID NO: 141. In some embodiments, the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XgTQGSTHYQXh (SEQ ID NO: 146), a DE loop having the amino acid sequence XiGMVYXj (SEQ ID NO: 147), and an FG loop having the amino acid sequence XkDYFDRSTHEYKYRTTX (SEQ ID NO: 148); wherein X is any amino acid and g, h, i, j, k and 1 are integers independently selected from 0 to 5. In some embodiments, the EGFR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence SWTQGSTHYQ (SEQ ID NO: 143), a DE loop having the amino acid sequence PGMVYT (SEQ ID NO: 144), and an FG loop having the amino acid sequence TDYFDRSTHEYKYRTTP (SEQ ID NO: 145). In some embodiments, the EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, or 100% identical to any one of SEQ ID NOs: 140-142. 27 24039697 .DOC In one embodiment, an antibody-like protein is provided comprising a tenth fibronectin type III domain (' 0 Fn3) that binds EGFR with a KD of less than 500 nM and comprises a BC loop having the amino acid sequence set forth in amino acids 13-22 of SEQ ID NO: 156, a DE loop having the amino acid sequence set forth in amino acids 43-48 of SEQ ID NO: 156, and an FG loop having the amino acid sequence set forth in amino acids 68-84 of SEQ ID NO: 156. In some embodiments, the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XgYWEGLPYQXh (SEQ ID NO: 161), a DE loop having the amino acid sequence XiRDVNXj (SEQ ID NO: 162), and an FG loop having the amino acid sequence XkDWYNPDTHEYIYHTIX (SEQ ID NO: 163); wherein X is any amino acid and g, h, i, j, k and 1 are integers independently selected from 0 to 5. In some embodiments, the EGFR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence SWYWEGLPYQ (SEQ ID NO: 158), a DE loop having the amino acid sequence PRDVNT (SEQ ID NO: 159), and an FG loop having the amino acid sequence TDWYNPDTHEYIYHTIP (SEQ ID NO: 160). In some embodiments, the EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, or 100% identical to any one of SEQ ID NOs: 155-157. In one embodiment, an antibody-like protein is provided comprising a tenth fibronectin type III domain ( 1 0 Fn3) that binds EGFR with a KD of less than 500 nM and comprises a BC loop having the amino acid sequence set forth in amino acids 13-22 of SEQ ID NO: 171, a DE loop having the amino acid sequence set forth in amino acids 43-48 of SEQ ID NO: 171, and an FG loop having the amino acid sequence set forth in amino acids 68-84 of SEQ ID NO: 171. In some embodiments, the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XgASNRGTYQX (SEQ ID NO: 176), a DE loop having the amino acid sequence XiGGVSXj (SEQ ID NO: 177), and an FG loop having the amino acid sequence XkDAFNPTTHEYNYFTTX (SEQ ID NO: 178); wherein X is any amino acid and g, h, i, j, k and 1 are integers independently selected from 0 to 5. In some embodiments, the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence SWASNRGTYQ (SEQ ID NO: 173), a DE loop having the amino acid sequence PGGVST (SEQ ID NO: 174), and an FG loop having the amino acid sequence TDAFNPTTHEYNYFTTP (SEQ ID NO: 175). In some embodiments, the 28 24039697_1.DOC EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, or 100% identical to any one of SEQ ID NOs: 170-172. In one embodiment, an antibody-like protein is provided comprising a tenth fibronectin type III domain ( 1 0 Fn3) that binds EGFR with a KD of less than 500 nM and comprises a BC loop having the amino acid sequence set forth in amino acids 13-22 of SEQ ID NO: 186, a DE loop having the amino acid sequence set forth in amino acids 43-48 of SEQ ID NO: 186, and an FG loop having the amino acid sequence set forth in amino acids 68-84 of SEQ ID NO: 186. In some embodiments, the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XgDAPTSRYQXh (SEQ ID NO: 190), a DE loop having the amino acid sequence XiGGLSXj (SEQ ID NO: 191), and an FG loop having the amino acid sequence XkDYKPHADGPHTYHESXi (SEQ ID NO: 139); wherein X is any amino acid and g, h, i, j, k and 1 are integers independently selected from 0 to 5. In some embodiments, the EGFR binding ' 0 Fn3 comprises a BC loop having the amino acid sequence SWDAPTSRYQ (SEQ ID NO: 188), a DE loop having the amino acid sequence PGGLST (SEQ ID NO: 189), and an FG loop having the amino acid sequence TDYKPHADGPHTYHESP (SEQ ID NO: 117). In some embodiments, the EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, or 100% identical to any one of SEQ ID NOs: 185-187. In one embodiment, an antibody-like protein is provided comprising a tenth fibronectin type III domain (' 0 Fn3) that binds EGFR with a KD of less than 500 nM and comprises a BC loop having the amino acid sequence set forth in amino acids 13-22 of SEQ ID NO: 199, a DE loop having the amino acid sequence set forth in amino acids 43-48 of SEQ ID NO: 199, and an FG loop having the amino acid sequence set forth in amino acids 68-84 of SEQ ID NO: 199. In some embodiments, the EGFR binding 1 Fn3 comprises a BC loop having the amino acid sequence XgDAGAVTYQXh (SEQ ID NO: 203), a DE loop having the amino acid sequence XiGGVRXj (SEQ ID NO: 135), and an FG loop having the amino acid sequence XkDYKPHADGPHTYHEYX (SEQ ID NO: 204); wherein X is any amino acid and g, h, i, j, k and 1 are integers independently selected from 0 to 5. In some embodiments, the EGFR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence SWDAGAVTYQ (SEQ ID NO: 201), a DE loop having the amino acid 29 24039697 I.DOC sequence PGGVRT (SEQ ID NO: 110), and an FG loop having the amino acid sequence TDYKPHADGPHTYHEYP (SEQ ID NO: 202). In some embodiments, the EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, or 100% identical to any one of SEQ ID NOs: 198-200. In certain embodiments, an EGFR binding 1 0 Fn3 domain is covalently or non-covalently linked to an EGF-IR binding 1 0 Fn3 domain. In exemplary embodiments, the IGF-IR binding 1 0 Fn3 may comrpise a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 76-83 of SEQ ID NO: 3. In some embodiments, the IGF-IR binding ' 0 Fn3 comprises a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50), wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k, and 1 are integers independently selected from 0 to 5, or wherein a is 2 and b-f are 1, or wherein a-f are zero. In some embodiments, the IGF-IR binding 10 Fn3 has an amino acid sequence at least 80, 90, 95, 98, 99, or 100% identical to SEQ ID NO: 3. In certain embodiments, the IGF-IR binding 1 0 Fn3 comprises a ' 0 Fn3 scaffold having from has anywhere from 0 to 20, from 0 to 15, from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, conservative substitutions, deletions or additions relative to the scaffold amino acid residues of SEQ ID NO: 1. In certain embodiments, the IGF-IR binding 10 Fn3 has anywhere from 0 to 15, from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, conservative substitutions, deletions or additions relative to the corresponding loop sequences of SEQ ID NO: 3.

'

0 Fn3 E/I Binders One aspect of the disclosure provides E/I binders constructed from antibody like protein multimers. In some embodiments, an antibody-like protein multimer comprises at least one EGFR binding ' 0 Fn3 covalently or non-covalently linked to at least one IGFIR binding 1 0 Fn3. In certain embodiments, the E/I binders described 30 24039697_ .DOC herein may be constructed as a single polypeptide chain wherein the E and I subunits may be in either orientation, e.g., from N-terminus to C-terminus, in the E-I orientation or in the I-E orientation. The disclosure relates, in part, to the surprising discovery that multiple ' 0 Fn3 joined via a polypeptide linker correctly fold independently of each other, retain high affinity binding, and that each of the domains retains its functional properties (see e.g., Examples 5-10). Additionally, these E/I ' 0 Fn3 based binders demonstrate desirable biophysical properties such as low aggregation and high melting temperature (Tm,) (see e.g., Example 4). The Examples characterize a variety of E/I 1 0 Fn3 based binders. An exemplary IGFIR binding 1 0 Fn3 is set forth in SEQ ID NO: 4. Exemplary EGFR binding ' 0 Fn3 are set forth in SEQ ID NOs: 6, 8, 52, 107, 113, 140, 155, 170, 185 and 198. In some embodiments, an E/I binder comprises an EGFR binding 1 0 Fn3 and an IGFIR binding 1 0 Fn3, independently having an amino acid sequence at least 40, 50, 60, 70, or 80% identical to the human 1 0 Fn3 domain, shown in SEQ ID NO: 1. Much of the variability will generally occur in one or more of the loops. In some embodiments, an E/I binder comprises an EGFR binding 1 0 Fn3 and an IGFIR binding 1 0 Fn3, independently having an amino acid sequence at least 70, 80, 85, 90, 95, 98, or 100% identical to SEQ ID NO: 32, wherein n is an integer from 1-20, o is an integer from 1-20, and p is an integer from 1-40. In some embodiments, n is an integer from 8-12, o is an integer from 4-8, and p is an integer from 4-28. In some embodiments, n is 10, o is 6, and p is 12. In some embodiments, the disclosure provides multimers of ' 0 Fn3 having at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10Fn3. By "altered" is meant one or more amino acid sequence alterations relative to a template sequence (corresponding human fibronectin domain) and includes amino acid additions, deletions, and substitutions. Altering an amino acid sequence may be accomplished through intentional, blind, or spontaneous sequence variation, generally of a nucleic acid coding sequence, and may occur by any technique, for example, PCR, error-prone PCR, or chemical DNA synthesis. In some 31 24039697_ .DOC embodiments, an amino acid sequence is altered by substituting with or adding naturally occurring amino acids. In some embodiments, one or more loops selected from BC, DE, and FG may be extended or shortened in length relative to the corresponding human fibronectin loop. In particular, the FG loop of the human 10Fn3 is 12 residues long, whereas the corresponding loop in antibody heavy chains ranges from 4-28 residues. To optimize antigen binding, therefore, the length of the FG loop of ' 0 Fn3 may be altered in length as well as in sequence to obtain the greatest possible flexibility and affinity in antigen binding. In some embodiments of the 1 0 Fn3 molecules, the altered BC loop has up to 10 amino acid substitutions, up to 9 amino acid deletions, up to 10 amino acid insertions, or a combination of substitutions and deletions or insertions. In some embodiments, the altered DE loop has up to 6 amino acid substitutions, up to 5 amino acid deletions, up to 14 amino acid insertions or a combination of substitutions and deletions or insertions. In some embodiments, the FG loop has up to 12 amino acid substitutions, up to 11 amino acid deletions, up to 28 amino acid insertions or a combination of substitutions and deletions or insertions. Naturally occurring 1 0 Fn3 comprises an "arginine-glycine-aspartic acid" (RGD) integrin-binding motif in the FG loop. Preferred multimers of 1 0 Fn3 lack an RGD integrin-binding motif In some embodiments, an E/I binder is an antibody-like protein dimer comprising a) an EGFR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 5, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 5, and an FG loop having the amino acid sequence set forth in amino acids 76-92 of SEQ ID NO: 5; covalently or non-covalently linked to b) an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 76-83 of SEQ ID NO: 3. In some embodiments, the EGFR binding ' 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, 99, or 100% identical to SEQ ID NO: 5. In some embodiments, the IGFIR binding 1 0 Fn3 has an amino acid sequence at 32 24039697_.DOC least 80, 90, 95, 98, 99, or 100% identical to SEQ ID NO: 3. In some embodiments, the E/I binder comprises an amino acid sequence at least 80, 85, 90, 95, 98, 99, or 100% identical to SEQ ID NOs: 20, 21, 23, 24, 90, 92, 101 or 103. In some embodiments, an E/I binder is an antibody-like protein dimer comprising a) an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 7, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 7, and an FG loop having the amino acid sequence set forth in amino acids 76-87 of SEQ ID NO: 7; covalently or non-covalently linked to b) an IGFIR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 76-83 of SEQ ID NO: 3. In some embodiments, the EGFR binding 10 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 7. In some embodiments, the IGFIR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 3. In some embodiments, the E/I binder comprises an amino acid sequence at least 80, 85, 90, 95, 98, or 100% identical to SEQ ID NOs: 26, 27, 29, 30, 89, 91, 100 or 102. In some embodiments, an E/I binder is an antibody-like protein dimer comprising a) an EGFR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 82, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 82, and an FG loop having the amino acid sequence set forth in amino acids 76-87 of SEQ ID NO: 82; covalently or non-covalently linked to b) an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 76-83 of SEQ ID NO: 3. In some embodiments, the EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 82. In some embodiments, the IGFIR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 3. In some embodiments, the E/I 33 24039697_1.DOC binder comprises an amino acid sequence at least 80, 85, 90, 95, 98, or 100% identical to SEQ ID NOs: 53, 54, 87, 88, 98, 99, 104 or 105. In some embodiments, an E/I binder is an antibody-like protein dimer comprising a) an EGFR binding 10Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 106, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 106, and an FG loop having the amino acid sequence set forth in amino acids 76-92 of SEQ ID NO: 106; covalently or non-covalently linked to b) an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 76-83 of SEQ ID NO: 3. In some embodiments, the EGFR binding 10Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 106. In some embodiments, the IGFIR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 3. In some embodiments, the E/I binder comprises an amino acid sequence at least 80, 85, 90, 95, 98, or 100% identical to SEQ ID NOs: 118-125. In some embodiments, an E/I binder is an antibody-like protein dimer comprising a) an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 112, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 112, and an FG loop having the amino acid sequence set forth in amino acids 76-92 of SEQ ID NO: 112; covalently or non-covalently linked to b) an IGFIR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 76-83 of SEQ ID NO: 3. In some embodiments, the EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 112. In some embodiments, the IGFIR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 3. In some embodiments, the E/I binder comprises an amino acid sequence at least 80, 85, 90, 95, 98, or 100% identical to SEQ ID NOs: 126-133. 34 24039697_.DOC In some embodiments, an E/I binder is an antibody-like protein dimer comprising a) an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 13-22 of SEQ ID NO: 141, a DE loop having the amino acid sequence set forth in amino acids 43-48 of SEQ ID NO: 141, and an FG loop having the amino acid sequence set forth in amino acids 68-84 of SEQ ID NO: 141; covalently or non-covalently linked to b) an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 76-83 of SEQ ID NO: 3. In some embodiments, the EGFR binding 10 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 140, 141, 142 or 300. In some embodiments, the IGFIR binding ' 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 3. In some embodiments, the E/I binder comprises an amino acid sequence at least 80, 85, 90, 95, 98, or 100% identical to SEQ ID NOs: 149-154. In some embodiments, an E/I binder is an antibody-like protein dimer comprising a) an EGFR binding 10 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 13-22 of SEQ ID NO: 156, a DE loop having the amino acid sequence set forth in amino acids 43-48 of SEQ ID NO: 156, and an FG loop having the amino acid sequence set forth in amino acids 68-84 of SEQ ID NO: 156; covalently or non-covalently linked to b) an IGFIR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 76-83 of SEQ ID NO: 3. In some embodiments, the EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 155, 156, 157 or 305. In some embodiments, the IGFIR binding ' 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 3. In some embodiments, the E/I binder comprises an amino acid sequence at least 80, 85, 90, 95, 98, or 100% identical to SEQ ID NOs: 158-166. In some embodiments, an E/I binder is an antibody-like protein dimer comprising a) an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid 35 24039697 1.DOC sequence set forth in amino acids 13-22 of SEQ ID NO: 171, a DE loop having the amino acid sequence set forth in amino acids 43-48 of SEQ ID NO: 171, and an FG loop having the amino acid sequence set forth in amino acids 68-84 of SEQ ID NO: 171; covalently or non-covalently linked to b) an IGFIR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 76-83 of SEQ ID NO: 3. In some embodiments, the EGFR binding 10Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 170, 171, 172 or 311. In some embodiments, the IGFIR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 3. In some embodiments, the E/I binder comprises an amino acid sequence at least 80, 85, 90, 95, 98, or 100% identical to SEQ ID NOs: 179-184. In some embodiments, an E/I binder is an antibody-like protein dimer comprising a) an EGFR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 13-22 of SEQ ID NO: 186, a DE loop having the amino acid sequence set forth in amino acids 43-48 of SEQ ID NO: 186, and an FG loop having the amino acid sequence set forth in amino acids 68-84 of SEQ ID NO: 186; covalently or non-covalently linked to b) an IGFIR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 76-83 of SEQ ID NO: 3. In some embodiments, the EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 185, 186, 187 or 320. In some embodiments, the IGFIR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 3. In some embodiments, the E/I binder comprises an amino acid sequence at least 80, 85, 90, 95, 98, or 100% identical to SEQ ID NOs: 192-197. In some embodiments, an E/I binder is an antibody-like protein dimer comprising a) an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 13-22 of SEQ ID NO: 199, a DE loop having the amino acid sequence set forth in amino acids 43-48 of SEQ ID NO: 199, and an FG 36 24039697 I.DOC loop having the amino acid sequence set forth in amino acids 68-84 of SEQ ID NO: 199; covalently or non-covalently linked to b) an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 76-83 of SEQ ID NO: 3. In some embodiments, the EGFR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 198, 199, 200 or 327. In some embodiments, the IGFIR binding 1 0 Fn3 has an amino acid sequence at least 80, 90, 95, 98, or 100% identical to SEQ ID NO: 3. In some embodiments, the E/I binder comprises an amino acid sequence at least 80, 85, 90, 95, 98, or 100% identical to SEQ ID NOs: 205-210. In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); covalently or non-covalently linked to an EGFR binding 1"Fn3 comprising a BC loop having the amino acid sequence XgDSGRGSYQX (SEQ ID NO: 40), a DE loop having the amino acid sequence XiGPVHXj (SEQ ID NO: 42), and an FG loop having the amino acid sequence XkDHKPHADGPHTYHEX (SEQ ID NO: 44); wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k, and 1 are integers independently selected from 0 to 5. In some embodiments, a, g, and I are 2; b-f and i-k are 1; and h is zero. In some embodiments, a-l are zero. In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWDSGRGSYQ (SEQ ID NO: 39), a DE loop having the amino acid sequence PGPVHT (SEQ ID NO: 41), and an FG loop having the amino acid sequence TDHKPHADGPHTYHESP (SEQ ID NO: 43). 37 24039697 I.DOC In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); covalently or non-covalently linked to an EGFR binding 10Fn3 comprising a BC loop having the amino acid sequence XmVAGAEDYQXI, (SEQ ID NO: 34), a DE loop having the amino acid sequence XoHDLVXp (SEQ ID NO: 36), and an FG loop having the amino acid sequence XqDMMHVEYTEHX, (SEQ ID NO: 38); wherein X is any amino acid and a, b, c, d, e, f, m, n, o, p, q, and r are integers from 0 to 5, independently. In some embodiments, a and m are 2; b-f and o-r are 1; and n is zero. In some embodiments, a-f and m-r are zero. In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence SWVAGAEDYQ (SEQ ID NO: 33), a DE loop having the amino acid sequence PHDLVT (SEQ ID NO: 35), and an FG loop having the amino acid sequence TDMMHVEYTEHP (SEQ ID NO: 37). In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 10Fn3 comprising a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); covalently or non-covalently linked to an EGFR binding 10Fn3 comprising a BC loop having the amino acid sequence XsLPGKLRYQXt (SEQ ID NO: 60), a DE loop having the amino acid sequence XuHDLRXw (SEQ ID NO: 62), and an FG loop having the amino acid sequence XyNMMHVEYSEYXz (SEQ ID NO: 64); wherein X is any amino acid and a, b, c, d, e, f, s, t, u, w, y, and z are integers from 0 to 5, independently. In some 38 24039697_.DOC embodiments, a and s are 2; b-f, u, w, y and z are 1; and t is zero. In some embodiments, a-f, s-u, w, y and z are zero. In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 10 Fn3 comprising a BC loop having the amino acid sequence SWLPGKLRYQ (SEQ ID NO: 59), a DE loop having the amino acid sequence PHDLRT (SEQ ID NO: 61), and an FG loop having the amino acid sequence TNMMHVEYSEYP (SEQ ID NO: 63). In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XeKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); covalently or non-covalently linked to an EGFR binding J0Fn3 comprising a BC loop having the amino acid sequence XgHERDGSRQXh (SEQ ID NO: 134), a DE loop having the amino acid sequence XiGGVRXj (SEQ ID NO: 135), and an FG loop having the amino acid sequence XkDYFNPTTHEYIYQTTXI (SEQ ID NO: 136); wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k and 1 are integers from 0 to 5, independently. In some embodiments, a and g are 2; b-f and i-i are 1; and h is zero. In some embodiments, a-l are zero. In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWHERDGSRQ (SEQ ID NO: 109), a DE loop having the amino acid sequence PGGVRT (SEQ ID NO: 110), and an FG loop having the amino acid sequence TDYFNPTTHEYIYQTTP (SEQ ID NO: 111). 39 24039697_.DOC In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); covalently or non-covalently linked to an EGFR binding 10Fn3 comprising a BC loop having the amino acid sequence XgWAPVDRYQXh (SEQ ID NO: 137), a DE loop having the amino acid sequence XjRDVYXj (SEQ ID NO: 138), and an FG loop having the amino acid sequence XkDYKPHADGPHTYHESXI (SEQ ID NO: 139); wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k and 1 are integers from 0 to 5, independently. In some embodiments, a and g are 2; b-f and i-l are 1; and h is zero. In some embodiments, a-1 are zero. In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence SWWAPVDRYQ (SEQ ID NO: 115), a DE loop having the amino acid sequence PRDVYT (SEQ ID NO: 116), and an FG loop having the amino acid sequence TDYKPHADGPHTYHESP (SEQ ID NO: 117). In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); covalently or non-covalently linked to an EGFR binding '0Fn3 comprising a BC loop having the amino acid sequence XgTQGSTHYQXh (SEQ ID NO: 146), a DE loop having the amino acid sequence XiGMVYXj (SEQ ID NO: 147), and an FG loop having the amino acid sequence XkDYFDRSTHEYKYRTTX (SEQ ID NO: 148); wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k and 1 are integers from 0 to 5, independently. In some 40 24039697_.DOC embodiments, a and g are 2; b-f and i-i are 1; and h is zero. In some embodiments, a-i are zero. In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWTQGSTHYQ (SEQ ID NO: 143), a DE loop having the amino acid sequence PGMVYT (SEQ ID NO: 144), and an FG loop having the amino acid sequence TDYFDRSTHEYKYRTTP (SEQ ID NO: 145). In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); covalently or non-covalently linked to an EGFR binding 'OFn3 comprising a BC loop having the amino acid sequence XgYWEGLPYQXh (SEQ ID NO: 161), a DE loop having the amino acid sequence XiRDVNXj (SEQ ID NO: 162), and an FG loop having the amino acid sequence XkDWYNPDTHEYIYHTIX (SEQ ID NO: 163); wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k and 1 are integers from 0 to 5, independently. In some embodiments, a and g are 2; b-f and i-i are 1; and h is zero. In some embodiments, a-l are zero. In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 10Fn3 comprising a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWYWEGLPYQ (SEQ ID NO: 158), a DE loop having the amino acid sequence PRDVNT (SEQ ID NO: 159), and an FG loop having the amino acid sequence TDWYNPDTHEYIYHTIP (SEQ ID NO: 160). 41 24039697 1.DOC In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); covalently or non-covalently linked to an EGFR binding 10Fn3 comprising a BC loop having the amino acid sequence XgASNRGTYQXh (SEQ ID NO: 176), a DE loop having the amino acid sequence XiGGVSXj (SEQ ID NO: 177), and an FG loop having the amino acid sequence XkDAFNPTTHEYNYFTTX (SEQ ID NO: 178); wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k and 1 are integers from 0 to 5, independently. In some embodiments, a and g are 2; b-f and i-l are 1; and h is zero. In some embodiments, a-1 are zero. In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 10 Fn3 comprising a BC loop having the amino acid sequence SWASNRGTYQ (SEQ ID NO: 173), a DE loop having the amino acid sequence PGGVST (SEQ ID NO: 174), and an FG loop having the amino acid sequence TDAFNPTTHEYNYFTTP (SEQ ID NO: 175). In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 10Fn3 comprising a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); covalently or non-covalently linked to an EGFR binding 10Fn3 comprising a BC loop having the amino acid sequence XgDAPTSRYQXh (SEQ ID NO: 190), a DE loop having the amino acid sequence XiGGLSXj (SEQ ID NO: 191), and an FG loop having the amino acid sequence XkDYKPHADGPHTYHESXI (SEQ ID NO: 139); wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k and I are integers from 0 to 5, independently. In some 42 24039697 _DOC embodiments, a and g are 2; b-f and i-i are 1; and h is zero. In some embodiments, a-i are zero. In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWDAPTSRYQ (SEQ ID NO: 188), a DE loop having the amino acid sequence PGGLST (SEQ ID NO: 189), and an FG loop having the amino acid sequence TDYKPHADGPHTYHESP (SEQ ID NO: 117). In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); covalently or non-covalently linked to an EGFR binding Fn3 comprising a BC loop having the amino acid sequence XgDAGAVTYQXh (SEQ ID NO: 203), a DE loop having the amino acid sequence XiGGVRXj (SEQ ID NO: 135), and an FG loop having the amino acid sequence XkDYKPHADGPHTYHEYX (SEQ ID NO: 204); wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k and 1 are integers from 0 to 5, independently. In some embodiments, a and g are 2; b-f and i-1 are 1; and h is zero. In some embodiments, a-i are zero. In some embodiments, an E/I binder is an antibody-like protein dimer comprising an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWDAGAVTYQ (SEQ ID NO: 201), a DE loop having the amino acid sequence PGGVRT (SEQ ID NO: 110), and an FG loop having the amino acid sequence TDYKPHADGPHTYHEYP (SEQ ID NO: 202). 43 24039697 1.DOC In some embodiments, an E/I binder is an antibody-like protein dimer comprising a) an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 23-29 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 52-55 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 77-82 of SEQ ID NO: 3; covalently or non-covalently linked to b) an EGFR binding 10Fn3 comprising a BC, DE and FG loop as set forth in any one of SEQ ID NOs: 219-327 (see e.g., Figure 45 wherein the BC, DE and FG loop sequences for each EGFR binding 10Fn3 are underlined). In some embodiments, an E/I binder is an antibody-like protein dimer comprising a) an IGFIR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids 23-29 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 52-55 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 77-82 of SEQ ID NO: 3; covalently or non-covalently linked to b) an EGFR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence set forth in amino acids corresponding to amino acid residues 23-30 of SEQ ID NO: 1 of any one of SEQ ID NOs: 5-8, 52, 66-68, 106-108, 112-114, 140-142, 155-157, 170-172, 182, 185-187, 198-200, or 219-327, a DE loop having the amino acid sequence set forth in amino acids corresponding to amino acid residues 52-55 of SEQ ID NO: 1 of any one of SEQ ID NOs: 5-8, 52, 66-68, 106-108, 112-114, 140-142, 155-157, 170-172, 182, 185-187, 198-200, or 219-327, and an FG loop having the amino acid sequence set forth in amino acids corresponding to amino acid residues 77-86 of SEQ ID NO: 15 8, 52, 66-68, 106-108, 112-114, 140-142, 155-157, 170-172, 182, 185-187, 198-200, or 219-327. In some embodiments, the EGFR binding 10Fn3 of the antibody-like protein dimer comprises an amino acid sequence at least 80, 90, 95, or 100% identical to the amino acid sequence of amino acid residues corresponding to E9 of SEQ ID NO: 1 through T94 of SEQ ID NO: 1 of any one of SEQ ID NOs: 5-8, 52, 66-68, 106-108, 112-114, 140-142, 155-157, 170-172, 182, 185-187, 198-200, or 219-327. In some embodiments, the IGFIR binding 10Fn3 of the antibody-like protein dimer has an amino acid sequence at least 80, 90, 95, 98, 99, or 100% identical to the amino acid sequence of amino acid residues corresponding to E9 of SEQ ID NO: 1 through T94 of SEQ ID NO: 1 of SEQ ID NO: 3. In some 44 24039697_1.DOC embodiments, the E/I binder comprises an amino acid sequence at least 80, 85, 90, 95, 98, 99, or 100% identical to any one of SEQ ID NOs: 20-31, 53-58, 87-92, 98 105, 118-133, 149-154, 164-169, 179-184, 192-197, 205-210 and 211-216. Preferably, X as defined herein is a naturally occurring amino acid. In certain embodiments, the E binders, or the E and/or I monomers of the E/I binders described herein may contain a Ser to Cys amino acid substitution at a position corresponding to serine 62 or serine 91 of SEQ ID NO: 1. In certain aspects, the disclosure provides short peptide sequences that mediate EGFR binding. Examples of such sequences include the amino acid residues that correspond to the BC, DE, and FG loops from SEQ ID NOs: 5, 7, 82, 106, 112, 141, 156, 171, 186 and 199. Other examples of such sequences include the amino acid residues that correspond to the BC, DE, and FG loops from SEQ ID NOs: 219-327. In some embodiments, the peptides bind to their respective ligand with a dissociation constant (KD) of less than 500nM, 100nM, 50nM, 5nM or less. Such sequences may mediate ligand binding in an isolated form or when inserted into a particular protein structure, such as an immunoglobulin or immunoglobulin like domain. In one embodiment, an antibody-like protein dimer comprises a polypeptide having the structure A-B-C, wherein A is a polypeptide comprising, consisting essentially of, or consisting of a 1 0 Fn3 domain that binds to EGFR, B is a polypeptide linker, and C is a polypeptide comprising, consisting essentially of, or consisting of a 1 0 Fn3 domain that binds to IGF-IR. In another embodiment, a antibody-like protein dimer comprises a polypeptide having the structure A-B-C, wherein A is a polypeptide comprising, consisting essentially of, or consisting of a

'

0 Fn3 domain that binds to IGF-IR, B is a polypeptide linker, and C is a polypeptide comprising, consisting essentially of, or consisting of a ' 0 Fn3 domain that binds to EGFR. Specific examples of antibody-like protein dimers having the structure A-B C are polypeptides comprising (i) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 20-31, 53-58, 87-92, 98-105, 118-133, 149-154, 164-169, 179-184, 192-197, 205-210 and 211-216, or (ii) a polypeptide comprising an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, or 99% identical to any 45 24039697 _DOC one of the amino acid sequences set forth in SEQ ID NOs: 20-31, 53-58, 87-92, 98 105, 118-133, 149-154, 164-169, 179-184, 192-197,205-210and211-216. In certain embodiments, the A or C region is a polypeptide comprising a 1 0 Fn3 domain that binds to EGFR; wherein the 1 0 Fn3 domain has the structure from N-terminus to C-terminus: beta strand A, loop AB, beta strand B, loop BC, beta strand C, loop CD, beta strand D, loop DE, beta strand E, loop EF, beta strand F, loop FG, beta strand G; wherein: (i) the BC loop has the amino acid sequence of SEQ ID NO: 33 or 34, the DE loop has the amino acid sequence of SEQ ID NO: 35 or 36, and the FG loop has the amino acid sequence of SEQ ID NO: 37 or 38, (ii) the BC loop has the amino acid sequence of SEQ ID NO: 39 or 40, the DE loop has the amino acid sequence of SEQ ID NO: 41 or 42, and the FG loop has the amino acid sequence of SEQ ID NO: 43 or 44, (iii) the BC loop has the amino acid sequence of SEQ ID NO: 59 or 60, the DE loop has the amino acid sequence of SEQ ID NO: 61 or 62, and the FG loop has the amino acid sequence of SEQ ID NO: 63 or 64, (iv) the BC loop has the amino acid sequence of SEQ ID NO: 109 or 134, the DE loop has the amino acid sequence of SEQ ID NO: 110 or 135, and the FG loop has the amino acid sequence of SEQ ID NO: 111 or 136, (v) the BC loop has the amino acid sequence of SEQ ID NO: 115 or 137, the DE loop has the amino acid sequence of SEQ ID NO: 116 or 138, and the FG loop has the amino acid sequence of SEQ ID NO: 117 or 139, (vi) the BC loop has the amino acid sequence of SEQ ID NO: 143 or 146, the DE loop has the amino acid sequence of SEQ ID NO: 144 or 147, and the FG loop has the amino acid sequence of SEQ ID NO: 145 or 148, (vii) the BC loop has the amino acid sequence of SEQ ID NO: 158 or 161, the DE loop has the amino acid sequence of SEQ ID NO: 159 or 162, and the FG loop has the amino acid sequence of SEQ ID NO: 160 or 163, (viii) the BC loop has the amino acid sequence of SEQ ID NO: 173 or 176, the DE loop has the amino acid sequence of SEQ ID NO: 174 or 177, and the FG loop has the amino acid sequence of SEQ ID NO: 175 or 178, (ix) the BC loop has the amino acid sequence of SEQ ID NO: 188 or 190, the DE loop has the amino acid sequence of SEQ ID NO: 189 or 191, and the FG loop has the amino acid sequence of SEQ ID NO: 117 or 139, (x) the BC loop has the amino acid sequence of SEQ ID NO: 201 or 203, the DE loop has the amino acid sequence of SEQ ID NO: 110 or 135, and the FG loop has the amino 46 24039697 LDOC acid sequence of SEQ ID NO: 202 or 204, or (xi) the BC, DE and FG loops have the amino acid sequences as set forth in any one of SEQ ID NOs: 219-327 (see e.g., Figure 45 wherein the BC, DE and FG loops for each of SEQ ID NOs: 219-327 are underlined); wherein the ' 0 Fn3 domain folds into an antibody heavy chain variable region-like structure; and wherein the polypeptide binds to EGFR with a KD of less than 100 nM. The 1 0 Fn3 domain that binds to EGFR preferably folds into a structure wherein the 7 beta strands are distributed between two beta sheets that pack against each other forming a stable core and wherein the beta strands are connected by the six loops which are solvent exposed. In exemplary embodiments, the ' 0 Fn3 domain is from 80-150 amino acids in length. In exemplary embodiments, the A or C region is a 1 0 Fn3 domain that binds to EGFR with a KD of less than 100 nM having a sequence selected from the group consisting of SEQ ID NO: 83-85 and 466-472 as set forth below: EVVAATXnI SLLIXaiSWVAGAEDYQXa 2 YYRITYGEX2OEFTVXa 3 PHDLVTX 4 ATIXn 3 DYTITVYAVXa 5 TDMMHVEYTEHPXa 6 ISINYRT (SEQ ID NO: 83); EVVAATXi SLLIXai SWDSGRGSYQX 2 YYRITYGEXn2OEFTVXa 3 PGPVHTXa 4 ATIXn 3 DYTITVYAVXa 5 TDHKPHADGPHTYHESPXa 6 ISINYRT (SEQ ID NO: 84); or

EVVAATX,

1 SLLIXai SWLPGKLRYQXa 2 YYRITYGEXn,2QEFTVXa 3 PHDLRTXa 4 ATIXn 3 DYTITVYAVXasTNMMHVEYSEYPXa 6 ISINYRT (SEQ ID NO: 85). EVVAATXnilSLLIXaiSWHERDGSRQXa 2 YYRITYGEXn2OEFTVXa 3 PGGVRTXa 4 ATIXn 3 DYTITVYAVXa 5 TDYFNPTTHEYIYQTTPXa 6 ISINYRT (SEQ ID NO: 466). EVVAATXni SLLIXaiSWWAPVDRYQXa 2 YYRITYGEXn2OEFTVXa 3 PRDVYTX a 4

ATIX

3 DYTITVYAVXasTDYKPHADGPHTYHESPXa 6 ISINYRT (SEQ ID NO: 467). 47 24039697_.DOC EVVAATX1i SLLIXaiSWTQGSTHYQX 2 YYRITYGEXn 2 QEFTVXa 3 PGMVYTX a 4

ATIX

3 DYTITVYAVXaTDYFDRSTHEYKYRTTPXa 6 ISINYRT (SEQ ID NO: 468). EVVAATX1i SLLIXaiSWYWEGLPYQXa 2 YYRITYGEXn2QEFTVXa 3 PRDVNTX a 4

ATIX

3 DYTITVYAVXaTDWYNPDTHEYIYHTIPXa 6 ISINYRT (SEQ ID NO: 469).

EVVAATX

1 aiSLLIXa1SWASNRGTYQX 2 YYRITYGEXi2QEFTVXa 3 PGGVSTXa 4 ATIXn 3 DYTITVYAVXaTDAFNPTTHEYNYFTTPXa 6 ISINYRT (SEQ ID NO: 470). EVVAATXaiI SLLIXaiSWDAPTSRYQXa 2 YYRITYGEX2QEFTVXa 3 PGGLSTXa 4 ATIXn 3 DYTITVYAVXa 5 TDYKPHADGPHTYHESPXa 6 ISINYRT (SEQ ID NO: 471). EVVAATXaiiSLLIXaiSWDAGAVTYQXa 2 YYRITYGEXn 2 QEFTVXa 3 PGGVRTX a 4

ATIX

3 DYTITVYAVXaTDYKPHADGPHTYHEYPXa 6 ISINYRT (SEQ ID NO: 472). In SEQ ID NOs: 83-85 and 466-472, the BC, DE and FG loops have a fixed sequence as shown in bold, or a sequence at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the sequences shown in bold, the AB loop is represented by Xi, the CD is represented by X,2, and EF loop is represented by X' 3 , and the beta strands A-G are underlined. X represents any amino acid and the subscript following the X represents an integer of the number of amino acids. In particular, nl may be anywhere from 1-15, 2-15, 1-10, 2-10, 1-8, 2-8, 1-5, 2-5, 1-4, 2-4, 1-3, 2-3, or 1-2 amino acids; n2 and n3 may each independently be anywhere from 2-20, 2 15, 2-10, 2-8, 5-20, 5-15, 5-10, 5-8, 6-20, 6-15, 6-10, 6-8, 2-7, 5-7, or 6-7 amino acids; and al-a6 may each independently comprise from 0-10, 0-5, 1-10, 1-5, or 2-5 amino acids. In preferred embodiments, ni is 2 amino acids, n2 is 7 amino acids, n3 is 7 amino acids, and al-a6 is 0 amino acids. The sequences of the beta strands may 48 24039697 I.DOC have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, deletions or additions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 1. In an exemplary embodiment, the sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 conservative substitutions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 1. In certain embodiments, the core amino acid residues are fixed and any substitutions, conservative substitutions, deletions or additions occur at residues other than the core amino acid residues. In certain embodiments, the EGFR binder is represented by one of the following amino acid sequences: EVVAATPTSLLISWVAGAEDYQYYRITYGETGGNSPVQEFTVPHDLVTATIS GLKPGVDYTITVYAVTDMMHVEYTEHPISINYRT (SEQ ID NO: 66); EVVAATPTSLLISWDSGRGSYQYYRITYGETGGNSPVQEFTVPGPVHTATIS GLKPGVDYTITVYAVTDHKPHADGPHTYHESPISINYRT (SEQ ID NO: 67); EVVAATPTSLLISWLPGKLRYQYYRITYGETGGNSPVQEFTVPHDLRTATIS GLKPGVDYTITVYAVTNMMHVEYSEYPISINYRT (SEQ ID NO: 68); EVVAATPTSLLISWHERDGSRQYYRITYGETGGNSPVQEFTVPGGVRTATIS GLKPGVDYTITVYAVTDYFNPTTHEYIYQTTPISINYRT (SEQ ID NO: 108); or EVVAATPTSLLISWWAPVDRYQYYRITYGETGGNSPVQEFTVPRDVYTATI SGLKPGVDYTITVYAVTDYKPHADGPHTYHESPISINYRT (SEQ ID NO: 114). EVVAATPTSLLISWTQGSTHYQYYRITYGETGGNSPVQEFTVPGMVYTATI SGLKPGVDYTITVYAVTDYFDRSTHEYKYRTTPISINYRT (SEQ ID NO: 141) 49 24039697_I.DOC EVVAATPTSLLISWYWEGLPYQYYRITYGETGGNSPVQEFTVPRDVNTATI SGLKPGVDYTITVYAVTDWYNPDTHEYIYHTIPISINYRT (SEQ ID NO: 156) EVVAATPTSLLISWASNRGTYQYYRITYGETGGNSPVQEFTVPGGVSTATIS GLKPGVDYTITVYAVTDAFNPTTHEYNYFTTPISINYRT (SEQ ID NO: 171) EVVAATPTSLLISWDAPTSRYQYYRITYGETGGNSPVQEFTVPGGLSTATIS GLKPGVDYTITVYAVTDYKPHADGPHTYHESPISINYRT (SEQ ID NO: 186) E112 EVVAATPTSLLISWDAGAVTYQYYRITYGETGGNSPVQEFTVPGGVRTATI SGLKPGVDYTITVYAVTDYKPHADGPHTYHEYPISINYRT (SEQ ID NO: 199) In SEQ ID NOs: 66-68, 108, 114, 141, 156, 171, 186 and 199, the sequence of the BC, DE and FG loops have a fixed sequence as shown in bold, or a sequence at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the sequences shown in bold, and the remaining sequence which is underlined (e.g., the sequence of the 7 beta strands and the AB, CD and EF loops) has anywhere from 0 to 20, from 0 to 15, from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, conservative substitutions, deletions or additions relative to the corresponding amino acids shown in SEQ ID NO: 66-68, 108, 114, 141, 156, 171, 186 and 199. In certain embodiments, the core amino acid residues are fixed and any substitutions, conservative substitutions, deletions or additions occur at residues other than the core amino acid residues. The 1 0 Fn3 domain that binds to EGFR may optionally comprise an N-terminal extension of from 1-20, 1 15, 1-10, 1-8, 1-5, 1-4, 1-3, 1-2, or 1 amino acids in length. Exemplary N-terminal extensions include (represented by the single letter amino acid code) M, MG, G, MGVSDVPRDL (SEQ ID NO: 69), GVSDVPRDL (SEQ ID NO: 70), and VSDVPRDL (SEQ ID NO: 71), or N-terminal truncations of any one of SEQ ID NOs: 69, 70, or 71. Other suitable N-terninal extensions include, for example, XnSDVPRDL (SEQ ID NO: 72), XnDVPRDL (SEQ ID NO: 73), XnVPRDL (SEQ ID NO: 74), XnPRDL (SEQ ID NO: 75), XnRDL (SEQ ID NO: 76), XDL (SEQ ID 50 24039697_I.DOC NO: 77), or XL, wherein n = 0, 1 or 2 amino acids, wherein when n = 1, X is Met or Gly, and when n = 2, X is Met-Gly. The 1 0 Fn3 domain that binds to EGFR may optionally comprise a C-terminal tail. Exemplary C-terminal tails include polypeptides that are from 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, 1-2, or 1 amino acids in length. Specific examples of C-terminal tails include EIDKPSQ (SEQ ID NO: 9), EIDKPCQ (SEQ ID NO: 10), and EIDK (SEQ ID NO: 78). In other embodiments, suitable C-terminal tails may be a C-terminally truncated fragment of SEQ ID NOs: 9, 10 or 78, including, for example, one of the following amino acid sequences (represented by the single letter amino acid code): E, El, EID, EIDKP (SEQ ID NO: 79), EIDKPS (SEQ ID NO: 80), or EIDKPC (SEQ ID NO: 81). Other suitable C terminal tails include, for example, ES, EC, EGS, EGC, EGSGS (SEQ ID NO: 96), EGSGC (SEQ ID NO: 97), or EIEK (SEQ ID NO: 217). In certain embodiments, the ' 0 Fn3 domain that binds to EGFR comprises both an N-terninal extension and a C-terminal tail. In exemplary embodiments, the A region comprises an N-terminal extension beginning with Gly or Met-Gly and a C-terminal extension that does not contain a cysteine residue and the B region comprises an N-terminal extension that does not start with a Met and a C-terminal extension that comprises a cysteine residue. Specific examples of I 0 Fn3 domains that bind to EGFR are polypeptides comprising (i) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 5-8, 52, 66-68, 82-85, 106-108, 112-114, 140-142, 155-157, 170-172, 185-187, 198-200, and 219-327, or (ii) a polypeptide comprising an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 5-8, 52, 66-68, 82-85, 106-108, 112 114, 140-142, 155-157, 170-172, 185-187, 198-200, and 219-327. In certain embodiments, the A or C region is a polypeptide comprising a 1 0 Fn3 domain that binds to IGF-IR, wherein the 1 0 Fn3 domain has the structure from N-terminus to C-terminus: beta strand A, loop AB, beta strand B, loop BC, beta strand C, loop CD, beta strand D, loop DE, beta strand E, loop EF, beta strand F, loop FG, beta strand G, wherein the BC loop has the amino acid sequence of SEQ ID NO: 45 or 46, the DE loop has the amino acid sequence of SEQ ID NO: 47 or 48, and the FG loop has the amino acid sequence of SEQ ID NO: 49 or 50, wherein the 1 0 Fn3 domain folds into an antibody heavy chain variable region-like structure, and 51 24039697 _DOC wherein the polypeptide binds to IGF-IR with a KD of less than 100 nM. The 1 0 Fn3 domain that binds to IGF-IR preferably folds into a structure wherein the 7 beta strands are distributed between two beta sheets that pack against each other forming a stable core and wherein the beta strands are connected by the six loops which are solvent exposed. In exemplary embodiments, the ' 0 Fn3 domain is from 80-150 amino acids in length. In exemplary embodiments, the A or C region is a 1 0 Fn3 domain that binds to IGF-IR with a KD of less than 100 nM having the sequence set forth below: EVVAATXI SL LIXaiSWSARLKVARXa 2 YYRITYGEXn 2 QEFTVXa 3 PKNVYTXa 4 ATIXn 3 DYTITVYAVXa 5 TRFRDYQPXa 6 ISINYRT (SEQ ID NO: 86). In SEQ ID NO: 86, the BC, DE and FG loops have a fixed sequence as shown in bold, or a sequence at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the sequences shown in bold, the AB loop is represented by X,,i, the CD loop is represented by Xn 2 , and the EF loop is represented by Xn 3 , and the beta strands A-G are underlined. X represents any amino acid and the subscript following the X represents an integer of the number of amino acids. In particular, n1 may be anywhere from 1-15, 2-15, 1-10, 2-10, 1-8, 2-8, 1-5, 2-5, 1-4, 2-4, 1-3, 2-3, or 1-2 amino acids; n2 and n3 may each independently be anywhere from 2-20, 2-15, 2-10, 2-8, 5-20, 5-15, 5-10, 5-8, 6-20, 6-15, 6-10, 6-8, 2-7, 5-7, or 6-7 amino acids; and al-a6 may each independently comprise from 0-10, 0-5, 1-10, 1-5, or 2-5 amino acids. In preferred embodiments, nl is 2 amino acids, n2 is 7 amino acids, n3 is 7 amino acids, and al-a6 is 0 amino acids. The sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, deletions or additions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 1. In an exemplary embodiment, the sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 conservative substitutions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 1. In certain embodiments, the core amino acid residues are fixed and any substitutions, conservative 52 24039697_I.DOC substitutions, deletions or additions occur at residues other than the core amino acid residues. In certain embodiments, the IGF-IR binder is represented by the following amino acid sequence: EVVAATPTSLLISWSARLKVARYYRITYGETGGNSPVQEFTVPKNVYTATIS GLKPGVDYTITVYAVTRFRDYQPISINYRT (SEQ ID NO: 65). In SEQ ID NO: 65, the sequence of the BC, DE and FG loops have a fixed sequence as shown in bold, or a sequence at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the sequences shown in bold, and the remaining sequence which is underlined (e.g., the sequence of the 7 beta strands and the AB, CD and EF loops) has anywhere from 0 to 20, from 0 to 15, from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, conservative substitutions, deletions or additions relative to the corresponding amino acids shown in SEQ ID NO: 65. In certain embodiments, the core amino acid residues are fixed and any substitutions, conservative substitutions, deletions or additions occur at residues other than the core amino acid residues. The "Fn3 domain that binds to IGF-IR may optionally comprise an N-terminal extension of from 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, 1-2, or 1 amino acids in length. Exemplary N-terminal extensions include (represented by the single letter amino acid code) M, MG, G, MGVSDVPRDL (SEQ ID NO: 69), GVSDVPRDL (SEQ ID NO: 70), and VSDVPRDL (SEQ ID NO: 71), or N-terminal truncations of any one of SEQ ID NOs: 69, 70, or 71. Other suitable N-terminal extensions include, for example, XnSDVPRDL (SEQ ID NO: 72), X,,DVPRDL (SEQ ID NO: 73), XnVPRDL (SEQ ID NO: 74), XIPRDL (SEQ ID NO: 75), XnRDL (SEQ ID NO: 76), XDL (SEQ ID NO: 77), or XnL, wherein n = 0, 1 or 2 amino acids, wherein when n = 1, X is Met or Gly, and when n = 2, X is Met-Gly. The 1 0 Fn3 domain that binds to IGF-IR may optionally comprise a C-terminal tail. Exemplary C-terminal tails include polypeptides that are from 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, 1-2, or 1 amino acids in length. Specific examples of C-terminal tails include EIDKPSQ (SEQ ID NO: 9), EIDKPCQ (SEQ ID NO: 10), and EIDK (SEQ ID NO: 78). In other embodiments, suitable C-terminal tails may be a C-terminally truncated fragment of SEQ ID NOs: 53 24039697 i.DOC 9, 10 or 78, including, for example, one of the following amino acid sequences (represented by the single letter amino acid code): E, El, EID, EIDKP (SEQ ID NO: 79), EIDKPS (SEQ ID NO: 80), or EIDKPC (SEQ ID NO: 81). Other suitable C terminal tails include, for example, ES, EC, EGS, EGC, EGSGS (SEQ ID NO: 96), EGSGC (SEQ ID NO: 97), or EIEK (SEQ ID NO: 217). In certain embodiments, the 10 Fn3 domain that binds to IGF-IR comprises both an N-terminal extension and a C-terminal tail. In exemplary embodiments, the A region comprises an N-terminal extension beginning with Gly or Met-Gly and a C-terminal extension that does not contain a cysteine residue and the B region comprises an N-terminal extension that does not start with a Met and a C-terminal extension that comprises a cysteine residue. Specific examples of 1 0 Fn3 domains that bind to IGF-IR are polypeptides comprising (i) a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 3, 4, 65 or 86, or (ii) a polypeptide comprising an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 3, 4, 65 or 86. The B region is a linker as described further herein. In exemplary embodiments, the B region is a polypeptide linker. Exemplary polypeptide linkers include polypeptides having from 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, or 1-2 amino acids. Specific examples of suitable polypeptide linkers are described further herein and include, for example, linkers having a sequence selected from the group consisting of SEQ ID NOs: 11-19, 51, 93-95 and 218. In certain embodiments, the linker may be a C-terminal tail polypeptide as described herein, an N-terminal extension polypeptide as described herein, or a combination thereof In one embodiment, an antibody-like protein dimer comprises a polypeptide having the structure XI-A-X 2

-B-X

3

-C-X

4 , wherein X 1 is an optional N-terminal extension, A is a 1 0 Fn3 domain that binds to EGFR, X 2 is an optional C-terminal tail, B is a polypeptide linker, X 3 is an optional N-terminal extension, C is a ' 0 Fn3 domain that binds to IGF-IR, and X 4 is an optional C-terminal tail. In another embodiment, an antibody-like protein dimer comprises a polypeptide having the structure Xi-A-X 2

-B-X

3

-C-X

4 , wherein X, is an optional N-terminal extension, A is a Fn3 domain that binds to IGF-IR, X 2 is an optional C-terminal tail, B is a polypeptide linker, X 3 is an optional N-terminal extension, C is a 1 0 Fn3 domain that 54 24039697_1.DOC binds to EGFR, and X 4 is an optional C-terminal tail. Specific examples of suitable N-terminal extensions and C-terminal tails are described above. In certain embodiments, one or more of Xi, X 2 , B, X 3 or X 4 may comprise an amino acid residue suitable for pegylation, such as a cysteine or lysine residue. In exemplary embodiments, X 4 comprises at least one amino acid suitable for pegylation, such as a cysteine or lysine residue. Specific examples of suitable polypeptide linkers are described further below. Specific examples of antibody-like protein dimers having the structure X 1

-A-X

2

-B-X

3

-C-X

4 are polypeptides comprising (i) a polypeptide having the amino acid sequence set forth in any one of SEQ ID NOs: 20-31, 53-58, 87-92, 98-105, 118-133, 149-154, 164-169, 179-184, 192-197, 205-210 and 211 216, or (ii) a polypeptide comprising an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 20-31, 53-58, 87-92, 98-105, 118-133, 149-154, 164-169, 179-184, 192-197, 205-210 and 211-216. In certain embodiments, it may be desirable to tune the potency of one " 0 Fn3 binding domain relative to the other ' 0 Fn3 binding domain in the antibody-like protein dimers described herein. For example, if the binding affinity of the first 10 Fn3 domain is significantly higher than the binding affinity of the second 14Fn3 domain, the biological effect of the first 14Fn3 domain could overwhelm the effects of the second of second ' 0 Fn3 domain. Accordingly, in certain embodiments, it may be desirable for the binding affinities of the first and second ' 0 Fn3 domains of an antibody-like protein dimer to be similar to each other, e.g., binding affinities within 100-fold, 30-fold, 10-fold, 3-fold, 1-fold, 0.3-fold or 0.1-fold, of each other, or binding affinities within 0.1-fold to 10-fold, within 0.3-fold to 10-fold, within 0.1 fold to 3-fold, within 0.3-fold to 3-fold, within 0.1-fold to 1-fold, within 0.3-fold to 1-fold, within 1-fold to 10-fold, within 3-fold to 10-fold, within 3-fold to 30-fold, or within 1-fold to 3-fold of each other. Conjugation Multimers of antibody-like proteins may be covalently or non-covalently linked. In some embodiments, an EGFR binding 1 0 Fn3 may be directly or indirectly linked to an IGFIR binding 1 0 Fn3 via a polypeptide linker. Suitable linkers for joining Fn3 are those which allow the separate domains to fold independently of 55 24039697_1.DOC each other forming a three dimensional structure that permits high affinity binding to a target molecule. The disclosure provides a number of suitable linkers that meet these requirements, including glycine-serine based linkers, glycine-proline based linkers, as well as the linker having the amino acid sequence PSTSTST (SEQ ID NO: 12). The Examples described herein demonstrate that Fn3 domains joined via polypeptide linkers retain their target binding function. In some embodiments, the linker is a glycine-serine based linker. These linkers comprise glycine and serine residues and may be between 8 and 50, 10 and 30, and 10 and 20 amino acids in length. Examples include linkers having an amino acid sequence GSGSGSGSGSGSGSGSGSGS (SEQ ID NO: 11), GSGSGSGSGS (SEQ ID NO: 13), GGGGS GGGGS GGGGS (SEQ ID NO: 14), GGGGS GGGGS GGGGS GGGGS (SEQ ID NO: 15), GGGGS GGGGS GGGGS GGGGS GGGGS (SEQ ID NO: 16), or GGGGSGGGGSGGGSG (SEQ ID NO: 17). In some embodiments, the linker is a glycine-proline based linker. These linkers comprise glycine and proline residues and may be between 3 and 30, 10 and 30, and 3 and 20 amino acids in length. Examples include linkers having an amino acid sequence GPGPGPG (SEQ ID NO: 18), GPGPGPGPGPG (SEQ ID NO: 19), and GPG (SEQ ID NO: 51). In some embodiments, the linker is a proline-alanine based linker. These linkers comprise proline and alanine residues and may be between 3 and 30, 10 and 30, 3 and 20 and 6 and 18 amino acids in length. Examples of such linkers include SEQ ID NOs: 93, 94 and 95. It is contemplated, that the optimal linker length and amino acid composition may be determined by routine experimentation by methods well known in the art. In some embodiments, multimers of antibody-like proteins are linked via a polypeptide linker having a protease site that is cleavable by a protease in the blood or target tissue. Such embodiments can be used to release two or more therapeutic proteins for better delivery or therapeutic properties or more efficient production compared to separately producing such proteins. Additional linkers or spacers, e.g., SEQ ID NOs: 9 and 10, may be introduced at the C-terminus of a Fn3 domain between the Fn3 domain and the 56 24039697 .DOC polypeptide linker. Additional linkers or spacers may be introduced at the N terminus of a Fn3 domain between the Fn3 domain and the polypeptide linker. In some embodiments, multimers of antibody-like proteins may be directly or indirectly linked via a polymeric linker. Polymeric linkers can be used to optimally vary the distance between each protein moiety to create a protein with one or more of the following characteristics: 1) reduced or increased steric hindrance of binding of one or more protein domain when binding to a protein of interest, 2) increased protein stability or solubility, 3) decreased protein aggregation, and 4) increased overall avidity or affinity of the protein. In some embodiments, multimers of antibody-like proteins are linked via a biocompatible polymer such as a polymeric sugar. The polymeric sugar can include an enzymatic cleavage site that is cleavable by an enzyme in the blood or target tissue. Such embodiments can be used to release two or more therapeutic proteins for better delivery or therapeutic properties or more efficient production compared to separately producing such proteins In some embodiments, multimers of antibody-like proteins are linked via a polyoxyalkylene, in particular a polyethylene glycol (PEG) moiety. Antibody-like proteins may comprise a cysteine containing linker, such as the linker set forth in SEQ ID NO: 10, 81, 97 or 218. PEG may be conjugated to the cysteine moiety in the linker sequence and may operably link the two domains. Pharmacokinetic moieties In one aspect, the disclosure provides E binders and E/I binders further comprising a pharmacokinetic (PK) moiety. In some embodiments, the E/I binder is a multimer of antibody-like proteins, in particular, a dimer of an EGFR binding 10Fn3 and an IGFIR binding 10Fn3. Improved pharmacokinetics may be assessed according to the perceived therapeutic need. Often it is desirable to increase bioavailability and/or increase the time between doses, possibly by increasing the time that a protein remains available in the serum after dosing. In some instances, it is desirable to improve the continuity of the serum concentration of the protein over time (e.g., decrease the difference in serum concentration of the protein shortly after administration and shortly before the next administration). E binders and E/I binders may be attached to a moiety that reduces the clearance rate of the polypeptide in a 57 24039697_.DOC mammal (e.g., mouse, rat, or human) by greater than three-fold relative to the unmodified polypeptide. Other measures of improved pharmacokinetics may include serum half-life, which is often divided into an alpha phase and a beta phase. Either or both phases may be improved significantly by addition of an appropriate moiety. Moieties that tend to slow clearance of a protein from the blood include polyoxyalkylene moieties (e.g., polyethylene glycol); sugars (e.g., sialic acid); and well-tolerated protein moieties (e.g., Fc, Fc fragments, transferrin, or serum albumin). In some embodiments, the PK moiety is a serum albumin binding protein such as those described in U.S. Publication Nos. 2007/0178082 and 2007/0269422. In some embodiments, the PK moiety is a serum immunoglobulin binding protein such as those described in U.S. Publication No. 2007/0178082. In some embodiments, the PK moiety is polyethylene glycol (PEG). The serum clearance rate of a PK-modified antibody-like protein multimer may be decreased by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or even 90%, relative to the clearance rate of the unmodified E/I binders. The PK-modified multimer may have a half-life (t 1

/

2 ) which is enhanced relative to the half-life of the unmodified multimer. The half-life of PK- binding polypeptide may be enhanced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 400% or 500%, or even by 1000% relative to the half life of the unmodified multimer. In some embodiments, the multimer half-life is determined in vitro, such as in a buffered saline solution or in serum. In other embodiments, the multimer half-life is an in vivo half life, such as the half-life of the multimer in the serum or other bodily fluid of an animal. In some embodiments, a PK moiety is linked to an antibody-like protein multimer via at least one disulfide bond, a peptide bond, a polypeptide, a polymeric sugar, or a polyethylene glycol moiety. Exemplary polypeptide linkers include PSTSTST (SEQ ID NO: 12), EIDKPSQ (SEQ ID NO: 9), and GS linkers, such as GSGSGSGSGS (SEQ ID NO: 13) and multimers thereof 58 24039697 1DOC Binding/Screening The disclosure provides E binders and E/I binders, in particular, antibody like protein multimers such as a dimer of an EGFR binding 1 0 Fn3 and an IGFIR binding 1 0 Fn3. Binding to EGFR or IGFIR may be assessed in terms of equilibrium constants (e.g., dissociation, KD) and in terms of kinetic constants (e.g., on rate constant, kon and off rate constant, koff). In some embodiments, an antibody-like protein monomer or multimer will bind to EGFR with a KD of less than 500nM, 1OOnM, 50nM, 5nM or less. In some embodiments, an antibody-like protein multimer will bind to IGFIR with a KD of less than 500nM, 1OOnM, 50nM, 5nM or less. Higher KD values may be tolerated where the koff is sufficiently low or the kon is sufficiently high. E binders and E/I binders may bind to any part of EGFR, including the extracellular domain of a EGFR, in particular the ligand binding domain of EGFR. Binding of E binders and E/I binders to EGFR may disrupt the interaction of EGFR with one or more ligands, including TGF-alpha and EGF, and/or disrupt receptor dimerization. In some embodiments, E binders and E/I binders compete with an anti-EGFR antibody for binding to EGFR. The anti-EGFR antibody may be selected from any known anti-EGFR antibody including panitumumab (Amgen), nimotuzumab (YM Biosciences), zalutumumab (Genmab), EMD72000 (Merck KGaA), and cetuximab (ImClone Systems). In some embodiments, E binders and E/I binders inhibit downstream signaling of EGFR. EGFR ligand binding leads to homo- or heterodimeric receptor dimerization with EGFR or another HER family member. Dimerization promotes receptor autophosphorylation, which in turn leads to the activation of several signaling pathways. E/I binders may bind to any part of IGFIR, including the extracellular domain of a IGFIR, in particular the ligand binding domain of IGFIR. Binding of E/I binders to IGFIR may disrupt the interaction of IGFIR with one or more ligands, e.g., IGF-I and IGF-II; and/or disrupt assembly of receptor heterotetramers. In some embodiments, E/I binders compete with an anti-IGFIR antibody for binding to IGFIR. The anti-IGFIR antibody may be selected from any known anti-IGFIR antibody. 59 24039697_.DOC In some embodiments, E/I binders inhibit downstream signaling of IGFIR. The IGF-I receptor is composed of two types of subunits: an alpha subunit (a 130 135 kDa protein that is entirely extracellular and functions in ligand binding) and a beta subunit (a 95-kDa transmembrane protein, with transmembrane and cytoplasmic domains). IGFIR is initially synthesized as a single chain proreceptor polypeptide that is processed by glycosylation, proteolytic cleavage, and covalent bonding to assemble into a mature 460-kDa heterotetramer comprising two alpha subunits and two beta-subunits. The beta subunit(s) possesses ligand-activated tyrosine kinase activity. EGFR and IGFIR receptor signaling independently activates the MAPK pathway, including the phosphorylation of MEK. Another activated pathway is the phosphatidylinositol 3-kinase (P13K) pathway, including phosphorylation of AKT. Receptor signaling is transduced to the nucleus, resulting in the activation of various transcription factors. Screening assays may be designed to identify and characterize E binders and E/I binders. Binding assays, such as surface plasmon resonance and ELISA, and assays that detect activated signaling pathways are well-known in the art, see e.g., Example 5. Various antibodies, including many that are commercially available, have been produced which specifically bind to phosphorylated, activated isoforms of EGFR and IGFIR, see e.g., Examples 6 and 7. Downstream signaling events may also be used as an indicator of receptor inhibition, such as by measuring levels of AKT phosphorylation, see e.g., Example 8. Cell proliferation assays are also a useful method for characterizing the ability of candidate E/I binders to bind and inhibit EGFR and IGFIR signaling, see e.g., Example 9. Polymer conjugation Conjugation to a biocompatible polymer may be used to link antibody-like protein multimers and/or to improve the pharmacokinetics of the proteins. The identity, size and structure of the polymer is selected so as to improve the circulation half-life of the multimer or decrease the antigenicity of the multimer without an unacceptable decrease in activity. Examples of polymers useful in the invention include, but are not limited to, poly(alkylene glycols) such as polyethylene glycol (PEG). The polymer is not 60 24039697 _DOC limited to a particular structure and can be linear (e.g., alkoxy PEG or bifunctional PEG), or non-linear such as branched, forked, multi-armed (e.g., PEGs attached to a polyol core), and dendritic. Typically, PEG and other water-soluble polymers (i.e., polymeric reagents) are activated with a suitable activating group appropriate for coupling to a desired site on the polypeptide. Thus, a polymeric reagent will possess a reactive group for reaction with the polypeptide. Representative polymeric reagents and methods for conjugating these polymers to an active moiety are well-known in the art and further described in Zalipsky, S., et al., "Use of Functionalized Poly(Ethylene Glycols) for Modification of Polypeptides" in Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications, J. M. Harris, Plenus Press, New York (1992), and in Zalipsky (1995) Advanced Drug Reviews 16: 157-182. Typically, the weight-average molecular weight of the polymer is from about 100 Daltons to about 150,000 Daltons. Exemplary weight-average molecular weights for the biocompatible polymer include about 20,000 Daltons, about 40,000 Daltons, about 60,000 Daltons and about 80,000 Daltons. Branched versions of the biocompatible polymer having a total molecular weight of any of the foregoing can also be used. In some embodiments, the polymer is PEG. PEG is a well-known, water soluble polymer that is commercially available or can be prepared by ring-opening polymerization of ethylene glycol according to methods well known in the art (Sandler and Karo, Polymer Synthesis, Academic Press, New York, Vol. 3, pages 138-161). The term "PEG" is used broadly to encompass any polyethylene glycol molecule, without regard to size or to modification at an end of the PEG, and can be represented by the formula: X-O(CH 2

CH

2 O)n 1

CH

2

CH

2 OH, where n is 20 to 2300 and X is H or a terminal modification, e.g., a C1A alkyl. PEG can contain further chemical groups which are necessary for binding reactions, which result from the chemical synthesis of the molecule; or which act as a spacer for optimal distance of parts of the molecule. In addition, such a PEG can consist of one or more PEG side chains which are linked together. PEGs with more than one PEG chain are called multiarmed or branched PEGs. Branched PEG are described in, for example, European Published Application No. 473084A and U.S. Patent No. 5,932,462. 61 24039697 1.DOC To effect covalent attachment of the polymer molecule(s) to a polypeptide, the hydroxyl end groups of the polymer molecule must be provided in activated form, i.e. with reactive functional groups. Suitably activated polymer molecules are commercially available, e.g. from Nektar Therapeutics, Inc., Huntsville, Ala., USA; PolyMASC Pharmaceuticals plc, UK; or SunBio Corporation, Anyang City, South Korea. Alternatively, the polymer molecules can be activated by conventional methods known in the art, e.g. as disclosed in WO 90/13540. Specific examples of activated PEG polymers include the following linear PEGs: NHS-PEG, SPA-PEG, SSPA-PEG, SBA-PEG, SS-PEG, SSA-PEG, SC-PEG, SG-PEG, SCM-PEG, NOR PEG, BTC-PEG, EPOX-PEG, NCO-PEG, NPC-PEG, CDI-PEG, ALD-PEG, TRES PEG, VS-PEG, OPSS-PEG, IODO-PEG, and MAL-PEG, and branched PEGs, such as PEG2-NHS, PEG2-MAL, and those disclosed in U.S. Pat. No. 5,932,462 and U.S. Pat. No. 5,643,575, both of which are incorporated herein by reference. In some embodiments where PEG molecules are conjugated to cysteine residues on an antibody-like protein multimer, the cysteine residues are native to the protein, whereas in other embodiments, one or more cysteine residues are engineered into the protein. Mutations may be introduced into a protein coding sequence to generate cysteine residues. This might be achieved, for example, by mutating one or more amino acid residues to cysteine. Preferred amino acids for mutating to a cysteine residue include serine, threonine, alanine and other hydrophilic residues. Preferably, the residue to be mutated to cysteine is a surface exposed residue. Algorithms are well-known in the art for predicting surface accessibility of residues based on primary sequence or a protein. Alternatively, surface residues may be predicted by comparing the amino acid sequences of binding polypeptides, given that the crystal structure of the framework based on which binding polypeptides are designed and evolved has been solved (see Himanen et al., Nature. (2001) 20-27;414(6866):933-8) and thus the surface-exposed residues identified. In some embodiments, cysteine residues are introduced into antibody like protein multimers at or near the N- and/or C-terminus, or within loop regions. Pegylation of cysteine residues may be carried out using, for example, PEG maleiminde, PEG-vinylsulfone, PEG-iodoacetamide, or PEG-orthopyridyl disulfide. In some embodiments, the pegylated antibody-like protein multimer 62 24039697_1.DOC comprises a PEG molecule covalently attached to the alpha amino group of the N terminal amino acid. Site specific N-terminal reductive amination is described in Pepinsky et al., (2001) JPET, 297,1059, and U.S. Patent No. 5,824,784. The use of a PEG-aldehyde for the reductive amination of a protein utilizing other available nucleophilic amino groups is described in U.S. Patent No. 4,002,531, in Wieder et al., (1979) J. Biol. Chem. 254,12579, and in Chamow et al., (1994) Bioconjugate Chem. 5, 133. In another embodiment, pegylated antibody-like protein multimer comprises one or more PEG molecules covalently attached to a linker, which in turn is attached to the alpha amino group of the amino acid residue at the N-terminus of the binding polypeptide. Such an approach is disclosed in U.S. Publication No. 2002/0044921 and PCT Publication No. WO 94/0145 1. In some embodiments, an antibody-like protein multimer is pegylated at the C-terminus. A protein may be pegylated at the C-terminus by the introduction of C terminal azido-methionine and the subsequent conjugation of a methyl-PEG triarylphosphine compound via the Staudinger reaction. This C-terminal conjugation method is described in Cazalis et al., C-Terminal Site-Specific PEGylation of a Truncated Thrombomodulin Mutant with Retention of Full Bioactivity, Bioconjug Chem. 2004;15(5):1005-1009. Conventional separation and purification techniques known in the art can be used to purify PEGylated antibody-like protein multimers, such as size exclusion (e.g., gel filtration) and ion exchange chromatography. Products may also be separated using SDS-PAGE. Products that may be separated include mono-, di-, tri , poly- and un- pegylated binding polypeptide, as well as free PEG. The percentage of mono-PEG conjugates can be controlled by pooling broader fractions around the elution peak to increase the percentage of mono-PEG in the composition. About ninety percent mono-PEG conjugates represents a good balance of yield and activity. In some embodiments, the pegylated antibody-like protein multimers will preferably retain at least about 25%, 50%, 60%, 70%, 80%, 85%, 90%, 95% or 100% of the biological activity associated with the unmodified protein. In some embodiments, biological activity refers to its ability to bind to EGFR and IGFIR, as 63 24039697_1.DOC assessed by KD, kon or koff. In some embodiments, the pegylated antibody-like protein multimer shows an increase in binding to EGFR and/or IGFIR relative to unpegylated protein. Deimmunization of binding polypeptides The amino acid sequences of E binders and E/I binders, in particular, antibody-like protein multimers, such as a dimer of an EGFR binding 1OFn3 and an IGFIR binding 1 0 Fn3, may be altered to eliminate one or more B- or T-cell epitopes. A protein, or a multimer of proteins, may be deimmunized to render it non immunogenic, or less immunogenic, to a given species. Deimmunization can be achieved through structural alterations to the protein. Any deimmunization technique known to those skilled in the art can be employed, see e.g., WO 00/34317, the disclosure of which is incorporated herein in its entirety. In one embodiment, the sequences of the E binders and E/I binders can be analyzed for the presence of MHC class II binding motifs. For example, a comparison may be made with databases of MHC-binding motifs such as, for example by searching the "motifs" database on the worldwide web at sitewehil.wehi.edu.au. Alternatively, MHC class II binding peptides may be identified using computational threading methods such as those devised by Altuvia et al. (J. Mol. Biol. 249 244-250 (1995)) whereby consecutive overlapping peptides from the polypeptide are testing for their binding energies to MHC class II proteins. Computational binding prediction algorithms include iTope TM, Tepitope, SYFPEITHI, EpiMatrix (EpiVax), and MHCpred. In order to assist the identificationof MHC class I-binding peptides, associated sequence features which relate to successfully presented peptides such as amphipathicity and Rothbard motifs, and cleavage sites for cathepsin B and other processing enzymes can be searched for. Having identified potential (e.g. human) T-cell epitopes, these epitopes are then eliminated by alteration of one or more amino acids, as required to eliminate the T-cell epitope. Usually, this will involve alteration of one or more amino acids within the T-cell epitope itself. This could involve altering an amino acid adjacent the epitope in terms of the primary structure of the protein or one which is not adjacent in the primary structure but is adjacent in the secondary structure of the 64 24039697_.DOC molecule. The usual alteration contemplated will be amino acid substitution, but it is possible that in certain circumstances amino acid addition or deletion will be appropriate. All alterations can be accomplished by recombinant DNA technology, so that the final molecule may be prepared by expression from a recombinant host, for example by well established methods, but the use of protein chemistry or any other means of molecular alteration may also be used. Once identified T-cell epitopes are removed, the deimmunized sequence may be analyzed again to ensure that new T-cell epitopes have not been created and, if they have, the epitope(s) can be deleted. Not all T-cell epitopes identified computationally need to be removed. A person skilled in the art will appreciate the significance of the "strength" or rather potential immunogenicity of particular epitopes. The various computational methods generate scores for potential epitopes. A person skilled in the art will recognize that only the high scoring epitopes may need to be removed. A skilled person will also recognize that there is a balance between removing potential epitopes and maintaining binding affinity of the protein. Therefore, one strategy is to sequentially introduce substitutions into the protein and then test for antigen binding and immunogenicity. In one aspect, the deimmunized protein is less immunogenic (or rather, elicits a reduced HAMA response) than the original protein in a human subject. Assays to determine immunogenicity are well within the knowledge of the skilled person. Art-recognized methods of determining immune response can be performed to monitor a HAMA response in a particular subject or during clinical trials. Subjects administered deimmunized protein can be given an immunogenicity assessment at the beginning and throughout the administration of said therapy. The HAMA response is measured, for example, by detecting antibodies to the deimmunized protein in serum samples from the subject using a method known to one in the art, including surface plasmon resonance technology (BlAcore) and/or solid-phase ELISA analysis. Alternatively, in vitro assays designed to measure a T cell activation event are also indicative of immunogenicity. 65 24039697 1.DOC Additional Modifications In certain embodiments, E binders and E/I binders, in particular, antibody like protein multimers such as a dimer of an EGFR binding 1 0 Fn3 and an IGFIR binding 1 0 Fn3, may further comprise post-translational modifications. Exemplary post-translational protein modification include phosphorylation, acetylation, methylation, ADP-ribosylation, ubiquitination, glycosylation, carbonylation, sumoylation, biotinylation or addition of a polypeptide side chain or of a hydrophobic group. As a result, the modified E binders and E/I binders may contain non-amino acid elements, such as lipids, poly- or mono-saccharide, and phosphates. A preferred form of glycosylation is sialylation, which conjugates one or more sialic acid moieties to the polypeptide. Sialic acid moieties improve solubility and serum half-life while also reducing the possible immunogenicity of the protein. See, e.g., Raju et al. Biochemistry. 2001 Jul 31;40(30):8868-76. Effects of such non-amino acid elements on the functionality of an E binder or E/I binder may be tested for its antagonizing role in EGFR and IGFIR signaling function. In some embodiments, E binders and E/I binders are modified to enhance antigen-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC). In some embodiments, the E/I binder is a dimer of an EGFR binding 1 0 Fn3 and an IGFIR binding ' 0 Fn3, further comprising an Fe region. In some embodiments, the Fc region is a variant that enhances ADCC or CDC. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g., a substitution) at one or more amino acid positions, including positions 256, 290, 298, 312, 326, 330, 333, 334, 360, 378 or 430, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat. Vectors & Polynucleotides Embodiments Also included in the present disclosure are nucleic acid sequences encoding any of the proteins described herein. As appreciated by those skilled in the art, because of third base degeneracy, almost every amino acid can be represented by more than one triplet codon in a coding nucleotide sequence. In addition, minor base pair changes may result in a conservative substitution in the amino acid sequence encoded but are not expected to substantially alter the biological activity of 66 24039697 1.DOC the gene product. Therefore, a nucleic acid sequence encoding a protein described herein may be modified slightly in sequence and yet still encode its respective gene product. Exemplary nucleic acids encoding the E/I binders described herein include nucleic acids having SEQ ID NOs: 442-465 or nucleic acids having a sequence at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 442-465. Isolated nucleic acids which differ from the nucleic acids as set forth in SEQ ID NOs: 442-465 due to degeneracy in the genetic code are also within the scope of the invention. Also provided are E/I binders comprising an I monomer encoded by a nucleotide sequence at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 328 and/or E/I binders comprising an E monomer encoded by a nucleotide sequence at 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 329-441 or 495. Also provided are E binders encoded by a nucleotide sequence at 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 329-441 or 495. In certain embodiments, the nucleotide sequences encoding the E/I binders, an E monomer, or an I monomer do not contain a sequence encoding a 6XHis tag (SEQ ID NO: 487). Nucleic acids encoding any of the various proteins or polypeptides disclosed herein may be synthesized chemically. Codon usage may be selected so as to improve expression in a cell. Such codon usage will depend on the cell type selected. Specialized codon usage patterns have been developed for E. coli and other bacteria, as well as mammalian cells, plant cells, yeast cells and insect cells. See for example: Mayfield et al., Proc Natl Acad Sci U S A. 2003 100(2):438-42; Sinclair et al. Protein Expr Purif. 2002 (1):96-105; Connell ND. Curr Opin Biotechnol. 2001 (5):446-9; Makrides et al. Microbiol Rev. 1996 60(3):512-38; and Sharp et al. Yeast. 1991 7(7):657-78. General techniques for nucleic acid manipulation are within the purview of one skilled in the art and are also described for example in Sambrook et al., Molecular Cloning: A Laboratory Manual, Vols. 1-3, Cold Spring Harbor Laboratory Press, 2 ed., 1989, or F. Ausubel et al., Current Protocols in Molecular Biology (Green Publishing and Wiley-Interscience: New York, 1987) and periodic updates, herein incorporated by reference. The DNA encoding a protein is operably 67 24039697_1.DOC linked to suitable transcriptional or translational regulatory elements derived from mammalian, viral, or insect genes. Such regulatory elements include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and sequences that control the termination of transcription and translation. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants are additionally incorporated. Suitable regulatory elements are well-known in the art. The proteins described herein may be produced as a fusion protein with a heterologous polypeptide, which is preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. The heterologous signal sequence selected preferably is one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process a native signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat stable enterotoxin II leaders. For yeast secretion, the native signal sequence may be substituted by, e.g., the yeast invertase leader, a factor leader (including Saccharomyces and Kluyveromyces alpha-factor leaders), or acid phosphatase leader, the C. albicans glucoamylase leader, or the signal described in PCT Publication No. WO 90/13646. In mammalian cell expression, mammalian signal sequences as well as viral secretory leaders, for example, the herpes simplex gD signal, are available. The DNA for such precursor regions may be ligated in reading frame to DNA encoding the protein. Expression vectors used in eukaryotic host cells (e.g., yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5 ' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the multivalent antibody. One useful transcription termination component is the bovine growth hormone polyadenylation 68 24039697 1.DOC region. See PCT Publication No. WO 94/11026 and the expression vector disclosed therein. The recombinant DNA can also include any type of protein tag sequence that may be useful for purifying the protein. Examples of protein tags include but are not limited to a histidine tag, a FLAG tag, a myc tag, an HA tag, or a GST tag. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts can be found in Cloning Vectors: A Laboratory Manual, (Elsevier, New York, 1985), the relevant disclosure of which is hereby incorporated by reference. The expression construct is introduced into the host cell using a method appropriate to the host cell, as will be apparent to one of skill in the art. A variety of methods for introducing nucleic acids into host cells are known in the art, including, but not limited to, electroporation; transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; and infection (where the vector is an infectious agent). Suitable host cells include prokaryotes, yeast, mammalian cells, or bacterial cells. Suitable bacteria include gram negative or gram positive organisms, for example, E. coli or Bacillus spp. Yeast, preferably from the Saccharomyces species, such as S. cerevisiae, may also be used for production of polypeptides. Various mammalian or insect cell culture systems can also be employed to express recombinant proteins. Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, (Bio/Technology, 6:47, 1988). In some instance it will be desired to produce proteins in vertebrate cells, such as for glycosylation, and the propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of suitable mammalian host cell lines include endothelial cells, COS-7 monkey kidney cells, CV-1, L cells, C127, 3T3, Chinese hamster ovary (CHO), human embryonic kidney cells, HeLa, 293, 293T, and BHK cell lines. For many applications, the small size of the protein multimers described herein would make E. coli the preferred method for expression. 69 24039697_1.DOC Protein Production Host cells are transformed with the herein-described expression or cloning vectors for protein production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The host cells used to produce the proteins of this invention may be cultured in a variety of media. Commercially available media such as Ham's F1O (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham et al., Meth. Enz. 58:44 (1979), Barnes et al., Anal. Biochem.102:255 (1980), U.S. Patent Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Patent No. Re. 30,985 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan. Proteins disclosed herein can also be produced using cell-translation systems. For such purposes, the nucleic acids encoding the proteins must be modified to allow in vitro transcription to produce mRNA and to allow cell-free translation of the mRNA in the particular cell-free system being utilized. Exemplary eukaryotic cell-free translation systems include, for example, mammalian or yeast cell-free translation systems, and exemplary prokaryotic cell-free translation systems include, for example, bacterial cell-free translation systems. 70 24039697 1.DOC Proteins disclosed herein can also be produced by chemical synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis, 2nd ed., 1984, The Pierce Chemical Co., Rockford, IL). Modifications to the protein can also be produced by chemical synthesis. The proteins disclosed herein can be purified by isolation/purification methods for proteins generally known in the field of protein chemistry. Non limiting examples include extraction, recrystallization, salting out (e.g., with ammonium sulfate or sodium sulfate), centrifugation, dialysis, ultrafiltration, adsorption chromatography, ion exchange chromatography, hydrophobic chromatography, normal phase chromatography, reversed-phase chromatography, gel filtration, gel permeation chromatography, affinity chromatography, electrophoresis, countercurrent distribution or any combinations of these. After purification, proteins may be exchanged into different buffers and/or concentrated by any of a variety of methods known to the art, including, but not limited to, filtration and dialysis. The purified proteins are preferably at least 85% pure, more preferably at least 95% pure, and most preferably at least 98% pure. Regardless of the exact numerical value of the purity, the proteins are sufficiently pure for use as a pharmaceutical product. Imaging, Diagnostic and Other Applications The E binders described herein can be detectably labeled and used to contact cells expressing EGFR for imaging or diagnostic applications. The E/I binders described herein can be detectably labeled and used to contact cells expressing EGFR and/or IGFIR for imaging or diagnostic applications. Any method known in the art for conjugating a protein to the detectable moiety may be employed, including those methods described by Hunter, et al., Nature 144:945 (1962); David, et al., Biochemistry 13:1014 (1974); Pain, et al., J. Immunol. Meth. 40:219 (1981); and Nygren, J. Histochem. and Cytochem. 30:407 (1982). In certain embodiments, the E binders and E/I binders described herein are further attached to a label that is able to be detected (e.g., the label can be a radioisotope, fluorescent compound, enzyme or enzyme co-factor). The label may be a radioactive agent, such as: radioactive heavy metals such as iron chelates, 71 24039697 1.DOC radioactive chelates of gadolinium or manganese, positron emitters of oxygen, nitrogen, iron, carbon, or gallium, 4 3 K, "Fe, "Co, 67 Cu, "Ga, "Ga, , 131 1, 132I, or 99Tc. An E binder or E/I binder affixed to such a moiety may be used as an imaging agent and is administered in an amount effective for diagnostic use in a mammal such as a human and the localization and accumulation of the imaging agent is then detected. The localization and accumulation of the imaging agent may be detected by radioscintigraphy, nuclear magnetic resonance imaging, computed tomography or positron emission tomography. As will be evident to the skilled artisan, the amount of radioisotope to be administered is dependent upon the radioisotope. Those having ordinary skill in the art can readily formulate the amount of the imaging agent to be administered based upon the specific activity and energy of a given radionuclide used as the active moiety. E binders and E/I binders also are useful as affinity purification agents. In this process, the proteins are immobilized on a suitable support, such a Sephadex resin or filter paper, using methods well known in the art. The proteins can be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays (Zola, Monoclonal Antibodies: A Manual of Techniques, pp. 147-158 (CRC Press, Inc., 1987)). E binders are useful in methods for detecting EGFR in a sample. E/I binders also are useful in methods for detecting EGFR and/or IGFIR in a sample. The sample will often by a biological sample, such as a biopsy, and particularly a biopsy of a tumor, a suspected tumor. The sample may be from a human or other mammal. The E binder or E/I binder may be labeled with a labeling moiety, such as a radioactive moiety, a fluorescent moiety, a chromogenic moiety, a chemiluminescent moiety, or a hapten moiety; and may be immobilized on a solid support. Detection may be carried out using any technique known in the art, such as, for example, radiography, immunological assay, fluorescence detection, mass spectroscopy, or surface plasmon resonance. Therapeutic/in vivo uses The E binders described herein are also useful in methods for treating conditions which respond to an inhibition of EGFR biological activity. The E/I binders described herein are also useful in methods for treating conditions which 72 24039697 1.DOC respond to an inhibition of EGFR and/or IGFIR biological activity. EGFR and IGFIR are involved either directly or indirectly in the signal transduction pathways of various cell activities, including proliferation, adhesion and migration, as well as differentiation. In one aspect, the application provides methods for treating a subject afflicted with a hyperproliferative disorder with a therapeutically effective amount of an E binder or an E/I binder. In particular, E binders and E/I binders are useful for the treatment and/or prophylaxis of tumors and/or tumor metastases. In exemplary embodiments, the E/I binder is an antibody-like protein multimer such as a dimer of an EGFR binding I 0 Fn3 and an IGFIR binding ' 0 Fn3. In some embodiments, pharmaceutical compositions comprising E binders or E/I binders are administered to a subject afflicted with a tumor, including but not limited to, a brain tumor, tumor of the urogenital tract, tumor of the lymphatic system, stomach tumor, laryngeal tumor, monocytic leukemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma and breast carcinoma; or a cancerous disease, including but not limited to, squamous cell carcinoma, bladder cancer, stomach cancer, liver cancer, kidney cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynecological cancer, thyroid cancer, lymphoma, chronic leukemia and acute leukemia. An E binder or an E/I binder can be administered alone or in combination with one or more additional therapies such as chemotherapy radiotherapy, immunotherapy, surgical intervention, or any combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described herein. Techniques and dosages for administration vary depending on the type of specific polypeptide and the specific condition being treated but can be readily determined by the skilled artisan. Additional Agents That May be Used with E/I Binders One aspect of the application provides combinations of E binder or E/I binders and an additional therapeutic agent, such as a cytotoxic agent. In some embodiments, an E binder or E/I binder is linked to a cytotoxic agent. Such embodiments can be prepared by in vitro or in vivo methods as appropriate. In vitro methods include conjugation chemistry well know in the art, such as conjugation to 73 24039697_I.DOC cysteine and lysine residues. In order to link a cytotoxic agent to a polypeptide, a linking group or reactive group is used. Suitable linking groups are well known in the art and include disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups and esterase labile groups. Cytotoxic agents can also be linked to E binders or E/I binders through an intermediary carrier molecule such as serum albumin Exemplary cytotoxic agents that may be linked to E binders or E/I binders, include maytansinoids, taxanes, analogs of CC-1065, bacterial toxin, plant toxin, ricin, abrin, a ribonuclease (RNase), DNase I, a protease, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtherin toxin, Pseudomonas exotoxin, Pseudomonas endotoxin, Ranpimase (Rap), Rap (N69Q), methotrexate, daunorubicin, doxorubicin, vincristine, vinblastine, melphalan, mitomycin C, chlorambucil, and calicheamicin. In other therapeutic treatments or compositions, E binders or E/I binders are co-administered, or administered sequentially, with one or more additional therapeutic agents. Suitable therapeutic agents include, but are not limited to, cytotoxic or cytostatic agents, such as cancer therapeutic agents. Cancer therapeutic agents are those agents that seek to kill or limit the growth of cancer cells while having minimal effects on the patient. Thus, such agents may exploit any difference in cancer cell properties (e.g., metabolism, vascularization or cell-surface antigen presentation) from healthy host cells. Therapeutic agents that can be combined with E/I binders for improved anti-cancer efficacy include diverse agents used in oncology practice (Reference: Cancer, Principles & Practice of Oncology, DeVita, V. T., Hellman, S., Rosenberg, S. A., 6th edition, Lippincott-Raven, Philadelphia, 2001), such as doxorubicin, epirubicin, cyclophosphamide, trastuzumab, capecitabine, tamoxifen, toremifene, letrozole, anastrozole, fulvestrant, exemestane, goserelin, oxaliplatin, carboplatin, cisplatin, dexamethasone, antide, bevacizumab, 5-fluorouracil, leucovorin, levamisole, irinotecan, etoposide, topotecan, gemcitabine, vinorelbine, estramustine, mitoxantrone, abarelix, zoledronate, streptozocin, rituximab, idarubicin, busulfan, chlorambucil, fludarabine, imatinib, cytarabine, ibritumomab, tositumomab, interferon alpha-2b, melphalam, bortezomib, altretamine, asparaginase, gefitinib, 74 24039697 I.DOC erlonitib, anti-EGF receptor antibody (e.g., cetuximab or panitumab), ixabepilone, epothilones or derivatives thereof, platinum agents (such as carboplatin, oxaliplatin, cisplatin), taxanes (such as paclitaxel, docetaxel), and camptothecin. Therapeutic Formulations and Modes of Administration The present application provides methods for treating conditions which respond to an inhibition of EGFR and/or IGFIR biological activity. Techniques and dosages for administration vary depending on the type of specific polypeptide and the specific condition being treated but can be readily determined by the skilled artisan. In general, regulatory agencies require that a protein reagent to be used as a therapeutic is formulated so as to have acceptably low levels of pyrogens. Accordingly, therapeutic formulations will generally be distinguished from other formulations in that they are substantially pyrogen free, or at least contain no more than acceptable levels of pyrogen as detennined by the appropriate regulatory agency (e.g., FDA). In some embodiments, the E binders and E/I binders are are pharmaceutically acceptable to a mammal, in particular a human. A "pharmaceutically acceptable" polypeptide refers to a polypeptide that is administered to an animal without significant adverse medical consequences. Examples of pharmaceutically acceptable E binders and E/I binders include ' 0 Fn3 domains that lack the integrin-binding domain (RGD) and ' 0 Fn3 domains that are essentially endotoxin free or have very low endotoxin levels. Therapeutic compositions may be administered with a pharmaceutically acceptable diluent, carrier, or excipient, in unit dosage form. Administration may be parenteral (e.g., intravenous, subcutaneous), oral, or topical, as non-limiting examples. In addition, any gene therapy technique using nucleic acids encoding E binders or E/I binders, may be employed, such as naked DNA delivery, recombinant genes and vectors, cell-based delivery, including ex vivo manipulation of patients' cells, and the like. The composition can be in the form of a pill, tablet, capsule, liquid, or sustained release tablet for oral administration; a liquid for intravenous, subcutaneous or parenteral administration; or a gel, lotion, ointment, cream, or a polymer or other sustained release vehicle for local administration. 75 24039697_1.DOC Methods well known in the art for making formulations are found, for example, in "Remington: The Science and Practice of Pharmacy" (20th ed., ed. A.R. Gennaro AR., 2000, Lippincott Williams & Wilkins, Philadelphia, PA). Formulations for parenteral administration may, for example, contain excipients, sterile water, saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Nanoparticulate formulations (e.g., biodegradable nanoparticles, solid lipid nanoparticles, liposomes) may be used to control the biodistribution of the compounds. Other potentially useful parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. The concentration of the compound in the formulation varies depending upon a number of factors, including the dosage of the drug to be administered, and the route of administration. The polypeptide may be optionally administered as a pharmaceutically acceptable salt, such as non-toxic acid addition salts or metal complexes that are commonly used in the pharmaceutical industry. Examples of acid addition salts include organic acids such as acetic, lactic, pamoic, maleic, citric, malic, ascorbic, succinic, benzoic, palmitic, suberic, salicylic, tartaric, methanesulfonic, toluenesulfonic, or trifluoroacetic acids or the like; polymeric acids such as tannic acid, carboxymethyl cellulose, or the like; and inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid phosphoric acid, or the like. Metal complexes include zinc, iron, and the like. In one example, the polypeptide is formulated in the presence of sodium acetate to increase thermal stability. Formulations for oral use include tablets containing the active ingredient(s) in a mixture with non-toxic pharmaceutically acceptable excipients. These excipients may be, for example, inert diluents or fillers (e.g., sucrose and sorbitol), lubricating agents, glidants, and anti-adhesives (e.g., magnesium stearate, zinc stearate, stearic acid, silicas, hydrogenated vegetable oils, or talc). Formulations for oral use may also be provided as chewable tablets, or as hard gelatin capsules wherein the active ingredient is mixed with an inert solid 76 24039697 1.DOC diluent, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium. A therapeutically effective dose refers to a dose that produces the therapeutic effects for which it is administered. The exact dose will depend on the disorder to be treated, and may be ascertained by one skilled in the art using known techniques. In general, the E binder or E/I binder is administered at about 0.01 pg/kg to about 50 mg/kg per day, preferably 0.01 mg/kg to about 30 mg/kg per day, most preferably 0.1 mg/kg to about 20 mg/kg per day. The polypeptide may be given daily (e.g., once, twice, three times, or four times daily) or less frequently (e.g., once every other day, once or twice weekly, or monthly). In addition, as is known in the art, adjustments for age as well as the body weight, general health, sex, diet, time of administration, drug interaction, and the severity of the disease may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. EXEMPLIFICATION The invention now being generally described will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention in any way. Summary of Sequences Many of the sequences referenced in this application are summarized in the table below. Unless otherwise specified, N-terminal extensions are indicated with a single underline, C-terminal tails are indicated with a double underline, and linker sequences are indicated in bold. SEQ ID Description Sequence NO: 1 WT human '"Fn3 domain VSDVPRDLEVVAATPTSLLISWDAPAVT VRYYRITYGETGGNSPVQEFTVPGSKST ATISGLKPGVDYTITVYAVTGRGDSPAS SKPISTNYRT 2 Variant human ' 0 Fn3 with the VSDVPRDLEVVAATPTSLLISWDAPAVT integrin binding motif removed VRYYRITYGETGGNSPVQEFTVPGSKST (RGD changed to SGE; changes ATISGLKPGVDYTITVYAVTGSGESPASS from SEQ ID NO: 1 are 77 24039697 I.DOC SEQ ID Description Sequence NO: underlined) KPISINYRT 3 Il IGF-IR monomer with N- VSDVPRDLEVVAATPTSLLISWSARLKV terminal extension (N+8) and no ARYYRITYGETGGNSPVQEFTVPKNVY tail TATISGLKPGVDYTITVYAVTRFRDYQPI SINYRT 4 Il IGF-IR monomer with MGVSDVPRDLEVVAATPTSLLISWSARL N-terminal extension (N+ 10) and KVARYYRITYGETGGNSPVQEFTVPKN Ser tail with His tag VYTATISGLKPGVDYTITVYAVTRFRDY QPISINYRTEIDKPSOHHHHHH 5 E2 EGFR monomer with VSDVPRDLEVVAATPTSLLISWDSGRGS N-terminal extension (N+8) and YQYYRITYGETGGNSPVQEFTVPGPVHT no tail ATISGLKPGVDYTITVYAVTDHKPHAD GPHTYHESPISINYRT 6 E2 EGFR monomer with MGVSDVPRDLEVVAATPTSLLISWDSG N-terminal extension (N+10) and RGSYQYYRITYGETGGNSPVQEFTVPGP Ser tail with his tag VHTATISGLKPGVDYTITVYAVTDHKPH ADGPHTYHESPISINYRTEIDKPSQHHHH HH 7 El EGFR monomer with VSDVPRDLEVVAATPTSLLISWVAGAE N-terminal extension (N+8) and DYQYYRITYGETGGNSPVQEFTVPHDL no tail VTATISGLKPGVDYTITVYAVTDMMHV EYTEHPISINYRT 8 El EGFR monomer with MGVSDVPRDLEVVAATPTSLLISWVAG N-terminal extension (N+ 10) and AEDYQYYRITYGETGGNSPVQEFTVPH Ser tail with his tag DLVTATISGLKPGVDYTITVYAVTDMM HVEYTEHPISINYRTEIDKPSOHHHHHH 9 Ser tail EIDKPSQ 10 Cys tail EIDKPCQ 11 (GS);o Linker GSGSGSGSGSGSGSGSGSGS 12 Fn Based Linker PSTSTST 13 (GS) 5 Linker GSGSGSGSGS 14 (GGGGS) 3 Linker GGGGS GGGGS GGGGS 15 (GGGGS) 4 Linker GGGGS GGGGS GGGGS GGGGS 16 (GGGGS) 5 Linker GGGGS GGGGS GGGGS GGGGS GGGGS 17 G 4

SG

4

SG

3 SG Linker GGGGS GGGGS GGGSG 18 Linker GPGPGPG 19 Linker GPGPGPGPGPG 20 I1-GS10-E2: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV II (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and short tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI 78 24039697 .DOC SEQ ID Description Sequence NO:

GS

1 o linker (GS10 is SEQ ID NO: SINYRTEIDKGSGSGSGSGSGSGSGSGS 11) to E2 (with N-terminal GSVSDVPRDLEVVAATPTSLLISWDSGR extension (N+8) and no tail) GSYQYYRITYGETGGNSPVQEFTVPGPV HTATISGLKPGVDYTITVYAVTDHKPHA DGPHTYHESPISlNYRT 21 I1-GS10-E2: I/E tandem having MGVSDVPRDLEVVAATPTSLLISWSARL Il (with N-terminal extension KVARYYRITYGETGGNSPVQEFTVPKN (N+ 10) and short tail) fused via VYTATISGLKPGVDYTITVYAVTRFRDY

GS

1 0 linker (GS10 is SEQ ID NO: QPISINYRTEIDKGSGSGSGSGSGSGSGS 11) to E2 (with N-terminal GSGSVSDVPRDLEVVAATPTSLLISWDS extension (N+8) and Ser tail) GRGSYQYYRITYGETGGNSPVQEFTVPG PVHTATISGLKPGVDYTITVYAVTDHKP HADGPHTYHESPISJNYRTEIDKPSQ 22 I1-GS10-E2: I/E tandem Il (with MGVSDVPRDLEVVAATPTSLLISWSARL N-terminal extension (N+ 10) and KVARYYRITYGETGGNSPVQEFTVPKN short tail) fused via GS 1 0 linker VYTATISGLKPGVDYT'I'VYAVTRFRDY (GS10 is SEQ ID NO: 11) to E2 QPISINYRTEIDKGSGSGSGSGSGSGSGS (with N-terminal extension (N+8) GSGSVSDVPRDLEVVAATPTSLLISWDS and Ser tail with his tag) GRGSYQYYRITYGETGGNSPVQEFTVPG PVHTATISGLKPGVDYTITVYAVTDHKP HADGPHTYHESPISlNYRTEDKPSQHHH HHH 23 E2-GS 10-I1: E/I tandem having VSDVPRDLEVVAATPTSLLISWDSGRGS E2 (with N-terminal extension YQYYRITYGETGGNSPVQEFTVPGPVHT (N+8) and short tail) fused via ATISGLKPGVDYTITVYAVTDHKPHAD GSIo linker (GS10 is SEQ ID NO: GPHTYHESPISINYRTEIDKGSGSGSGSG 11) to Il (with N-terminal SGSGSGSGSGSVSDVPRDLEVVAATPTS extension (N+8) and Ser tail) LLISWSARLKVARYYRITYGETGGNSPV QEFTVPKNVYTATISGLKPGVDYTITVY AVTRFRDYQPISINYRTEIDKPSQ 24 E2-GS 10-Il: E/I tandem having MGVSDVPRDLEVVAATPTSLLISWDSG E2 (with N-terminal extension RGSYQYYRITYGETGGNSPVQEFTVPGP (N+10) and short tail) fused via VHTATISGLKPGVDYTITVYAVTDHKPH

GS

1 0 linker (GS10 is SEQ ID NO: ADGPHTYHESPISINYRTEIDKGSGSGSG 11) to Il (with N-terminal SGSGSGSGSGSGSVSDVPRDLEVVAAT extension (N+8) and Ser tail) PTSLLISWSARLKVARYYRITYGETGGN SPVQEFTVPKNVYTATISGLKPGVDYTI TVYAVTRFRDYQPISINYRTEIDKPSO 25 E2-GS 10-I1: E/I tandem having MGVSDVPRDLEVVAATPTSLLISWDSG E2 (with N-terminal extension RGSYQYYRITYGETGGNSPVQEFTVPGP (N+10) and short tail) fused via VHTATISGLKPGVDYTITVYAVTDHKPH

GS

10 linker (GS10 is SEQ ID NO: ADGPHTYHESPISlTYRTEIDKGSGSGSG 11) to Il (with N-terminal SGSGSGSGSGSGSVSDVPRDLEVVAAT extension (N+8) and Ser tail with PTSLLISWSARLKVARYYRITYGETGGN his tag) SPVQEFTVPKNVYTATISGLKPGVDYTI TVYAVTRFRDYQPISlNYRTEIDKPSOHH HHHH 79 24039697_I.DOC SEQ ID Description Sequence NO: 26 Il -GS 10-El: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV Il (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and short tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI GSio linker (GS10 is SEQ ID NO: SINYRTEIDKGSGSGSGSGSGSGSGSGS 11) to El (with N-terminal GSVSDVPRDLEVVAATPTSLLISWVAG extension (N+8) and no tail) AEDYQYYRITYGETGGNSPVQEFTVPH DLVTATISGLKPGVDYTITVYAVTDMM HVEYTEHPISINYRT 27 Il-GS 10-El: I/E tandem having MGVSDVPRDLEVVAATPTSLLISWSARL Il (with N-terminal extension KVARYYRITYGETGGNSPVQEFTVPKN (N+10) and short tail) fused via VYTATISGLKPGVDYTITVYAVTRFRDY

GS

1 o linker (GS 10 is SEQ ID NO: QPISINYRTEIDKGSGSGSGSGSGSGSGS 11) to El (with N-terminal GSGSVSDVPRDLEVVAATPTSLLISWVA extension (N+8) and Ser tail) GAEDYQYYRITYGETGGNSPVQEFTVP HDLVTATISGLKPGVDYTITVYAVTDM MHVEYTEHPISINYRTEIDKPSO 28 Il-GS 10-E1: I/E tandem having MGVSDVPRDLEVVAATPTSLLISWSARL Il (with N-terminal extension KVARYYRITYGETGGNSPVQEFTVPKN (N+10) and short tail) fused via VYTATISGLKPGVDYTITVYAVTRFRDY GSio linker (GS 10 is SEQ ID NO: QPISINYRTEIDKGSGSGSGSGSGSGSGS 11) to El (with N-terminal GSGSVSDVPRDLEVVAATPTSLLISWVA extension (N+8) and Ser tail with GAEDYQYYRITYGETGGNSPVQEFTVP his tag) HDLVTATISGLKPGVDYTITVYAVTDM MHVEYTEHPISINYRTEIDKPSHHHHH H 29 El-GS 10-I1: E/I tandem having VSDVPRDLEVVAATPTSLLISWVAGAE El (with N-terminal extension DYQYYRITYGETGGNSPVQEFTVPHDL (N+8) and short tail) fused via VTATISGLKPGVDYTITVYAVTDMMHV GSio linker (GS 10 is SEQ ID NO: EYTEHPISINYRTEIDKGSGSGSGSGSGS 11) to Il (with N-terminal GSGSGSGSVSDVPRDLEVVAATPTSLLI extension (N+8) and no tail) SWSARLKVARYYRITYGETGGNSPVQE FTVPKNVYTATISGLKPGVDYTITVYAV TRFRDYQPISINYRT 30 El -GS 10-I1: E/I tandem having MGVSDVPRDLEVVAATPTSLLISWVAG El (with N-terminal extension AEDYQYYRITYGETGGNSPVQEFTVPH (N+10) and short tail) fused via DLVTATISGLKPGVDYTITVYAVTDMM GSi0 linker (GS10 is SEQ ID NO: HVEYTEHPISINYRTEIDKGSGSGSGSGS 11) to Il (with N-terminal GSGSGSGSGSVSDVPRDLEVVAATPTS extension (N+8) and Ser tail) LLISWSARLKVARYYRITYGETGGNSPV QEFTVPKNVYTATISGLKPGVDYTITVY AVTRFRDYQPISINYRTEIDKPSQ 31 El -GS 10-I1: E/I tandem having MGVSDVPRDLEVVAATPTSLLISWVAG El (with N-terminal extension AEDYQYYRITYGETGGNSPVQEFTVPH (N+10) and short tail) fused via DLVTATISGLKPGVDYTITVYAVTDMM GSi1 linker (GS10 is SEQ ID NO: HVEYTEHPISINYRTEIDKGSGSGSGSGS 11) to I1 (with N-terminal GSGSGSGSGSVSDVPRDLEVVAATPTS extension (N+8) and Ser tail with LLISWSARLKVARYYRITYGETGGNSPV 80 24039697 IDOC SEQ ID Description Sequence NO: his tag) QEFTVPKNVYTATISGLKPGVDYTITVY AVTRFRDYQPISINYRTEIDKPSOHHHH HH 32 ' 0 Fn3 scaffold, wherein the BC, VSDVPRDLEVVAATPTSLLI DE, and FG loops are represented (X).YYRITYGETGGNSPVQEFTV(X)oATI by (X).,, (X)., and (X),, SGLKPGVDYTITVYAV(X),ISINYRT respectively, and n is an integer from 1-20, o is an integer from 1 20, and p is an integer from 1-40 33 BC loop sequence from EGFR SWVAGAEDYQ binder El 34 BC loop sequence from EGFR XmVAGAEDYQX,, binder El, wherein X is any amino acid and m and n are independently selected from 0 to 5 amino acids 35 DE loop sequence from EGFR PHDLVT binder El 36 DE loop sequence from EGFR XOHDLVX, binder El, wherein X is any amino acid and o and p are independently selected from 0 to 5 amino acids 37 FG loop sequence from EGFR TDMMHVEYTEHP binder El 38 FG loop sequence from EGFR XqDMMHVEYTEHX, binder El, wherein X is any amino acid and q and r are independently selected from 0 to 5 amino acids 39 BC loop sequence from EGFR SWDSGRGSYQ binder E2 40 BC loop sequence from EGFR XgDSGRGSYQXI binder E2, wherein X is any amino acid and g and h are independently selected from 0 to 5 amino acids 41 DE loop sequence from EGFR PGPVHT binder E2 42 DE loop sequence from EGFR XiGPVHXj binder E2, wherein X is any amino acid and i and j are independently selected from 0 to 81 24039697_l.DOC SEQ ID Description Sequence NO: 5 amino acids 43 FG loop sequence from EGFR TDHKPHADGPHTYHESP binder E2 44 FG loop sequence from EGFR XkDHKPHADGPHTYHEX, binder E2, wherein X is any amino acid and k and 1 are independently selected from 0 to 5 amino acids 45 BC loop sequence from IGF-IR SWSARLKVAR binder Il 46 BC loop sequence from IGF-IR XaSARLKVAXb binder I, wherein X is any amino acid and a and b are independently selected from 0 to 5 amino acids 47 DE loop sequence from IGF-IR PKNVYT binder Il 48 DE loop sequence from IGF-IR XcKNVYXd binder I, wherein X is any amino acid and c and d are independently selected from 0 to 5 amino acids 49 FG loop sequence from IGF-IR TRFRDYQP binder I 50 FG loop sequence from IGF-IR XeRFRDYQXf binder I, wherein X is any amino acid and e and f are independently selected from 0 to 5 amino acids 51 Linker GPG 52 E3 EGFR monomer with N- MGVSDVPRDLEVVAATPTSLLISWLPG terminal extension (N+10), Ser KLRYQYYRITYGETGGNSPVQEFTVPH tail and his tag DLRTATISGLKPGVDYTITVYAVTNMM HVEYSEYPISINYRTEIDKPSOHHHHHH 53 E3-GS 10-Il: E/I tandem having MGVSDVPRDLEVVAATPTSLLISWLPG E3 (with N-terminal extension KLRYQYYRITYGETGGNSPVQEFTVPH (N+ 10) and short tail) fused via DLRTATISGLKPGVDYTITVYAVTNMM

GS

1 0 linker (GS10 is SEQ ID NO: HVEYSEYPISINYRTEIDKGSGSGSGSGS 11) to II (with N-terminal GSGSGSGSGSVSDVPRDLEVVAATPTS extension (N+8) and Cys tail with LLISWSARLKVARYYRITYGETGGNSPV his tag) QEFTVPKNVYTATISGLKPGVDYTITVY AVTRFRDYQPISINYRTEIDKPCOHHHH HH 54 I1-GSO-E3: I/E tandem having MGVSDVPRDLEVVAATPTSLLISWSARL 82 24039697 I.DOC SEQ ID Description Sequence NO: II with N-terminal extension KVARYYRITYGETGGNSPVQEFTVPKN (N+10) and short tail) fused via VYTATISGLKPGVDYTITVYAVTRFRDY GSio linker (GS10 is SEQ ID NO: QPISINYRTEIDKGSGSGSGSGSGSGSGS 11) to E3 (with N-terminal GSGSVSDVPRDLEVVAATPTSLLISWLP extension (N+8) and Cys tail with GKLRYQYYRITYGETGGNSPVQEFTVP his tag) HDLRTATISGLKPGVDYTITVYAVTNM MHVEYSEYPISlNYRTEIDKPCQHHHHH H 55 El-GS 10-I1: E/I tandem having MGVSDVPRDLEVVAATPTSLLISWVAG El (with N-terminal extension AEDYQYYRITYGETGGNSPVQEFTVPH (N+10) and short tail) fused via DLVTATISGLKPGVDYTITVYAVTDMM

GS

10 linker (GS10 is SEQ ID NO: HVEYTEHPISINYRTEIDKGSGSGSGSGS 11) to Il (with N-terminal GSGSGSGSGSVSDVPRDLEVVAATPTS extension (N+8) and Cys tail with LLISWSARLKVARYYRITYGETGGNSPV his tag) QEFTVPKNVYTATISGLKPGVDYTITVY AVTRFRDYQPISTNYRTEIDKPCQHHHH HH 56 E2-GS10-I1: E/I tandem having MGVSDVPRDLEVVAATPTSLLISWDSG E2 (with N-terminal extension RGSYQYYRITYGETGGNSPVQEFTVPGP (N+10) and short tail) fused via VHTATISGLKPGVDYTITVYAVTDHKPH

GS

10 linker (GS10 is SEQ ID NO: ADGPHTYHESPISINYRTEIDKGSGSGSG 11) to Il (with N-terminal SGSGSGSGSGSGSVSDVPRDLEVVAAT extension (N+8) and Cys tail with PTSLLISWSARLKVARYYRITYGETGGN his tag) SPVQEFTVPKNVYTATISGLKPGVDYTI TVYAVTRFRDYQPISINYRTEIDKPCQH HHHHH 57 Il -GS 10-E1: I/E tandem having MGVSDVPRDLEVVAATPTSLLISWSARL Il (with N-terminal extension KVARYYRITYGETGGNSPVQEFTVPKN (N+10) and short tail) fused via VYTATISGLKPGVDYTITVYAVTRFRDY

GS

10 linker (GS 10 is SEQ ID NO: QPISINYRTEIDKGSGSGSGSGSGSGSGS 11) to El (with N-terminal GSGSVSDVPRDLEVVAATPTSLLISWVA extension (N+8) and Cys tail with GAEDYQYYRITYGETGGNSPVQEFTVP his tag) HDLVTATISGLKPGVDYTITVYAVTDM MHVEYTEHPISlNYRTEIDKPCOHHHHH H 58 Il-GS 10-E2: I/E tandem having MGVSDVPRDLEVVAATPTSLLISWSARL Il (with N-terminal extension KVARYYRITYGETGGNSPVQEFTVPKN (N+10) and short tail) fused via VYTATISGLKPGVDYTITVYAVTRFRDY GSie linker (GS 10 is SEQ ID NO: QPISINYRTEIDKGSGSGSGSGSGSGSGS 11) to E2 (with N-terminal GSGSVSDVPRDLEVVAATPTSLLISWDS extension (N+8) and Cys tail with GRGSYQYYRITYGETGGNSPVQEFTVPG his tag) PVHTATISGLKPGVDYTITVYAVTDHKP HADGPHTYHESPISINYRTEIDKPCOHH HHHH 59 BC loop sequence from EGFR SWLPGKLRYQ binder E3 83 24039697_1.DOC SEQ ID Description Sequence NO: 60 BC loop sequence from EGFR XsLPGKLRYQXt binder E3, wherein X is any amino acid and s and t are independently selected from 0 to 5 amino acids 61 DE loop sequence from EGFR PHDLRT binder E3 62 DE loop sequence from EGFR XUHDLRX, binder E3, wherein X is any amino acid and u and w are independently selected from 0 to 5 amino acids 63 FG loop sequence from EGFR TNMMHVEYSEYP binder E3 64 DE loop sequence from EGFR XyNMMHVEYSEYX, binder E3, wherein X is any amino acid and y and z are independently selected from 0 to 5 amino acids 65 Il IGF-IR monomer core EVVAATPTSLLISWSARLKVARYYRITY sequence: Il without N-terminal GETGGNSPVQEFTVPKNVYTATISGLKP extension or C-terminal tail GVDYTITVYAVTRFRDYQPISINYRT 66 El EGFR monomer core EVVAATPTSLLISWVAGAEDYQYYRITY sequence: El without N-terminal GETGGNSPVQEFTVPHDLVTATISGLKP extension or C-terminal tail GVDYTITVYAVTDMMHVEYTEHPISIN YRT 67 E2 EGFR monomer core EVVAATPTSLLISWDSGRGSYQYYRITY sequence: E2 without N-terminal GETGGNSPVQEFTVPGPVHTATISGLKP extension or C-terminal tail GVDYTITVYAVTDHKPHADGPHTYHES PISINYRT 68 E3 EGFR monomer core EVVAATPTSLLISWLPGKLRYQYYRITY sequence: SEQ ID NO: 82 GETGGNSPVQEFTVPHDLRTATISGLKP without N-terminal extension or GVDYTITVYAVTNMMHVEYSEYPISINY C-terminal tail RT 69 Exemplary N-terminal extension MGVSDVPRDL (N+10) 70 Exemplary N-terminal extension GVSDVPRDL 71 Exemplary N-terminal extension VSDVPRDL (N+8) 72 Exemplary N-terminal extension, XaSDVPRDL wherein X is any amino acid and n is 0, 1 or 2, preferably when n=--_1, X is Met or Gly and when 84 24039697 1DOC SEQ ID Description Sequence NO: n=2, X is Met-Gly 73 Exemplary N-terminal extension, XnDVPRDL wherein X is any amino acid and n is 0, 1 or 2, preferably when n=1, X is Met or Gly and when n=-2, X is Met-Gly 74 Exemplary N-terminal extension, XVPRDL wherein X is any amino acid and n is 0, 1 or 2, preferably when n=l, X is Met or Gly and when n=2, X is Met-Gly 75 Exemplary N-terminal extension, XPRDL wherein X is any amino acid and n is 0, 1 or 2, preferably when n=1, X is Met or Gly and when n=2, X is Met-Gly 76 Exemplary N-terminal extension, X,,RDL wherein X is any amino acid and n is 0, 1 or 2, preferably when n=1, X is Met or Gly and when n=2, X is Met-Gly 77 Exemplary N-terminal extension, XIDL wherein X is any amino acid and n is 0, 1 or 2, preferably when n=1, X is Met or Gly and when n=2, X is Met-Gly 78 Short tail EIDK 79 Exemplary C-terminal tail EIDKP 80 Exemplary C-terminal tail EIDKPS 81 Exemplary C-terminal tail EIDKPC 82 E3 EGFR monomer with N- VSDVPRDLEVVAATPTSLLISWLPGKLR terminal extension (N+8) and no YQYYRITYGETGGNSPVQEFTVPHDLRT tail ATISGLKPGVDYTITVYAVTNMMHVEY SEYPISlNYRT 87 E3-GS 10-Il: E/I tandem having VSDVPRDLEVVAATPTSLLISWLPGKLR E3 (with N-terminal extension YQYYRITYGETGGNSPVQEFTVPHDLRT (N+8) and short tail) fused via ATISGLKPGVDYTITVYAVTNMMHVEY

GS

10 linker (GS10 is SEQ ID NO: SEYPISINYRTEIDKGSGSGSGSGSGSGS 11) to Il (with N-terminal GSGSGSVSDVPRDLEVVAATPTSLLISW extension (N+8) and Cys tail) SARLKVARYYRITYGETGGNSPVQEFTV PKNVYTATISGLKPGVDYTITVYAVTRF RDYQPISINYRTEIDKPCO 88 Il-GS10-E3: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV 85 24039697 1.DOC SEQ ID Description Sequence NO: I1 (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and short tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI GS1o linker (GS 10 is SEQ ID NO: SINYRTEIDKGSGSGSGSGSGSGSGSGS 11) to E3 (with N-terminal GSVSDVPRDLEVVAATPTSLLISWLPGK extension (N+8) and Cys tail) LRYQYYRITYGETGGNSPVQEFTVPHDL RTATISGLKPGVDYTITVYAVTNMMHV EYSEYPISINYRTEIDKPCO 89 El-GS10-I1: E/I tandem having VSDVPRDLEVVAATPTSLLISWVAGAE El (with N-terminal extension DYQYYRITYGETGGNSPVQEFTVPHDL (N+8) and short tail) fused via VTATISGLKPGVDYTITVYAVTDMMHV GSio linker (GS10 is SEQ ID NO: EYTEHPISINYRTEIDKGSGSGSGSGSGS 11) to II (with N-terminal GSGSGSGSVSDVPRDLEVVAATPTSLLI extension (N+8) and Cys tail) SWSARLKVARYYRITYGETGGNSPVQE FTVPKNVYTATISGLKPGVDYTITVYAV TRFRDYQPISINYRTEIDKPC 90 E2-GS 10-I1: E/I tandem having VSDVPRDLEVVAATPTSLLISWDSGRGS E2 (with N-terminal extension YQYYRITYGETGGNSPVQEFTVPGPVHT (N+8) and short tail) fused via ATISGLKPGVDYTITVYAVTDHKPHAD GSie linker (GS10 is SEQ ID NO: GPHTYHESPISINYRTEIDKGSGSGSGSG 11) to Il (with N-terminal SGSGSGSGSGSVSDVPRDLEVVAATPTS extension (N+8) and Cys tail) LLISWSARLKVARYYRITYGETGGNSPV QEFTVPKNVYTATISGLKPGVDYTITVY AVTRFRDYQPISINYRTEIDKPCO 91 Il-GS 10-El: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV Il (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and short tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI GS1 0 linker (GS10 is SEQ ID NO: SINYRTEIDKGSGSGSGSGSGSGSGSGS 11) to El (with N-terminal GSVSDVPRDLEVVAATPTSLLISWVAG extension (N+8) and Cys tail) AEDYQYYRITYGETGGNSPVQEFTVPH DLVTATISGLKPGVDYTITVYAVTDMM HVEYTEHPISINYRTEIDKPC 92 I1-GS10-E2: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV II (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and short tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI

GS

10 linker (GS10 is SEQ ID NO: SINYRTEIDKGSGSGSGSGSGSGSGSGS 11) to E2 (with N-terminal GSVSDVPRDLEVVAATPTSLLISWDSGR extension (N+8) and Cys tail) GSYQYYRITYGETGGNSPVQEFTVPGPV HTATISGLKPGVDYTITVYAVTDHKPHA DGPHTYHESPISINYRTEIDKPCO 93 PA3 Linker PAPAPA 94 PA6 Linker PAPAPAPAPAPA 95 PA9 Linker PAPAPAPAPAPAPAPAPA 96 Modified Ser tail EGSGS 97 Modified Cys tail EGSGC 86 24039697_1.DOC SEQ ID Description Sequence NO: 98 E3-(PA)n-Il: E/I tandem having VSDVPRDLEVVAATPTSLLISWLPGKLR E3 (with N-terminal extension YQYYRITYGETGGNSPVQEFTVPHDLRT (N+8) and an E tail) fused via ATISGLKPGVDYTITVYAVTNMMHVEY (PA)n linker ((PA), is SEQ ID SEYPISINYRTE(PA).VSDVPRDLEVVAA NO: 488) to Il (with N-terminal TPTSLLISWSARLKVARYYRITYGETGG extension (N+8) and a modified NSPVQEFTVPKNVYTATISGLKPGVDYT Ser or Cys tail), wherein n= 3, 6 ITVYAVTRFRDYQPISINYRTEGSGX or 9, and X = Ser or Cys 99 Il-(PA)a-E3: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV Il (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and an E tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI (PA), linker ((PA), is SEQ ID SINYRTE(PA).VSDVPRDLEVVAATPTSL NO: 488) to E3 (with N-terminal LISWLPGKLRYQYYRITYGETGGNSPVQ extension (N+8) and a modified EFTVPHDLRTATISGLKPGVDYTITVYA Ser or Cys tail), wherein n = 3, 6 VTNMMHVEYSEYPISINYRTEGSGX or 9, and X = Ser or Cys 100 El-(PA)a-Il: E/I tandem having VSDVPRDLEVVAATPTSLLISWVAGAE El (with N-terminal extension DYQYYRITYGETGGNSPVQEFTVPHDL (N+8) and an E tail) fused via VTATISGLKPGVDYTITVYAVTDMMHV (PA),, linker ((PA), is SEQ ID EYTEHPISINYRTE(PA).VSDVPRDLEVV NO: 488) to Il (with N-terminal AATPTSLLISWSARLKVARYYRITYGET extension (N+8) and a modified GGNSPVQEFTVPKNVYTATISGLKPGVD Ser or Cys tail), wherein n = 3, 6 YTITVYAVTRFRDYQPISINYRTEGSGX or 9, and X = Ser or Cys 101 E2-(PA),-Il: E/I tandem having VSDVPRDLEVVAATPTSLLISWDSGRGS E2 (with N-terminal extension YQYYRITYGETGGNSPVQEFTVPGPVHT (N+8) and an E tail) fused via ATISGLKPGVDYTITVYAVTDHKPHAD (PA),, linker ((PA), is SEQ ID GPHTYHESPISINYRTE(PA).VSDVPRDL NO: 488) to Il (with N-terminal EVVAATPTSLLISWSARLKVARYYRITY extension (N+8) and a modified GETGGNSPVQEFTVPKNVYTATISGLKP Ser or Cys tail), wherein n= 3, 6 GVDYTITVYAVTRFRDYQPISINYRTEG or 9, and X = Ser or Cys SGX 102 Il-(PA)n-El: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV Il (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and an E tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI (PA), linker ((PA), is SEQ ID SINYRTE(PA)IIVSDVPRDLEVVAATPTSL NO: 488) to El (with N-terminal LISWVAGAEDYQYYRITYGETGGNSPV extension (N+8) and a modified QEFTVPHDLVTATISGLKPGVDYTITVY Ser or Cys tail), wherein n = 3, 6 AVTDMMHVEYTEHPISINYRTEGSGX or 9, and X = Ser or Cys 103 I1-(PA),-E2: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV Il (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and an E tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI (PA), linker ((PA), is SEQ ID SINYRTE(PA).VSDVPRDLEVVAATPTSL NO: 488) to E2 (with N-terminal LISWDSGRGSYQYYRITYGETGGNSPVQ extension (N+8) and a modified EFTVPGPVHTATISGLKPGVDYTITVYA Ser or Cys tail), wherein n = 3, 6 VTDHKPHADGPHTYHESPISINYRTEGS 87 24039697_.DOC SEQ ID Description Sequence NO: or 9, and X = Ser or Cys GX 104 E3-GS 10-I1: E/I tandem having VSDVPRDLEVVAATPTSLLISWLPGKLR E3 (with N-terminal extension YQYYRITYGETGGNSPVQEFTVPHDLRT (N+8) and short tail) fused via ATISGLKPGVDYTITVYAVTNMMHVEY

GS

1 0 linker (GS10 is SEQ ID NO: SEYPISINYRTEIDKGSGSGSGSGSGSGS 11) to II (with N-terminal GSGSGSVSDVPRDLEVVAATPTSLLISW extension (N+8) and Ser tail) SARLKVARYYRITYGETGGNSPVQEFTV PKNVYTATISGLKPGVDYTITVYAVTRF RDYQPISINYRTEIDKPSO 105 I1-GS1O-E3: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV I1 with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and short tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI

GS

10 linker (GS10 is SEQ ID NO: SINYRTEIDKGSGSGSGSGSGSGSGSGS 11) to E3 (with N-terminal GSVSDVPRDLEVVAATPTSLLISWLPGK extension (N+8) and Ser tail) LRYQYYRITYGETGGNSPVQEFTVPHDL RTATISGLKPGVDYTITVYAVTNMMHV EYSEYPISJNYRTEIDKPSO 106 E4 EGFR monomer with N- VSDVPRDLEVVAATPTSLLISWHERDGS terminal extension (N+8) and no RQYYRITYGETGGNSPVQEFTVPGGVRT tail ATISGLKPGVDYTITVYAVTDYFNPTTH EYIYQTTPISINYRT 107 E4 EGFR monomer with N- MGVSDVPRDLEVVAATPTSLLISWHER terminal extension (N+10) and a DGSRQYYRITYGETGGNSPVQEFTVPGG Ser with His tag VRTATISGLKPGVDYTITVYAVTDYFNP TTHEYIYQTTPISINYRTEIDKPSOHHHH HH 108 E4 EGFR monomer core EVVAATPTSLLISWHERDGSRQYYRITY sequence: E4 without N-terminal GETGGNSPVQEFTVPGGVRTATISGLKP extension or C-terminal tail GVDYTITVYAVTDYFNPTTHEYIYQTTP ISINYRT 109 BC loop sequence from EGFR SWHERDGSRQ binder E4 110 DE loop sequence from EGFR PGGVRT binder E4 111 FG loop sequence from EGFR TDYFNPTTHEYIYQTTP binder E4 112 E5 EGFR monomer with N- VSDVPRDLEVVAATPTSLLISWWAPVD terminal extension (N+8) and no RYQYYRITYGETGGNSPVQEFTVPRDV tail YTATISGLKPGVDYTITVYAVTDYKPHA DGPHTYHESPISINYRT 113 E5 EGFR monomer with N- MGVSDVPRDLEVVAATPTSLLISWWAP terminal extension (N+10) and a VDRYQYYRITYGETGGNSPVQEFTVPR modified Ser or Cys tail, wherein DVYTATISGLKPGVDYTITVYAVTDYKP X = Ser or Cys; may optionally HADGPHTYHESPISINYRTEIDKPXO 88 24039697_1.DOC SEQ ID Description Sequence NO: comprise a 6X His tag (SEQ ID NO: 487) 114 E5 EGFR monomer core EVVAATPTSLLISWWAPVDRYQYYRIT sequence: E5 without N-terminal YGETGGNSPVQEFTVPRDVYTATISGLK extension or C-terminal tail PGVDYTITVYAVTDYKPHADGPHTYHE SPISINYRT 115 BC loop sequence from EGFR SWWAPVDRYQ binder E5 116 DE loop sequence from EGFR PRDVYT binder E5 117 FG loop sequence from EGFR TDYKPHADGPHTYHESP binder E5 118 E4-GS 10-I1: E/I tandem having VSDVPRDLEVVAATPTSLLISWHERDGS E4 (with N-terminal extension RQYYRITYGETGGNSPVQEFTVPGGVRT (N+8) and short tail) fused via ATISGLKPGVDYTITVYAVTDYFNPTTH GS10 linker (GS10 is SEQ ID EYIYQTTPISINYRTEIDKGSGSGSGSGS NO: 11) to I1 (with N-terminal GSGSGSGSGSVSDVPRDLEVVAATPTS extension (N+8) and no tail) LLISWSARLKVARYYRITYGETGGNSPV QEFTVPKNVYTATISGLKPGVDYTITVY AVTRFRDYQPISINYRT 119 E4-GS 10-I1: E/I tandem having VSDVPRDLEVVAATPTSLLISWHERDGS E4 (with N-terminal extension RQYYRITYGETGGNSPVQEFTVPGGVRT (N+8) and short tail) fused via ATISGLKPGVDYTITVYAVTDYFNPTTH GS 10 linker (GS 10 is SEQ ID EYIYQTTPISINYRTEIDKGSGSGSGSGS NO: 11) to II (with N-terminal GSGSGSGSGSVSDVPRDLEVVAATPTS extension (N+8) and modified Ser LLISWSARLKVARYYRITYGETGGNSPV or Cys tail), wherein X = Ser or QEFTVPKNVYTATISGLKPGVDYTITVY Cys; may optionally comprise a AVTRFRDYQPISINYRTEIDKPXO 6X His tag (SEQ ID NO: 487) 120 E4-GS 10-I1: E/I tandem having MGVSDVPRDLEVVAATPTSLLISWHER E4 (with N-terminal extension DGSRQYYRITYGETGGNSPVQEFTVPGG (N+ 10) and short tail) fused via VRTATISGLKPGVDYTITVYAVTDYFNP GS10 linker (GS10 is SEQ ID TTHEYIYQTTPISINYRTEIDKGSGSGSG NO: 11) to II (with N-terminal SGSGSGSGSGSGSVSDVPRDLEVVAAT extension (N+8) and Cys tail) PTSLLISWSARLKVARYYRITYGETGGN with his tag SPVQEFTVPKNVYTATISGLKPGVDYTI TVYAVTRFRDYQPISINYRTEIDKPCOH HHHHH 121 E4-(PA)n-I1: E/I tandem having VSDVPRDLEVVAATPTSLLISWHERDGS E4 (with N-terminal extension RQYYRITYGETGGNSPVQEFTVPGGVRT (N+8) and an E tail) fused via ATISGLKPGVDYTITVYAVTDYFNPTTH (PA)n linker ((PA), is SEQ ID EYIYQTTPISINYRTE(PA)VSDVPRDLE NO: 488) to Il (with N-terminal VVAATPTSLLISWSARLKVARYYRITYG extension (N+8) and modified Ser ETGGNSPVQEFTVPKNVYTATISGLKPG or Cys tail), wherein n = 3, 6 or 9, VDYTITVYAVTRFRDYQPISINYRTEIDK 89 24039697 I.DOC SEQ ID Description Sequence NO: and X = Ser or Cys; may PQHHHHHH optionally comprise a 6X His tag (SEQ ID NO: 487) 122 Il-GS10-E4: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV II (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and short tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI GS10 linker (GS10 is SEQ ID SINYRTEIDKGSGSGSGSGSGSGSGSGS NO: 11) to E4 (having N-terminal GSVSDVPRDLEVVAATPTSLLISWHERD extension (N+8) and no tail) GSRQYYRITYGETGGNSPVQEFTVPGGV RTATISGLKPGVDYTITVYAVTDYFNPT THEYIYQTTPISINYRT 123 I1-GS1O-E4: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV II (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and short tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI GS10 linker (GS10 is SEQ ID SINYRTEIDKGSGSGSGSGSGSGSGSGS NO: 11) to E4 (with N-terminal GSVSDVPRDLEVVAATPTSLLISWHERD extension (N+8) and modified Ser GSRQYYRITYGETGGNSPVQEFTVPGGV or Cys tail), wherein X = Ser or RTATISGLKPGVDYTITVYAVTDYFNPT Cys; may optionally comprise a THEYIYQTTPISINYRTEIDKPXO 6X His tag (SEQ ID NO: 487) 124 Il-GSO-E4: I/E tandem having MGVSDVPRDLEVVAATPTSLLISWSARL Il (with N-terminal extension KVARYYRITYGETGGNSPVQEFTVPKN (N+ 10) and short tail) fused via VYTATISGLKPGVDYTITVYAVTRFRDY GS10 linker (GS10 is SEQ ID QPISINYRTEIDKGSGSGSGSGSGSGSGS NO: 11) to E4 (with N-terminal GSGSVSDVPRDLEVVAATPTSLLISWHE extension (N+8) and a Cys tail) RDGSRQYYRITYGETGGNSPVQEFTVPG with his tag GVRTATISGLKPGVDYTITVYAVTDYFN PTTHEYIYQTTPISINYRTEIDKPCOHHH HHH 125 Il-(PA).-E4: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV Il (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and an E tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI (PA),, linker ((PA)n is SEQ ID SINYRTE(PA).VSDVPRDLEVVAATPTSL NO: 488) to E4 (with N-terminal LISWHERDGSRQYYRITYGETGGNSPVQ extension (N+8) and modified Ser EFTVPGGVRTATISGLKPGVDYTITVYA or Cys tail), wherein n = 3, 6 or 9, VTDYFNPTTHEYIYQTTPISINYRTEIDKP and X = Ser or Cys; may XQ optionally comprise a 6X His tag (SEQ ID NO: 487) 126 E5-GS 10-I1: E/I tandem having VSDVPRDLEVVAATPTSLLISWWAPVD E5 (with N-terminal extension RYQYYRITYGETGGNSPVQEFTVPRDV (N+8) and short tail) fused via YTATISGLKPGVDYTITVYAVTDYKPHA GS 10 linker (GS 10 is SEQ ID DGPHTYHESPISINYRTEIDKGSGSGSGS NO: 11) to Il (with N-terminal GSGSGSGSGSGSVSDVPRDLEVVAATP extension (N+8) and no tail) TSLLISWSARLKVARYYRITYGETGGNS PVQEFTVPKNVYTATISGLKPGVDYTIT VYAVTRFRDYQPISINYRT 90 24039697 .DOC SEQ ID Description Sequence NO: 127 E5-GS 10-I1: E/I tandem having VSDVPRDLEVVAATPTSLLISWWAPVD E5 (with N-terminal extension RYQYYRITYGETGGNSPVQEFTVPRDV (N+8) and short tail) fused via YTATISGLKPGVDYTITVYAVTDYKPHA GS 10 linker (GS 10 is SEQ ID DGPHTYHESPISINYRTEIDKGSGSGSGS NO: 11) to Il (with N-terminal GSGSGSGSGSGSVSDVPRDLEVVAATP extension (N+8) and modified Ser TSLLISWSARLKVARYYRITYGETGGNS or Cys tail), wherein X = Ser or PVQEFTVPKNVYTATISGLKPGVDYTIT Cys; may optionally comprise a VYAVTRFRDYQPISINYRTEIDKPXO 6X His tag (SEQ ID NO: 487) 128 E5-GS 10-Il: E/I tandem having MGVSDVPRDLEVVAATPTSLLISWWAP E5 (with N-terminal extension VDRYQYYRITYGETGGNSPVQEFTVPR (N+10) and short tail) fused via DVYTATISGLKPGVDYTITVYAVTDYKP GS10 linker (GS10 is SEQ ID HADGPHTYHESPISINYRTEIDKGSGSGS NO: 11) to I1 (with N-terminal GSGSGSGSGSGSGSVSDVPRDLEVVAA extension (N+8) and a Cys tail), TPTSLLISWSARLKVARYYRITYGETGG with a His tag NSPVQEFTVPKNVYTATISGLKPGVDYT ITVYAVTRFRDYQPISINYRTEIDKPCQH HHHHH 129 E5-(PA).-Il: E/I tandem having VSDVPRDLEVVAATPTSLLISWWAPVD E5 (with N-terminal extension RYQYYRITYGETGGNSPVQEFTVPRDV (N+8) and an E tail) fused via YTATISGLKPGVDYTITVYAVTDYKPHA (PA),, linker ((PA),, is SEQ ID DGPHTYHESPISINYRTE(PA)VSDVPRD NO: 488) to Il (with N-terminal LEVVAATPTSLLISWSARLKVARYYRIT extension (N+8) and modified Ser YGETGGNSPVQEFTVPKNVYTATISGLK or Cys tail), wherein n = 3, 6 or 9, PGVDYTITVYAVTRFRDYQPISINYRTFI and X = Ser or Cys; may DKPXQ optionally comprise a 6X His tag (SEQ ID NO: 487) 130 Il-GS1O-E5: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV Il (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and short tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI GS10 linker (GS10 is SEQ ID SINYRTEIDKGSGSGSGSGSGSGSGSGS NO: 11) to E5 (with N-terminal GSVSDVPRDLEVVAATPTSLLISWWAP extension (N+8) and no tail) VDRYQYYRITYGETGGNSPVQEFTVPR DVYTATISGLKPGVDYTITVYAVTDYKP HADGPHTYHESPISINYRT 131 Il-GS1O-E5: I/E tandem having VSDVPRDLEVVAATPTSLLISWSARLKV II (with N-terminal extension ARYYRITYGETGGNSPVQEFTVPKNVY (N+8) and short tail) fused via TATISGLKPGVDYTITVYAVTRFRDYQPI GS10 linker (GS10 is SEQ ID SINYRTEIDKGSGSGSGSGSGSGSGSGS NO: 11) to E5 (with N-terminal GSVSDVPRDLEVVAATPTSLLISWWAP extension (N+8) and modified Ser VDRYQYYRITYGETGGNSPVQEFTVPR or Cys tail), wherein X = Ser or DVYTATISGLKPGVDYTITVYAVTDYKP Cys; may optionally comprise a HADGPHTYHESPISINYRTEIDKPXO 6X His tag (SEQ ID NO: 487) 132 Il-GS 10-E5: I/E tandem having MGVSDVPRDLEVVAATPTSLLISWSARL I (with N-terminal extension KVARYYRITYGETGGNSPVQEFTVPKN 91 24039697_ 1.DOC SEQ ID Description Sequence NO: (N+10) and short tail) fused via VYTATISGLKPGVDYTITVYAVTRFRDY GS10 linker (GS10 is SEQ ID QPISINYRTEIDKGSGSGSGSGSGSGSGS NO: 11) to E5 (with N-terminal GSGSVSDVPRDLEVVAATPTSLLISWW extension (N+8) and a Cys tail) APVDRYQYYRITYGETGGNSPVQEFTVP with a His tag RDVYTATISGLKPGVDYTITVYAVTDY KPHADGPHTYHESPISINYRTEIDKPCOH HHHHH 133 I1l-(PA).-E5: I/E tandem having MGVSDVPRDLEVVAATPTSLLISWSARL II (with N-terminal extension KVARYYRITYGETGGNSPVQEFTVPKN (N+8) and an E tail) fused via VYTATISGLKPGVDYTITVYAVTRFRDY (PA), linker ((PA), is SEQ ID QPISINYRTE(PA).VSDVPRDLEVVAATP NO: 488) to E5 (with N-terminal TSLLISWWAPVDRYQYYRITYGETGGN extension (N+8) and modified Ser SPVQEFTVPRDVYTATISGLKPGVDYTIT or Cys tail), wherein n = 3, 6 or 9, VYAVTDYKPHADGPHTYHESPISINYRT and X = Ser or Cys; may EIDKPXO optionally comprise a 6X His tag (SEQ ID NO: 487) 134 BC loop sequence from EGFR XgHERDGSRQX, binder E4, wherein X is any amino acid and g and h are independently selected from 0 to 5 amino acids 135 DE loop sequence from EGFR XiGGVRXj binder E4, wherein X is any amino acid and i and j are independently selected from 0 to 5 amino acids 136 FG loop sequence from EGFR XkDYFNPTTHEYIYQTTX binder E4, wherein X is any amino acid and k and 1 are independently selected from 0 to 5 amino acids 137 BC loop sequence from EGFR XgWAPVDRYQX, binder E5, wherein X is any amino acid and g and h are independently selected from 0 to 5 amino acids 138 DE loop sequence from EGFR XiRDVYXj binder E5, wherein X is any amino acid and i and j are independently selected from 0 to 5 amino acids 139 FG loop sequence from EGFR XkDYKPHADGPHTYHESX binder E5, wherein X is any amino acid and k and I are independently selected from 0 to 92 24039697 .DOC SEQ ID Description Sequence NO: 5 amino acids 140 E85 EGFR monomer with N- MGVSDVPRDLEVVAATPTSLLISWTQG terminal extension (N+ 10) and STHYQYYRITYGETGGNSPVQEFTVPG Ser tail with his tag MVYTATISGLKPGVDYTITVYAVTDYF DRSTHEYKYRTTPISINYRTEIDKPSOHH HHHH 141 E85 EGFR monomer core: E85 EVVAATPTSLLISWTQGSTHYQYYRITY monomer without N-terminal GETGGNSPVQEFTVPGMVYTATISGLKP extension or C-terminal tail GVDYTITVYAVTDYFDRSTHEYKYRTT PISINYRT 142 E85 EGFR monomer, wherein X, XIEVVAATPTSLLISWTQGSTHYQYYRIT is selected from the group YGETGGNSPVQEFTVPGMVYTATISGL consisting of SEQ ID NOs: 69-77 KPGVDYTITVYAVTDYFDRSTHEYKYR and X 2 is selected from the group TTPISINYRTX,, consisting of SEQ ID NOs: 9, 10, or 78-81; in exemplary emobidments, Xi is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10; may optionally comprise a his tag 143 BC loop sequence from EGFR SWTQGSTHYQ binder E85 144 DE loop sequence from EGFR PGMVYT binder E85 145 FG loop sequence from EGFR TDYFDRSTHEYKYRTTP binder E85 146 BC loop sequence from EGFR XgTQGSTHYQXh binder E85, wherein X is any amino acid and g and h are independently selected from 0 to 5 amino acids 147 DE loop sequence from EGFR XiGMVYX, binder E85, wherein X is any amino acid and i and j are independently selected from 0 to 5 amino acids 148 FG loop sequence from EGFR XkDYFDRSTHEYKYRTTX binder E85, wherein X is any amino acid and k and 1 are independently selected from 0 to 5 amino acids 149 E85-GS10-I1: E/I tandem having MGVSDVPRDLEVVAATPTSLLISWTQG E85 (with N-terminal extension STHYQYYRITYGETGGNSPVQEFTVPG (N+10) and a short tail) fused via MVYTATISGLKPGVDYTITVYAVTDYF 93 24039697_1.DOC SEQ ID Description Sequence NO: GS10 linker (GS10 is SEQ ID DRSTHEYKYRTTPISINYRTEIDKGSGSG NO: 11) to Il (with N-terminal SGSGSGSGSGSGSGSVSDVPRDLEVVA extension (N+8) and Cys tail) ATPTSLLISWSARLKVARYYRITYGETG with a 6X His tag (SEQ ID NO: GNSPVQEFTVPKNVYTATISGLKPGVDY 487) TITVYAVTRFRDYQPISINYRTEIDKPCO HHHHHH 150 E85-GS 10-Il core, wherein X 1 is XIEVVAATPTSLLISWTQGSTHYQYYRIT optional and when present is YGETGGNSPVQEFTVPGMVYTATISGL selected from the group KPGVDYTITVYAVTDYFDRSTHEYKYR consisting of SEQ ID NOs: 69- TTPISINYRTEIDKGSGSGSGSGSGSGSG 77, X 2 is optional and when SGSGSVSDVPRDLEVVAATPTSLLISWS present is selected from the group ARLKVARYYRITYGETGGNSPVQEFTVP consisting of SEQ ID NOs: 9, 10, KNVYTATISGLKPGVDYTITVYAVTRFR or 78-81, and n = 3, 6 or 9; in DYQPISINYRTX, exemplary embodiments, X 1 is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 151 E85-(PA),-Il core, wherein X, is XiEVVAATPTSLLISWTQGSTHYQYYRIT optional and when present is YGETGGNSPVQEFTVPGMVYTATISGL selected from the group KPGVDYTITVYAVTDYFDRSTHEYKYR consisting of SEQ ID NOs: 69- TTPISINYRTFE(PA).VSDVPRDLEVVAAT 77, X2 is optional and when PTSLLISWSARLKVARYYRITYGETGGN present is selected from the group SPVQEFTVPKNVYTATISGLKPGVDYTI consisting of SEQ ID NOs: 9, 10, TVYAVTRFRDYQPISINYRTX, or 78-81, and n = 3, 6 or 9; in exemplary embodiments, X, is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 152 Il-GS10-E85: I/E tandem having MGVSDVPRDLEVVAATPTSLLISWSARL 11 (with N-terminal extension KVARYYRITYGETGGNSPVQEFTVPKN (N+10) and a short tail) fused via VYTATISGLKPGVDYTITVYAVTRFRDY GS10 linker (GS10 is SEQ ID QPISINYRTEIDKGSGSGSGSGSGSGSGS NO: 11) to E85 (with N-terminal GSGSVSDVPRDLEVVAATPTSLLISWTQ extension (N+8) and Cys tail) GSTHYQYYRITYGETGGNSPVQEFTVPG with a 6X His tag (SEQ ID NO: MVYTATISGLKPGVDYTITVYAVTDYF 487) DRSTHEYKYRTTPISINYRTEIDKPCOHH HHHH 153 Il-GS10-E85 core, wherein X, is XiEVVAATPTSLLISWSARLKVARYYRIT optional and when present is YGETGGNSPVQEFTVPKNVYTATISGLK selected from the group PGVDYTITVYAVTRFRDYQPISINYRTEI consisting of SEQ ID NOs: 69- DKGSGSGSGSGSGSGSGSGSGSVSDVP 77, X 2 is optional and when RDLEVVAATPTSLLISWTQGSTHYQYY present is selected from the group RITYGETGGNSPVQEFTVPGMVYTATIS consisting of SEQ ID NOs: 9, 10, GLKPGVDYTITVYAVTDYFDRSTHEYK or 78-81, and n = 3, 6 or 9; in YRTTPISINYRTX exemplary embodiments, X, is SEQ ID NO: 69 or 71 and X2 is 94 24039697_ .DOC SEQ ID Description Sequence NO: SEQ ID NO: 9 or 10 154 I1-(PA),-E85 core, wherein Xi is XIEVVAATPTSLLISWSARLKVARYYRIT optional and when present is YGETGGNSPVQEFTVPKNVYTATISGLK selected from the group PGVDYTITVYAVTRFRDYQPISINYRTE( consisting of SEQ ID NOs: 69- PA),VSDVPRDLEVVAATPTSLLISWTQG 77, X 2 is optional and when STHYQYYRITYGETGGNSPVQEFTVPG present is selected from the group MVYTATISGLKPGVDYTITVYAVTDYF consisting of SEQ ID NOs: 9, 10, DRSTHEYKYRTTPISINYRTX2 or 78-81, and n = 3, 6 or 9; in exemplary embodiments, X, is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 155 E90 EGFR monomer with N- MGVSDVPRDLEVVAATPTSLLISWYWE terminal extension (N+ 10) and GLPYQYYRITYGETGGNSPVQEFTVPRD Ser tail with his tag VNTATISGLKPGVDYTITVYAVTDWYN PDTHEYIYHTIPISINYRTEIDKPSOHHHH HH 156 E90 EGFR monomer core: E90 EVVAATPTSLLISWYWEGLPYQYYRITY monomer without N-terminal GETGGNSPVQEFTVPRDVNTATISGLKP extension or C-terminal tail GVDYTITVYAVTDWYNPDTHEYIYHTIP ISINYRT 157 E90 EGFR monomer, wherein X, X 1 EVVAATPTSLLISWYWEGLPYQYYRI is selected from the group TYGETGGNSPVQEFTVPRDVNTATISGL consisting of SEQ ID NOs: 69-77 KPGVDYTITVYAVTDWYNPDTHEYIYH and X2 is selected from the group TIPISINYRTX? consisting of SEQ ID NOs: 9, 10, or 78-81; in exemplary emobidments, Xi is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10; may optionally comprise a his tag 158 BC loop sequence from EGFR SWYWEGLPYQ binder E90 159 DE loop sequence from EGFR PRDVNT binder E90 160 FG loop sequence from EGFR TDWYNPDTHEYIYHTIP binder E90 161 BC loop sequence from EGFR XgYWEGLPYQX, binder E90, wherein X is any amino acid and g and h are independently selected from 0 to 5 amino acids 162 DE loop sequence from EGFR X;RDVNXj binder E90, wherein X is any amino acid and i and j are 95 24039697 .DOC SEQ ID Description Sequence NO: independently selected from 0 to 5 amino acids 163 FG loop sequence from EGFR XkDWYNPDTHEYIYHTIXI binder E90, wherein X is any amino acid and k and 1 are independently selected from 0 to 5 amino acids 164 E90-GS 10-I1: E/I tandem having MGVSDVPRDLEVVAATPTSLLISWYWE E90 (with N-terminal extension GLPYQYYRITYGETGGNSPVQEFTVPRD (N+10) and a short tail) fused via VNTATISGLKPGVDYTITVYAVTDWYN GS10 linker (GS10 is SEQ ID PDTHEYIYHTIPISINYRTEIDKGSGSGSG NO: 11) to Il (with N-terminal SGSGSGSGSGSGSVSDVPRDLEVVAAT extension (N+8) and Cys tail) PTSLLISWSARLKVARYYRITYGETGGN with a 6X His tag (SEQ ID NO: SPVQEFTVPKNVYTATISGLKPGVDYTI 487) TVYAVTRFRDYQPISINYRTEIDKPCQH HHHHH 165 E90-GS10-Il core, wherein X, is XIEVVAATPTSLLISWYWEGLPYQYYRI optional and when present is TYGETGGNSPVQEFTVPRDVNTATISGL selected from the group KPGVDYTITVYAVTDWYNPDTHEYIYH consisting of SEQ ID NOs: 69- TIPISINYRTEIDKGSGSGSGSGSGSGSG 77, X 2 is optional and when SGSGSVSDVPRDLEVVAATPTSLLISWS present is selected from the group ARLKVARYYRITYGETGGNSPVQEFTVP consisting of SEQ ID NOs: 9, 10, KNVYTATISGLKPGVDYTITVYAVTRFR or 78-81, and n = 3, 6 or 9; in DYQPISINYRTX2 exemplary embodiments, Xi is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 166 E90-(PA),-Il core, wherein Xl is XIEVVAATPTSLLISWYWEGLPYQYYRI optional and when present is TYGETGGNSPVQEFTVPRDVNTATISGL selected from the group KPGVDYTITVYAVTDWYNPDTHEYIYH consisting of SEQ ID NOs: 69- TIPISINYRTE(PA).VSDVPRDLEVVAATP 77, X 2 is optional and when TSLLISWSARLKVARYYRITYGETGGNS present is selected from the group PVQEFTVPKNVYTATISGLKPGVDYTIT consisting of SEQ ID NOs: 9, 10, VYAVTRFRDYQPISINYRTX or 78-81, and n = 3, 6 or 9; in exemplary embodiments, Xi is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 167 Il-GS10-E90: I/E tandem having MGVSDVPRDLEVVAATPTSLLISWSARL Il (with N-terminal extension KVARYYRITYGETGGNSPVQEFTVPKN (N+ 10) and a short tail) fused via VYTATISGLKPGVDYTITVYAVTRFRDY GS10 linker (GS10 is SEQ ID QPISINYRTEIDKGSGSGSGSGSGSGSGS NO: 11) to E90 (with N-terminal GSGSVSDVPRDLEVVAATPTSLLISWY extension (N+8) and Cys tail) WEGLPYQYYRITYGETGGNSPVQEFTV with a 6X His tag (SEQ ID NO: PRDVNTATISGLKPGVDYTITVYAVTD 487) WYNPDTHEYIYHTIPISINYRTEIDKPCO HHHHHH 96 24039697_L.DOC SEQ ID Description Sequence NO: 168 I1-GS10-E90 core, wherein Xi is XiEVVAATPTSLLISWSARLKVARYYRIT optional and when present is YGETGGNSPVQEFTVPKNVYTATISGLK selected from the group PGVDYTITVYAVTRFRDYQPISINYRTEI consisting of SEQ ID NOs: 69- DKGSGSGSGSGSGSGSGSGSGSVSDVP 77, X2 is optional and when RDLEVVAATPTSLLISWYWEGLPYQYY present is selected from the group RITYGETGGNSPVQEFTVPRDVNTATIS consisting of SEQ ID NOs: 9, 10, GLKPGVDYTITVYAVTDWYNPDTHEYI or 78-81, and n = 3, 6 or 9; in YHTIPISINYRTX,, exemplary embodiments, Xi is SEQ ID NO: 69 or 71 and X2 is SEQ ID NO: 9 or 10 169 I1-(PA)a-E90 core, wherein XI is XiEVVAATPTSLLISWSARLKVARYYRIT optional and when present is YGETGGNSPVQEFTVPKNVYTATISGLK selected from the group PGVDYTITVYAVTRFRDYQPISINYRTE( consisting of SEQ ID NOs: 69- PA),IVSDVPRDLEVVAATPTSLLISWYW 77, X 2 is optional and when EGLPYQYYRITYGETGGNSPVQEFTVPR present is selected from the group DVNTATISGLKPGVDYTITVYAVTDWY consisting of SEQ ID NOs: 9, 10, NPDTHEYIYHTIPISINYRTX or 78-81, and n = 3, 6 or 9; in exemplary embodiments, Xi is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 170 E96 EGFR monomer with N- MGVSDVPRDLEVVAATPTSLLISWASN terminal extension (N+ 10) and RGTYQYYRITYGETGGNSPVQEFTVPG Ser tail with his tag GVSTATISGLKPGVDYTITVYAVTDAFN PTTHEYNYFTTPISINYRTEDKPSQHHH HHH 171 E96 EGFR monomer core: E96 EVVAATPTSLLISWASNRGTYQYYRITY monomer without N-terminal GETGGNSPVQEFTVPGGVSTATISGLKP extension or C-terminal tail GVDYTITVYAVTDAFNPTTHEYNYFTTP ISINYRT 172 E96 EGFR monomer, wherein X, X 1 EVVAATPTSLLISWASNRGTYQYYRI is selected from the group TYGETGGNSPVQEFTVPGGVSTATISGL consisting of SEQ ID NOs: 69-77 KPGVDYTITVYAVTDAFNPTTHEYNYF and X 2 is selected from the group TTPISINYRTX consisting of SEQ ID NOs: 9, 10, or 78-81; in exemplary emobidments, Xi is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10; may optionally comprise a his tag 173 BC loop sequence from EGFR SWASNRGTYQ binder E96 174 DE loop sequence from EGFR PGGVST binder E96 97 24039697_i.DOC SEQ ID Description Sequence NO: 175 FG loop sequence from EGFR TDAFNPTTHEYNYFTTP binder E96 176 BC loop sequence from EGFR XgASNRGTYQX, binder E96, wherein X is any amino acid and g and h are independently selected from 0 to 5 amino acids 177 DE loop sequence from EGFR XiGGVSXj binder E96, wherein X is any amino acid and i and j are independently selected from 0 to 5 amino acids 178 FG loop sequence from EGFR XkDAFNPTTHEYNYFTTX binder E96, wherein X is any amino acid and k and 1 are independently selected from 0 to 5 amino acids 179 E96-GS10-II: E/I tandem having MGVSDVPRDLEVVAATPTSLLISWASN E96 (with N-terminal extension RGTYQYYRITYGETGGNSPVQEFTVPG (N+10) and a short tail) fused via GVSTATISGLKPGVDYTITVYAVTDAFN GS 10 linker (GS 10 is SEQ ID PTTHEYNYFTTPISINYRTEIDKGSGSGS NO: 11) to Il (with N-terminal GSGSGSGSGSGSGSVSDVPRDLEVVAA extension (N+8) and Cys tail) TPTSLLISWSARLKVARYYRITYGETGG with a 6X His tag (SEQ ID NO: NSPVQEFTVPKNVYTATISGLKPGVDYT 487) ITVYAVTRFRDYQPISINYRTEIDKPCQH HHHHH 180 E96-GS 10-Il core, wherein X, is XIEVVAATPTSLLISWASNRGTYQYYRI optional and when present is TYGETGGNSPVQEFTVPGGVSTATISGL selected from the group KPGVDYTITVYAVTDAFNPTTHEYNYF consisting of SEQ ID NOs: 69- TTPISINYRTEIDKGSGSGSGSGSGSGSG 77, X 2 is optional and when SGSGSVSDVPRDLEVVAATPTSLLISWS present is selected from the group ARLKVARYYRITYGETGGNSPVQEFTVP consisting of SEQ ID NOs: 9, 10, KNVYTATISGLKPGVDYTITVYAVTRFR or 78-81, and n = 3, 6 or 9; in DYQPISINYRTX, exemplary embodiments, X, is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 181 E96-(PA)n-Il core, wherein X1 is XIEVVAATPTSLLISWASNRGTYQYYRI optional and when present is TYGETGGNSPVQEFTVPGGVSTATISGL selected from the group KPGVDYTITVYAVTDAFNPTTHEYNYF consisting of SEQ ID NOs: 69- TTPISINYRTE(PA).VSDVPRDLEVVAAT 77, X 2 is optional and when PTSLLISWSARLKVARYYRITYGETGGN present is selected from the group SPVQEFTVPKNVYTATISGLKPGVDYTI consisting of SEQ ID NOs: 9, 10, TVYAVTRFRDYQPISINYRTX2 or 78-81, and n = 3, 6 or 9; in exemplary embodiments, X 1 is 98 24039697 .DOC SEQ ID Description Sequence NO: SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 182 Il -GS 1 O-E96: I/E tandem having MGVSDVPRDLEVVAATPTSLLISWSARL Il (with N-terminal extension KVARYYRITYGETGGNSPVQEFTVPKN (N+10) and a short tail) fused via VYTATISGLKPGVDYTITVYAVTRFRDY GS10 linker (GS10 is SEQ ID QPISINYRTEIDKGSGSGSGSGSGSGSGS NO: 11) to E96 (with N-terminal GSGSVSDVPRDLEVVAATPTSLLISWAS extension (N+8) and Cys tail) NRGTYQYYRITYGETGGNSPVQEFTVP with a 6X His tag (SEQ ID NO: GGVSTATISGLKPGVDYTITVYAVTDAF 487) NPTTHEYNYFTTPISINYRTEIDKPCOHH HHHH 183 Il-GS10-E96 core, wherein X 1 is XIEVVAATPTSLLISWSARLKVARYYRIT optional and when present is YGETGGNSPVQEFTVPKNVYTATISGLK selected from the group PGVDYTITVYAVTRFRDYQPISINYRTEI consisting of SEQ ID NOs: 69- DKGSGSGSGSGSGSGSGSGSGSVSDVP 77, X 2 is optional and when RDLEVVAATPTSLLISWASNRGTYQYY present is selected from the group RITYGETGGNSPVQEFTVPGGVSTATISG consisting of SEQ ID NOs: 9, 10, LKPGVDYTITVYAVTDAFNPTTHEYNY or 78-81, and n = 3, 6 or 9; in FTTPISINYRTX& exemplary embodiments, X 1 is SEQ ID NO: 69 or 71 and X2 is SEQ ID NO: 9 or 10 184 II -(PA),,-E96 core, wherein Xi is XIEVVAATPTSLLISWSARLKVARYYRIT optional and when present is YGETGGNSPVQEFTVPKNVYTATISGLK selected from the group PGVDYTITVYAVTRFRDYQPISINYRTE( consisting of SEQ ID NOs: 69- PA)IIVSDVPRDLEVVAATPTSLLISWASN 77, X 2 is optional and when RGTYQYYRITYGETGGNSPVQEFTVPG present is selected from the group GVSTATISGLKPGVDYTITVYAVTDAFN consisting of SEQ ID NOs: 9, 10, PTTHEYNYFTTPISINYRTX, or 78-81, and n = 3, 6 or 9; in exemplary embodiments, X, is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 185 E105 EGFR monomer with N- MGVSDVPRDLEVVAATPTSLLISWDAP terminal extension (N+ 10) and TSRYQYYRITYGETGGNSPVQEFTVPGG Ser tail with his tag LSTATISGLKPGVDYTITVYAVTDYKPH ADGPHTYHESPISINYRTEIDKPSOHHHH HH 186 E105 EGFR monomer core: E105 EVVAATPTSLLISWDAPTSRYQYYRITY monomer without N-terminal GETGGNSPVQEFTVPGGLSTATISGLKP extension or C-terminal tail GVDYTITVYAVTDYKPHADGPHTYHES PISINYRT 187 E105 EGFR monomer, wherein XIEVVAATPTSLLISWDAPTSRYQYYRIT

X

1 is selected from the group YGETGGNSPVQEFTVPGGLSTATISGLK consisting of SEQ ID NOs: 69-77 PGVDYTITVYAVTDYKPHADGPHTYHE and X 2 is selected from the group SPISINYRTX, 99 24039697_1.DOC SEQ ID Description Sequence NO: consisting of SEQ ID NOs: 9, 10, or 78-81; in exemplary emobidments, X, is SEQ ID NO: 69 or 71 and X2 is SEQ ID NO: 9 or 10; may optionally comprise a his tag 188 BC loop sequence from EGFR SWDAPTSRYQ binder E105 189 DE loop sequence from EGFR PGGLST binder E105 117 FG loop sequence from EGFR TDYKPHADGPHTYHESP binder E105 190 BC loop sequence from EGFR XgDAPTSRYQXI, binder E105, wherein X is any amino acid and g and h are independently selected from 0 to 5 amino acids 191 DE loop sequence from EGFR XiGGLSX 1 binder E105, wherein X is any amino acid and i and j are independently selected from 0 to 5 amino acids 139 FG loop sequence from EGFR XkDYKPHADGPHTYHESX, binder E105, wherein X is any amino acid and k and I are independently selected from 0 to 5 amino acids 192 E105-GS10-I1: E/I tandem MGVSDVPRDLEVVAATPTSLLISWDAP having E105 (with N-terminal TSRYQYYRITYGETGGNSPVQEFTVPGG extension (N+10) and a short tail) LSTATISGLKPGVDYTITVYAVTDYKPH fused via GS10 linker (GS10 is ADGPHTYHESPISINYRTEIDKGSGSGSG SEQ ID NO: 11) to Il (with N- SGSGSGSGSGSGSVSDVPRDLEVVAAT terminal extension (N+8) and Cys PTSLLISWSARLKVARYYRITYGETGGN tail) with a 6X His tag (SEQ ID SPVQEFTVPKNVYTATISGLKPGVDYTI NO: 487) TVYAVTRFRDYQPISINYRTEIDKPCOH HHHHH 193 E105-GS10-Il core, wherein X, XEVVAATPTSLLISWDAPTSRYQYYRIT is optional and when present is YGETGGNSPVQEFTVPGGLSTATISGLK selected from the group PGVDYTITVYAVTDYKPHADGPHTYHE consisting of SEQ ID NOs: 69- SPISINYRTEIDKGSGSGSGSGSGSGSGS 77, X 2 is optional and when GSGSVSDVPRDLEVVAATPTSLLISWSA present is selected from the group RLKVARYYRITYGETGGNSPVQEFTVPK consisting of SEQ ID NOs: 9, 10, NVYTATISGLKPGVDYTITVYAVTRFRD or 78-81, and n = 3, 6 or 9; in YQPISINYRTX, exemplary embodiments, X 1 is 100 24039697 1.DOC SEQ ID Description Sequence NO: SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 194 E105-(PA)n-Il core, wherein X1 XIEVVAATPTSLLISWDAPTSRYQYYRIT is optional and when present is YGETGGNSPVQEFTVPGGLSTATISGLK selected from the group PGVDYTITVYAVTDYKPHADGPHTYHE consisting of SEQ ID NOs: 69- SPISINYRTE(PA).VSDVPRDLEVVAATP 77, X 2 is optional and when TSLLISWSARLKVARYYRITYGETGGNS present is selected from the group PVQEFTVPKNVYTATISGLKPGVDYTIT consisting of SEQ ID NOs: 9, 10, VYAVTRFRDYQPISINYRTX2 or 78-81, and n = 3, 6 or 9; in exemplary embodiments, X, is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 195 Il -GS 10-E105: I/E tandem MGVSDVPRDLEVVAATPTSLLISWSARL havingl1 (with N-terminal KVARYYRITYGETGGNSPVQEFTVPKN extension (N+10) and a short tail) VYTATISGLKPGVDYTITVYAVTRFRDY fused via GS10 linker (GS10 is QPISINYRTEIDKGSGSGSGSGSGSGSGS SEQ ID NO: 11) to E105 (with GSGSVSDVPRDLEVVAATPTSLLISWDA N-terminal extension (N+8) and PTSRYQYYRITYGETGGNSPVQEFTVPG Cys tail) with a 6X His tag (SEQ GLSTATISGLKPGVDYTITVYAVTDYKP ID NO: 487) HADGPHTYHESPISINYRTEIDMKPCHH HHHH 196 I1 -GS 10-El 05 core, wherein Xi XIEVVAATPTSLLISWSARLKVARYYRIT is optional and when present is YGETGGNSPVQEFTVPKNVYTATISGLK selected from the group PGVDYTITVYAVTRFRDYQPISINYRTEI consisting of SEQ ID NOs: 69- DKGSGSGSGSGSGSGSGSGSGSVSDVP 77, X 2 is optional and when RDLEVVAATPTSLLISWDAPTSRYQYYR present is selected from the group ITYGETGGNSPVQEFTVPGGLSTATISGL consisting of SEQ ID NOs: 9, 10, KPGVDYTITVYAVTDYKPHADGPHTYH or 78-81, and n= 3, 6 or 9; in ESPISINYRTX, exemplary embodiments, X, is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 197 I1-(PA)-E105 core, wherein Xi XIEVVAATPTSLLISWSARLKVARYYRIT is optional and when present is YGETGGNSPVQEFTVPKNVYTATISGLK selected from the group PGVDYTITVYAVTRFRDYQPISINYRTE( consisting of SEQ ID NOs: 69- PA).VSDVPRDLEVVAATPTSLLISWDAP 77, X2 is optional and when TSRYQYYRITYGETGGNSPVQEFTVPGG present is selected from the group LSTATISGLKPGVDYTITVYAVTDYKPH consisting of SEQ ID NOs: 9, 10, ADGPHTYHESPISINYRTX or 78-81, and n = 3, 6 or 9; in exemplary embodiments, X 1 is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 198 E 112 EGFR monomer with N- MGVSDVPRDLEVVAATPTSLLISWDAG terminal extension (N+ 10) and AVTYQYYRITYGETGGNSPVQEFTVPG Ser tail with his tag GVRTATISGLKPGVDYTITVYAVTDYKP 101 24039697 I.DOC SEQ ID Description Sequence NO: HADGPHTYHEYPISINYRTEIDKPSOHH HHHH 199 El 12 EGFR monomer core: El 12 EVVAATPTSLLISWDAGAVTYQYYRITY monomer without N-terminal GETGGNSPVQEFTVPGGVRTATISGLKP extension or C-terminal tail GVDYTITVYAVTDYKPHADGPHTYHEY PISINYRT 200 E 112 EGFR monomer, wherein XIEVVAATPTSLLISWDAGAVTYQYYRI X, is selected from the group TYGETGGNSPVQEFTVPGGVRTATISGL consisting of SEQ ID NOs: 69-77 KPGVDYTITVYAVTDYKPHADGPHTYH and X 2 is selected from the group EYPISINYRTX2 consisting of SEQ ID NOs: 9, 10, or 78-81; in exemplary emobidments, X, is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10; may optionally comprise a his tag 201 BC loop sequence from EGFR SWDAGAVTYQ binder E112 110 DE loop sequence from EGFR PGGVRT binder E112 202 FG loop sequence from EGFR TDYKPHADGPHTYHEYP binder E112 203 BC loop sequence from EGFR XgDAGAVTYQXI binder E 112, wherein X is any amino acid and g and h are independently selected from 0 to 5 amino acids 135 DE loop sequence from EGFR XiGGVRX, binder E 112, wherein X is any amino acid and i and j are independently selected from 0 to 5 amino acids 204 FG loop sequence from EGFR XkDYKPHADGPHTYHEYX binder El 12, wherein X is any amino acid and k and I are independently selected from 0 to 5 amino acids 205 El 12-GS10-I1: E/I tandem MGVSDVPRDLEVVAATPTSLLISWDAG having E 112 (with N-terminal AVTYQYYRITYGETGGNSPVQEFTVPG extension (N+10) and a short tail) GVRTATISGLKPGVDYTITVYAVTDYKP fused via GS 10 linker (GS 10 is HADGPHTYHEYPISINYRTEIDKGSGSG SEQ ID NO: 11) to Il (with N- SGSGSGSGSGSGSGSVSDVPRDLEVVA terminal extension (N+8) and Cys ATPTSLLISWSARLKVARYYRITYGETG tail) with a 6X His tag (SEQ ID GNSPVQEFTVPKNVYTATISGLKPGVDY TITVYAVTRFRDYQPISINYRTEIDKPCO 102 24039697 .DOC SEQ ID Description Sequence NO: NO: 487) HHHHHH 206 El 12-GS 10-Il core, wherein XI XIEVVAATPTSLLISWDAGAVTYQYYRI is optional and when present is TYGETGGNSPVQEFTVPGGVRTATISGL selected from the group KPGVDYTITVYAVTDYKPHADGPHTYH consisting of SEQ ID NOs: 69- EYPISINYRTEIDKGSGSGSGSGSGSGSG 77, X2 is optional and when SGSGSVSDVPRDLEVVAATPTSLLISWS present is selected from the group ARLKVARYYRITYGETGGNSPVQEFTVP consisting of SEQ ID NOs: 9, 10, KNVYTATISGLKPGVDYTITVYAVTRFR or 78-81, and n = 3, 6 or 9; in DYQPISINYRTX, exemplary embodiments, Xi is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 207 E1 12-(PA),,-II core, wherein X1 XiEVVAATPTSLLISWDAGAVTYQYYRI is optional and when present is TYGETGGNSPVQEFTVPGGVRTATISGL selected from the group KPGVDYTITVYAVTDYKPHADGPHTYH consisting of SEQ ID NOs: 69- EYPISINYRTE(PA).VSDVPRDLEVVAAT 77, X 2 is optional and when PTSLLISWSARLKVARYYRITYGETGGN present is selected from the group SPVQEFTVPKNVYTATISGLKPGVDYTI consisting of SEQ ID NOs: 9, 10, TVYAVTRFRDYQPISINYRTX or 78-81, and n = 3, 6 or 9; in exemplary embodiments, X, is SEQ ID NO: 69 or 71 and X2 is SEQ ID NO: 9 or 10 208 Il-GS 10-E 112: I/E tandem MGVSDVPRDLEVVAATPTSLLISWSARL having Il (with N-terminal KVARYYRITYGETGGNSPVQEFTVPKN extension (N+10) and a short tail) VYTATISGLKPGVDYTITVYAVTRFRDY fused via GS10 linker (GS10 is QPISINYRTEIDKGSGSGSGSGSGSGSGS SEQ ID NO: 11) to El 12 (with GSGSVSDVPRDLEVVAATPTSLLISWDA N-terminal extension (N+8) and GAVTYQYYRITYGETGGNSPVQEFTVP Cys tail) with a 6X His tag (SEQ GGVRTATISGLKPGVDYTITVYAVTDY ID NO: 487) KPHADGPHTYHEYPISINYRTEIDKPCO HHHHHH 209 I1-GS 10-El 12 core, wherein X 1 XIEVVAATPTSLLISWSARLKVARYYRIT is optional and when present is YGETGGNSPVQEFTVPKNVYTATISGLK selected from the group PGVDYTITVYAVTRFRDYQPISINYRTEI consisting of SEQ ID NOs: 69- DKGSGSGSGSGSGSGSGSGSGSVSDVP 77, X 2 is optional and when RDLEVVAATPTSLLISWDAGAVTYQYY present is selected from the group RITYGETGGNSPVQEFTVPGGVRTATIS consisting of SEQ ID NOs: 9, 10, GLKPGVDYTITVYAVTDYKPHADGPHT or 78-81, and n = 3, 6 or 9; in YHEYPISINYRTX2 exemplary embodiments, Xi is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 210 I1-(PA).-E 112 core, wherein XI XIEVVAATPTSLLISWSARLKVARYYRIT is optional and when present is YGETGGNSPVQEFTVPKNVYTATISGLK selected from the group PGVDYTITVYAVTRFRDYQPISINYRTE( consisting of SEQ ID NOs: 69- PA),IVSDVPRDLEVVAATPTSLLISWDAG 103 24039697 1.DOC SEQ ID Description Sequence NO: 77, X 2 is optional and when AVTYQYYRITYGETGGNSPVQEFTVPG present is selected from the group GVRTATISGLKPGVDYTITVYAVTDYKP consisting of SEQ ID NOs: 9, 10, HADGPHTYHEYPISINYRTX, or 78-81, and n = 3, 6 or 9; in exemplary embodiments, X 1 is SEQ ID NO: 69 or 71 and X 2 is SEQ ID NO: 9 or 10 211 I1-GSGCGS8-E5: I/E tandem MGVSDVPRDLEVVAATPTSLLISWSARL having Il (with N-terminal KVARYYRITYGETGGNSPVQEFTVPKN extension (N+ 10) and a modified VYTATISGLKPGVDYTITVYAVTRFRDY short tail) fused via GSGCGS8 QPISINYRTEIEKGSGCGSGSGSGSGSGS linker (GSGCGS8 is SEQ ID NO: GSGSVSDVPRDLEVVAATPTSLLISWW 218) to E5 (with N-terminal APVDRYQYYRITYGETGGNSPVQEFTVP extension (N+8) and an E tail) RDVYTATISGLKPGVDYTITVYAVTDY with an optional 6X His tag (SEQ KPHADGPHTYHESPISJNYRTEHHHHHH ID NO: 487) 212 Il -GS 10-E5-GSGC: I/E tandem MGVSDVPRDLEVVAATPTSLLISWSARL having I1 (with N-terminal KVARYYRITYGETGGNSPVQEFTVPKN extension (N+ 10) and a modified VYTATISGLKPGVDYTITVYAVTRFRDY short tail) fused via GS10 linker QPISINYRTEIEKGSGSGSGSGSGSGSGS (GS10 is SEQ ID NO: 11) to E5 GSGSVSDVPRDLEVVAATPTSLLISWW (with N-terminal extension (N+8) APVDRYQYYRITYGETGGNSPVQEFTVP and a modified Cys tail) with an RDVYTATISGLKPGVDYTITVYAVTDY optional 6X His tag (SEQ ID NO: KPHADGPHTYHESPISINYRTEGSGCHH 487) HHHH 213 I1 (S62C)-GS 10-E5: I/E tandem MGVSDVPRDLEVVAATPTSLLISWSARL having Il (with N-terminal KVARYYRITYGETGGNSPVQEFTVPKN extension (N+10), an S62C VYTATICGLKPGVDYTITVYAVTRFRDY substitution (boxed), and a QPISINYRTEIEKGSGSGSGSGSGSGSGS modified short tail) fused via GSGSVSDVPRDLEVVAATPTSLLISWW GS10 linker (GS10 is SEQ ID APVDRYQYYRITYGETGGNSPVQEFTVP NO: 11) to E5 (with N-terminal RDVYTATISGLKPGVDYTITVYAVTDY extension (N+8) and an E tail) KPHADGPHTYHESPISINYRTEHHHHHH with an optional 6X His tag (SEQ ID NO: 487); position 62 refers to the amino acid corresponding to position 62 of SEQ ID NO:1 214 Il-GS10-E5(S62C): I/E tandem MGVSDVPRDLEVVAATPTSLLISWSARL having II (with N-terminal KVARYYRITYGETGGNSPVQEFTVPKN extension (N+10) and a modified VYTATISGLKPGVDYTITVYAVTRFRDY short tail) fused via GS10 linker QPISINYRTEIEKGSGSGSGSGSGSGSGS (GS10 is SEQ ID NO: 11) to E5 GSGSVSDVPRDLEVVAATPTSLLISWW (with N-terminal extension APVDRYQYYRITYGETGGNSPVQEFTVP (N+8), an S62C substitution RDVYTATICGLKPGVDYTITVYAVTDY (boxed), and an E tail) with an KPHADGPHTYHESPISINYRTEHHHHHH optional 6X His tag (SEQ ID NO: 487); position 62 refers to the 104 24039697 I.DOC SEQ ID Description Sequence NO: amino acid corresponding to position 62 of SEQ ID NO: 1 215 11(S91 C)-GS 10-E5: I/E tandem MGVSDVPRDLEVVAATPTSLLISWSARL having I1 (with N-terminal KVARYYRITYGETGGNSPVQEFTVPKN extension (N+ 10), an S91C VYTATISGLKPGVDYTITVYAVTRFRDY substitution (boxed), and a QPI1INYRTEEKGSGSGSGSGSGSGSGS modified short tail) fused via GSGSVSDVPRDLEVVAATPTSLLISWW GS10 linker (GS10 is SEQ ID APVDRYQYYRITYGETGGNSPVQEFTVP NO: 11) to E5 (with N-terminal RDVYTATISGLKPGVDYTITVYAVTDY extension (N+8) and an E tail) KPHADGPHTYHESPISTNYRTEHHHHHH with an optional 6X His tag (SEQ ID NO: 487); position 91 refers to the amino acid corresponding to position 91 of SEQ ID NO:l 216 Il -GS 10-E5(S91 C): I/E tandem MGVSDVPRDLEVVAATPTSLLISWSARL having Il (with N-terminal KVARYYRITYGETGGNSPVQEFTVPKN extension (N+10) and a modified VYTATISGLKPGVDYTITVYAVTRFRDY short tail) fused via GS10 linker QPISINYRTEIEKGSGSGSGSGSGSGSGS (GS10 is SEQ ID NO: 11) to E5 GSGSVSDVPRDLEVVAATPTSLLISWW (with N-terminal extension APVDRYQYYRITYGETGGNSPVQEFTVP (N+8), an S91C substitution RDVYTATISGLKPGVDYTITVYAVTDY (boxed), and an E tail) with an KPHADGPHTYHESPIINYRTEHHHHHH optional 6X His tag (SEQ ID NO: 487); position 91 refers to the amino acid corresponding to position 91 of SEQ ID NO:1 217 Modified short tail EIEK 218 GSGCGS8 Linker GSGCGSGSGSGSGSGSGSGS Example 1: In Cell Western Assay to Screen for EGFR Activity In Cell Western assays were developed to screen various single ' 0 Fn3 clones for the ability to inhibit EGFR activity in order to identify those that could be linked with IGFIR 1 0 Fn3 binders to construct E/I binders. In Cell Western assays were also used to screen and determine relative potency of specific E/I 1 0 Fn3 binders. Two In Cell Western assays were developed to measure 1) inhibition of EGF stimulated EGFR phosphorylation or 2) inhibition of EGF-stimulated ERK phosphorylation. Cells were seeded into poly-D-lysine coated 96-well microtiter plates (Becton Dickinson, Franklin Lakes, NJ) at 24,000 cells/well for A431 epidermoid carcinoma or FaDu head & neck carcinoma cells and allowed to adhere overnight. Cells were washed once and then incubated for 24 hours in serum free 105 24039697 1.DOC media. Serial dilutions of the 1 0 Fn3-based binders were next applied to the cells and incubated for 2-3 hours prior to stimulation with 100 ng/ml EGF for 10 minutes. Following stimulation, cells were fixed for 20 minutes in PBS containing 3.7% formaldehyde and then permeabilized in PBS containing 0.1% triton-X-100 for 15 minutes. Cells were blocked for one hour in Odyssey blocker (Li-Cor Biosciences, Lincoln, Nebraska) and incubated with antibodies to detect either EGFR phosphorylated on tyrosine 1068 (Cell Signaling, Beverly, MA) and f-actin (Sigma, St. Louis, MO) or pERK (MAP kinase phosphorylated on tyrosine 202/threonine 204) and total ERK (Santa Cruz Biotechnology, Santa Cruz, CA). After washing three times in PBS containing 0.1% tween-20, secondary antibodies were added (Invitrogen, Carlsbad, CA or Rockland, Gilbertsville, PA). Cells were washed three times in PBS containing 0.1% tween-20 and imaged on a Li-Cor Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, Nebraska). Each clone was assayed in duplicate or triplicate and values were normalized to f-actin for the pEGFR assay and total ERK for the pERK assay. IC50 values were calculated from linear regression analysis of percent inhibition of maximum signal minus background. Results yielded various ' 0 Fn3 clones that had ability to inhibit activity of EGFR, and showed that certain specific E/I ' 0 Fn3 binders possessed similar activity to the example shown in Figure 9. Example 2: Expression of 10 Fn3-based binders E/I binders were produced by covalently linking an EGFR-binding ' 0 Fn3 to an IGFIR-binding 1 0 Fn3 using a glycine-serine linker, thereby generating 10Fn3 dimers, wherein each ' 0 Fn3 domain binds to a different target. The IGFIR-binding

'

0 Fn3 (Il) was previously described as SEQ ID NO: 226 in PCT Publication No. WO 2008/066752. Two novel EGFR-binding 1 0 Fn3 (E2 and El) were identified by screening an RNA-protein fusion library, as described in PCT Publication No. WO 2008/066752, for binders to EGFR-Fc (R&D Systems, Minneapolis, MN). The following examples describe results using a variety of His-tagged E/I ' 0 Fn3-based binders (non-pegylated): E2-GS10-Il (SEQ ID NO: 25), El-GS1O-I1 (SEQ ID NO: 31), I1-GS1O-El (SEQ ID NO: 28), and Il-GS1O-E2 (SEQ ID NO: 22). 106 24039697_I.DOC The following examples also describe results with the following pegylated, His-tagged E/I 1 0 Fn3-based binders: El-GS10-Il (SEQ ID NO: 55), E2-GS10-Il (SEQ ID NO: 56), E3-GS10-Il (SEQ ID NO: 53), Il-GS1O-El (SEQ ID NO: 57), I1-GS10-E2 (SEQ ID NO: 58), Il-GS10-E3 (SEQ ID NO: 54), E4-GS10-Il (SEQ ID NO: 120), Il-GS10-E4 (SEQ ID NO: 124), E5-GS10-Il (SEQ ID NO: 128), Il GS10-E5 (SEQ ID NO: 132), E85-GS1O-I1 (SEQ ID NO: 149), Il-GS10-E85 (SEQ ID NO: 152), E90-GS10-I1 (SEQ ID NO: 164), E96-GS1O-Il (SEQ ID NO: 179), E105-GS10-Il (SEQ ID NO: 192), Il-GS10-E105 (SEQ ID NO: 195), E112-GS10 Il (SEQ ID NO: 205), I1-GS10-E112 (SEQ ID NO: 208), I1-GSGCGS8-E5 (SEQ ID NO: 211), Il-GS10-E5-GSGC (SEQ ID NO: 212), Il(S62C)-GSO-E5 (SEQ ID NO: 213), I1-GS10-E5(S62C) (SEQ ID NO: 214), I1(S91C)-GSO-E5 (SEQ ID NO: 215), and I1-GS10-E5(S91C) (SEQ ID NO: 216). The examples also describe results using a His-tagged IGFRIR ' 0 Fn3-based binder, Il (SEQ ID NO: 4), and ten His-tagged EGFR 1 0 Fn3-based binders, E2 (SEQ ID NO: 6), El (SEQ ID NO: 8), E3 (SEQ ID NO: 52), E4 (SEQ ID NO: 107), E5 (SEQ ID NO: 113, wherein X = Ser and with a His tag at the C-terminus), E5 pegylated (SEQ ID NO: 113, wherein X = Cys and with a His tag at the C-terminus), E85 (SEQ ID NO: 140), E90 (SEQ ID NO: 155), E96 (SEQ ID NO: 170), E105 (SEQ ID NO: 185), and E112 (SEQ ID NO: 198). Examples 32 also describes a variety of E monomers having the sequences set forth in Figure 45 and including a His tag at the C-terminus. The various ' 0 Fn3-based binders were purified using a high throughput protein production process (HTPP). Selected binders were cloned into the pET9d vector in order to generate His 6 tag (SEQ ID NO: 487) fusions. DNA was transformed into . coli HMS 1 74(DE3), and cells were inoculated in 5 ml LB medium containing 50 ptg/mL kanamycin in a 24-well format and grown at 37 'C overnight. Fresh 5 ml LB medium (50 ptg/mL kanamycin) cultures were prepared for inducible expression by aspirating 200 pl from the overnight culture and dispensing it into the appropriate well. The cultures were grown at 37 'C until A 6 00 0.6-0.9. After induction with 1 mM isopropyl--thiogalactoside (IPTG), the culture was grown for another 6 hours at 30 C and harvested by centrifugation for 10 minutes at 3220 x g at 4 C. Cell pellets were frozen at 80 C. 107 24039697_.DOC Cell pellets (in 24-well format) were lysed by resuspension in 450 tl of Lysis buffer (50 mM NaH 2

PO

4 , 0.5 M NaCl, lx Complete TM Protease Inhibitor Cocktail EDTA free (Roche), 1 mM PMSF, 10 mM CHAPS, 40 mM imidazole, 1 mg/ml lysozyme, 30 ug/ml DNAse, 2 pg/ml aprotonin, pH 8.0) and shaken at room temperature for 1 hour. Lysates were clarified and re-racked into a 96-well format by transfer into a 96-well Whatman GF/D Unifilter fitted with a 96-well, 650 ptl catch plate and centrifuged for 5 minutes at 200 x g. The clarified lysates were transferred to a 96-well Ni-Chelating Plate that had been equilibrated with equilibration buffer (50 mM NaH 2

PO

4 , 0.5 M NaCl,10 mM CHAPS, 40 mM imidazole, pH 8.0) and incubated for 5 minutes. Unbound material was removed by vacuum. The resin was washed 2 x 0.3 ml/well with Wash buffer #1 (50 mM NaH 2

PO

4 , 0.5 M NaCl, 5 mM CHAPS, 40 mM imidazole, pH 8.0) with each wash removed by vacuum. Next, the resin was washed with 3 x 0.3 ml/well with PBS with each wash step removed by vacuum. Prior to elution, each well was washed with 50 pl Elution buffer (PBS + 20 mM EDTA), incubated for 5 minutes, and the wash discarded by vacuum. Protein was eluted by applying an additional 100 pl of Elution buffer to each well. After a 30 minute incubation at room temperature, the plate(s) were centrifuged for 5 minutes at 200 x g and eluted protein collected in 96 well catch plates containing 5 pl of 0.5 M MgCl 2 affixed to the bottom of the Ni plates. Eluted protein was quantified using a BCA Protein assay with SEQ ID NO: 2 as the protein standard. HTPP yielded active 1 0 Fn3-based binders that were expressed in a soluble form and purified from the soluble fraction of the bacterial cytosol. Figure 1 depicts an exemplary SDS-PAGE analysis from one of the E/I 1 0 Fn3-based binders. SEC analysis on a Superdex 200 5/150 GL in a mobile phase of 100 mM NaPO4, 100 mM NaSO4, 150 mM NaCl, pH 6.8 (GE Healthcare) demonstrated predominantly monomeric proteins (see Example 4). In addition, midscale expression and purification of select 1 0 Fn3-based binders was performed. The selected binders, fused to a His 6 tag (SEQ ID NO: 487), were cloned into a pET9d or pET29 vector and expressed in E. coli HMS 1 74(DE3) or BL212(DE3) (EMD Biosciences, San Diego, CA) cells. 20 ml of an inoculum culture (generated from a single plated colony) was used to inoculate 1 liter of LB 108 24039697_ .DOC medium containing 50 pg/mL kanamycin. The culture was grown at 37 'C until

A

6 0 0 0.6-1.0. After induction with 1 mM isopropyl-f-thiogalactoside (IPTG), the culture was grown for another 6 hours at 30 C. Alternatively, expression was carried out at 18 C after initial growth at 37 C using autoinduction media ("ONE" medium, EMD Biosciences, San Diego, CA). Cell pellets were harvested by centrifugation for 30 minutes at : 0,000 x g at 4 0 C and frozen at 80 C. The cell pellet was resuspended in 25 mL of lysis buffer (20 mM NaH 2

PO

4 , 0.5 M NaCl, lx Complete TM Protease Inhibitor Cocktail-EDTA free (Roche), pH 7.4) using an Ultra turrax homgenizer on ice. Cell lysis was achieved by high pressure homogenization ( - 8,000psi) using a Model M- 1IOS Microfluidizer (Microfluidics). The soluble fraction was separated by centrifugation for 30 minutes at 23,300 x g at 4 'C. The supernatant was clarified via 0.45 ptm filter. The clarified lysate was loaded onto a HisTrap column (GE) pre-equilibrated with 20 mM NaH 2

PO

4 , 0.5 M NaCl, pH 7.4. The column was then washed with 25 column volumes of 20 mM NaH 2

PO

4 , 0.5 M NaCl, pH 7.4, followed by 20 column volumes of 20 mM NaH 2

PO

4 , 0.5 M NaCl, 25 mM imidazole, pH 7.4, and then 35 column volumes of 20 mM NaH 2

PO

4 , 0.5 M NaCl, 40 mM imidazole, pH 7.4. Protein was eluted with 15 column volumes of 20 mM NaH 2

PO

4 , 0.5 M NaCl, 500 mM imidazole, pH 7.4, fractions pooled based on absorbance at A 280 and dialyzed against lx PBS, 50 mM Tris, 150 mM NaCl, pH 8.5 or 50 mM NaOAc, 150 mM NaCl, pH4.5. Any precipitate was removed by filtering at 0.22 ,m. Midscale expression and purification yielded highly pure and active proteins that were expressed in a soluble form and purified from the soluble fraction of the bacterial cytosol. SEC analysis on a Superdex 200 10/30GL in a mobile phase of 100 mM NaPO 4 , 100 mM NaSO 4 , 150 mM NaCl, pH 6.8 (GE Healthcare) demonstrated predominantly monomeric proteins (see Example 4). Example 3: Pegylation of E/I Fn3-Based Binders Multi-valent fibronectin based scaffold proteins, such as E/I 1 0 Fn3-based binders, can be pegylated with various sizes and types of PEG. To allow for pegylation, the protein is typically modified near the C-terminus by a single point mutation of an amino acid, typically a serine, to a cysteine. PEGylation of the 109 24039697_i.DOC protein at the single cysteine residue is accomplished through conjugation with various maleimide-derivatized PEG forms by combining the derivitized-PEG reagent with the protein solution and incubating. Progress and confirmation of the PEGylation conjugation reaction can be confirmed by SDS-PAGE and/or SE-HPLC methods that separate the non-PEGylated protein from the PEGylated protein. For example, the construct E2-GS 10-Il (SEQ ID NO: 25) was pegylated by replacing a serine that was at position 221 with a cysteine. The resulting construct, SEQ ID NO: 56, was then conjugated with a maleimide-derivatized 40 kDa branched PEG (NOF America Corporation, White Plains, NY). The derivatized PEG reagent was mixed with the protein construct in solution and incubated at pH 7.40 at Room temperature until the reaction was complete, typically 30 minutes or overnight at 4 C. The pH was lowered to pH 4.5 or pH 5.0 by dialysis or rapid desalting using size exclusion column chromotography into in 50 NaOAc, 150 mM NaCl buffer. The mixture of products and excess reactants from the PEGylation reaction were then loaded onto a cation exchange chromotography column at the lowered pH and eluted with a 150 mM to 1 M NaCl gradient. Studies to confirm the pegylation were also conducted as described in the paragraph above. The conjugations can be performed with the His tagged or the His-Tag free versions of the protein. On occasions in which E coli endotoxin contamination needed to be depleted in the sample, two methods used either separately or in conjunction with one another were empoloyed. The first was to wash the cation exchange column with typically 5 column volumes NaOAc buffer supplemented with 0.5% Triton X- 100, followed by 20 column volumes (or more) of the same buffer without Triton X-100. Additionally or in place of this procedure, the protein was passed very slowly through a Sartorius Sartobind@ Q filter (Sartorius Stedim Biotech Bohemia, New York). Two of the E/I I 0 Fn3-based binders, E2-GS1O-Il-cys (with his) (SEQ ID NO: 56) and E3-GS1O-I1-Cys (with his) (SEQ ID NO: 53), were pegylated using an alternative procedure. Five ml of an inoculum culture of BL21(DE3) E. coli cells containing a T7 ploymerase driven pET29 plasmid encoding either E2-GS 10-Il -cys (with his) or E3-GS10-Il-Cys (with his), were generated from a single plated colony 110 24039697_l.DOC and used to inoculate 1 liter of auto-induction media ("ONE" medium, EMD Biosciences, San Diego, CA) containing 50 tg/mL kanamycin. Expression was carried out at 18 "C after initial growth at 37 'C and harvested by centrifugation for 10 minutes at -10,000 x g at 4 C. Cell pellets were frozen at 80 C. The cell pellet was resuspended in 10 mL of lysis buffer (20 mM NaH 2

PO

4 , 0.5 M NaCl, 5 mM Immidazole, pH 7.4) and mechanically lysed using an Avestin homgenizer. The soluble fraction was separated by centrifugation for 15 minutes at 23,300 x g at 4 'C. The supernatant was decanted and the pellet was solubilized in Lysis buffer (above) supplemented with 4 M to 6 M guanidine hydrochloride (GdnHCl). Solubilized protein was then purified on a suitably sized NiNTA column (Qiagen, Inc.) pre-equilibrated with the GdnHCL supplemented Lysis Buffer. The column was then washed with 5 to 10 column volumes of the same buffer, followed by elution with the same buffer supplemented with 300 mM Immidazole. The fractions eluted off the column containing the protein of interest were diluted to 2-3 mgs/mL protein and then combined with a 1.2-1.5 molar excess of solid NEM-PEG (40 kDa branched or other). The mixture was allowed to react at room temperature for 30 minutes or until the reaction was complete. The entire reaction volume was then placed into a dialysis bag (5,000 Da Molecular Weight cutoff) and the mixture was subjected to a dialysis refolding process. For example, this process may consist of two 10-16 hour 500:1 (buffer: dialysate) dialysis exchanges against 50mM NaOAc, 150 mm NaCl, pH 4.5. The dialysate from this procedure contains properly folded, PEGylated materials plus excess reactants. The mixture of products and excess reactants from the PEGylation reaction were clarified via centrifugation or filtration prior to loading them onto a cation exchange chromotography column (SP Sepharose or Resource S, GE Healthcare). The column was developed with 150 mM to 1 M NaCl gradient in the NaOAc background buffer. Studies to confirm the pegylation were conducted as described above. Example 4: Biophysical Characterization of 1 0 Fn3-Based Binders Standard size exclusion chromatography (SEC) was performed on the proteins purified from the HTPP and the midscale processes (0.1 to 1 tg of protein for HTPP and 10-50 ug for midscale). SEC of HTPP derived material was 111 24039697 I.DOC performed using a Superdex 200 5/150 column (GE Healthcare) or on a Superdex 200 10/30 column (GE Healthcare) for midscaled material on an Agilent 1100 or 1200 HPLC system with UV detection at A 21 4 nm and A 280 nm and with fluorescence detection (excitation = 28Onm, emission = 3 5 onm). A buffer of 100 mM sodium sulfate, 100 mM sodium phosphate, 150 mM sodium chloride, pH 6.8 at appropriate flow rate of the SEC column employed. Gel filtration standards (Bio-Rad Laboratories, Hercules, CA) were used for molecular weight calibration. The results of the SEC on the HTPP purified ' 0 Fn3-based binders showed predominantly monomeric proteins and elution in the approximate range of 25 kDa vs. globular Gel Filtration standards (BioRad). The results of the SEC on the midscaled purified 10 Fn3-based binders showed predominantly monomeric proteins and elution in the approximate range of 25 kDa vs. globular Gel Filtration standards (BioRad). Figure 2 depicts exemplary SEC profiles for E/I I 0 Fn3-based binders (Il-GS1O-E2 in Figure 2A and E2-GS10-Il in Figure 2B). Select midscale ' 0 Fn3-based binders were further analyzed by LC-MS (Water's 2695 liquid chromatography HPLC system coupled with Waters Q-TOF API mass spectrometer, Waters Corporation, Milford, MA). Samples were diluted to approximately 0.5 mg/ml with HPLC grade water. Approximately 5 ptl of diluted sample was injected onto a Jupiter C18 column (Catalog number OOG-4053-80, Phenomenex). Buffer A: 0.02%TFA+0.08% formic acid in HPLC grade water. Buffer B: 0.02% TFA + 0.08 % formic acid in HPLC grade acetonitrile. Sample was eluted with gradient (Table 1 ) at flow rate 0.2 ml/minutes. Table 1 Time %A B% 0 95 5 5.00 75 25 25.00 55 45 30.00 5 95 32.00 95 5 45.00 95 5 HPLC elution was split at approximately to 1:1 ratio and half sent to UV detector and the other half to mass spectrometer. Mass spectrometer had the following instrument settings: capillary voltage 3.5 KV, cone voltage 40, source 112 24039697_1.DOC temperature 80 'C, desolvation temperature 250 'C, desolvation gas flow 450 and multi channel photo detector voltage 2200. Raw spectra were deconvoluted with MaxEnl (Waters Corporation). The molecular weight of Il-GS10-E2 (SEQ ID NO: 22) as measured by LC MS is 24,445 Dalton, which is within 1 Dalton from the molecular weight calculated from the amino acid composition. This indicates that the protein has the correct amino acid composition and the N terminal methionine is processed. There is no other post translational modification on the protein. Differential Scanning Calorimetry (DSC) analysis of the midscaled Il-GS 10 E2 was performed to determine the Tm. A 1 mg/ml solution was scanned in a N DSC II calorimeter (Calorimetry Sciences Corp) by ramping the temperature from 5 'C to 95 'C at a rate of 1 degree per minute under 3 atm pressure. The data was analyzed versus a control run of the appropriate buffer using a best fit using Orgin Software (OrginLab Corp). The results of this assay demonstrate that the E/I binder has a Tm, of 50.69 'C (see Figure 3A). Using the same methods, the Tm, of E2-GS10 Il (with Peg) was determined to be 50.72 'C and the Tm of E2-GS1O-Il (without Peg) was determined to be 56.82 0 C (see Figure 3B). Example 5: Determination of Binding Affinity Surface plasmon resonance (BlAcore) analysis was performed on solution phase 1 0 Fn3-based binders in order to determine off-rates and/or binding affinities using captured EGFR-Fc and IGF1R-Fc. The extracellular domain of human IGF1R (aa 1-932) was cloned into a mammalian expression vector containing the hinge and constant regions of human IgG1. Transient transfection of the plasmid produced a fusion protein, IGF1R-Fc which was subsequently purified by Protein A chromatography. Recombinant human EGFR-Fc (aa 1-645 of the extracellular domain of human EGFR fused to human Fc) was purchased from R&D systems (Minneapolis, MN). IGF1R-Fc was captured on immobilized Protein A whereas EGFR-Fc was captured on immobilized anti-human antibody. In a typical experiment, anti-human IgG was immobilized on flow cells 1 and 2 of a CM5 chip following the manufacturer's recommendations (GE Healthcare, Piscataway, NJ). EGFR-Fc (50 nM) was injected at 5 uL for 2 minutes 113 24039697_.DOC on flow cell 2 (Fc2). Two 30 second injections of 3 M MgCl 2 were used for regeneration of the bound EGFR-Fc from the anti-human IgG surface. Protein A was diluted to 80 ug/mL in acetate pH 4.5 and immobilized to -3000 RU on flow cells 3 and 4 of a CM5 chip surface. Approximately 1300 RU of IGF1R-Fc was captured on Fc 4. Two 30 second injections of 50 mM glycine pH 1.5 were used to regenerate the surface between samples. A concentration series of 100 nM to 1 nM of HTPP purified protein (three data points collected) or 300 nM to 0.05 nM of midscale purified protein (eleven data points collected) was evaluated for binding to EGFR-Fc or IGF1R-Fc. Sensorgrams were obtained at each concentration and were evaluated using Biacore T100 Evaluation Software, Version 1.1.1 (GE healthcare/Biacore) to determine the rate constants ka (ko 0 ) and kd (koff). For the HTPP evaluation the off-rate was fitted from the 3 point curves. The affinity KD was calculated from the ratio of rate constants kof/kon. The EGFR 10 Fn3-based binders were evaluated for specificity in a similar format using anti-human IgG to capture HER2-Fc. The ' 0 Fn3-based binders did not show any discernible binding to captured HER2-Fc under conditions where robust binding was seen for EGFR-Fc. As shown in Table 2, both domains of the E/I ' 0 Fn3-based binders are functional, retaining their binding properties to the respective targets. The off rates shown in Table 2 are from midscale material and are similar to the qualitative results obtained with the HTPP material. Table 2: Summary of binding constants for 1 0 Fn3-based binders Target Protein ka (1/Ms) kd (1/s) KD (nM) EGFR-Fc El 1.19E+05 1.18E-03 9.92 1.43E+05 1.89E+03 13.2 El-GS1O-I1 6.29E+04 4.74E-04 7.53 3.82E+04 3.89E+04 10.17 Il-GS10-El 1.26E+05 6.03E-04 4.8 4.13E+04 4.25E+04 10.28 E2 3.73E+05 2.72E-04 0.73 3.27E+05 3.2E+04 0.98 E2-GS1O-I1 3.93E+05 1.75E-04 0.45 3.75E+05 1.67E+04 0.45 I1-GS10-E2 6.47E+05 1.42E-04 0.22 3.90E+05 1.14E+04 0.29 114 24039697_.DOC Target Protein ka (1/Ms) kd (1/s) KD (nM) E3 2.83E+05 3.98E+04 3.4 1.4 E3-GS10-I1 3.49E+05 2.29E+04 0.66 I-GS1O-E3 1.17E+05 2.91E+04 2.48 IGF1R-Fc II 3.84E+06 4.34E-04 0.11 El-GS10-11 5.13E+05 3.38E-04 0.66 Il-GS10-E1 1.47E+06 3.98E-04 0.27 E2-GS10-I1 1.24E+06 3.95E-04 0.32 Il-GS10-E2 3.82E+06 4.79E-04 0.13 E3-GS10-I1 1.8E+06 2.09E+04 0.12 I1-GS10-E3 1.37E+06 4.54E_05 0.03 Example 6: Inhibition of IGFR activity in H292 Cells The ability of E/I 1 0 Fn3-based binders to inhibit phosphorylation of IGF1R on tyrosine 1131 was determined using an H292 cell in vitro assay. Briefly, 65 X 10 3 H292 cells were plated in 96-well microplates (Biocoat Poly-D-Lysine coated 96-well plate, cat#356640, Becton Dickinson, Franklin Lakes, NJ) in RPMI-1640 culture medium containing 10 mM Hepes pH 7.4 and 10% fetal bovine serum. Cells were allowed to adhere for 24 hours at 37 C, 5% CO 2 . The next day cells were washed once with 200 microliters per well of serum free RPMI-1640 and incubated overnight in 100 jL per well of serum free RPMI-1640. Serial dilutions of HTPP material was added and cells were incubated for an additional 3 hours. Cells were stimulated with 100 ng/ml of IGF- 1 (cat#500-P 11, PeproTech, Rocky Hill, NJ) for 10 minutes at 37 0 C. Media was dumped from the plate and 100 yL of cell lysis buffer (Cell Signaling cat#9803, Beverly, MA) was added to each well. Cells were incubated at room temperature for 15 minutes to allow lysis and lysate was transferred to a phospho-IGFR ELISA (cat#7302, Cell Signaling, Beverly, MA). The manufacturer's procedure was followed to carry out the ELISA. As demonstrated in Figure 4, His tagged El-GS1O-Il inhibited IGF1 stimulated phosphorylation of the IGF1R (IC 5 0 = 0.004 uM) with comparable potency to the isolated IGF1R binder, II (IC 5 o = 0.018uM). The EGFR binder, E1, alone had very little effect on IGF1R phosphorylation (IC 5 0 > 3.5uM). As shown in Figure 9, additional E/I binders demonstrated ability to inhibit IGF1R-stimulated phosphorylation with an IC50 in the range of 0.1 nM to 19 nM, including several 115 24039697_I.DOC pegylated E/I binders that were tested . In particular, for the pegylated E/I binders El-GS10-I1, and I1-GS10-E1, inhibition of pIGFR was shown at 0.9 nM and 4 nM, respectively. For pegylated E/I binders E2-GS 10-Il and Il -GS 10-E2, inhibition of pIGFR was shown at 0.3 nM and 0.8 nM, respectively. Example 7: Inhibition of EGFR activity in H292 Cells The ability of E/I 1 0 Fn3-based binders to inhibit phosphorylation of the EGFR on tyrosine 1068 was determined using an H292 cell in vitro assay. The assay was carried out as described in Example 6, except that cells were stimulated with 100 ng/ml of EGF (cat#236-EG-200, R & D Systems, Minneapolis, MN) and a phospho-EGFR ELISA was performed (cat#7240, Cell Signaling, Beverly, MA). The manufacturer's procedure was followed to carry out the ELISA. As demonstrated in Figure 5, His-tagged El-GS10-I1 inhibited EGF stimulated phosphorylation of the EGFR (IC 5 0 = 0.020uM) with comparable potency to the isolated EGFR binder, El (IC 50 = 0.007uM). The IGFlR binder, Il alone had very little effect on EGFR phosphorylation (IC 5 0 > 6.2luM). As shown in Figure 9, additional E/I binders demonstrated ability to inhibit EGF-stimulated phosphorylation with an IC50 in the range of 7 nM to 127 nM, including several pegylated E/I binders that were tested. In particular, for pegylated E2-GS 10-Il and Il-GS1O-E2, inhibition of pEGFR was shown at 32 nM and 47 nM, respectively. Similar data is shown in Figure 11 for the pegylated E/I binders E2-GS 10-Il, and II GS 10-E2. Example 8: Inhibition of EGF+IGF1-inducedpAKT in H292 Cells The ability of E/I ' 0 Fn3-based binders to inhibit phosphorylation of AKT on serine 473 was determined using an H292 cell in vitro assay. The assay was carried out as described in Example 6, except that cells were simultaneously stimulated with both EGF and IGF1 as described above and lysates were analyzed with a phospho AKT ELISA (cat#7160, Cell Signaling, Beverly, MA). The manufacturer's procedure was followed to carry out the ELISA. Signal transduction at EGFR and IGF1R feeds into the PI3K-AKT signaling pathway and stimulates phosphorylation of AKT. As demonstrated in Figure 6, El 116 24039697_1.DOC GS10-I1 inhibited EGF and IGF1-stimulated phosphorylation of AKT in H292 cells. The E/I 1 0 Fn3-based binder was slightly more potent in its ability to block AKT activation (IC 5 0 = 0.004 uM) than the IGFIR binder, Ii, by itself (IC 50 = 0.031 uM). The EGFR binder, El, exhibited only modest activity in its ability to block AKT activation by both ligands (IC 50 = 1.28 uM). As shown in Figure 9, additional E/I binders demonstrated ability to inhibit EGF and IGF1-stimulated phosphorylation of AKT with an IC50 in the range of 0.1 nM to 26 nM, including several pegylated E/I binders that were tested. Example 9: Inhibition of cell proliferation in RH41 and H292 cells E/I '4Fn3-based binders were evaluated for antiproliferative activity in the H292 non-small cell lung carcinoma cell line, which depends on EGFR signaling for growth, or the RH41 Ewing sarcoma cell line, which depends on IGF1R signaling for growth. Antiproliferative activity of binders was assessed in monolayer cultures by staining cellular DNA with the CyQuantNF fluorescent stain (cat#C35006, Invitrogen, Carlsbad, CA). Briefly, 2 X 10' H292 or 5 X 103 RH41 cells were plated into 96-well microplates (View Plates 96F cat#6005225, Perkin-Elmer, Waltham, MA) in RPMI- 1640 culture medium containing 10 mM Hepes pH 7.4 and 10% fetal bovine serum and allowed to adhere for 24 hours at 37 0 C, 5% CO 2 . Cells were maintained as exponentially growing monolayers and remained in logarithmic growth phase during the period of the assay without reaching confluence during the course of the assay. Twenty-four hours after plating, serial dilutions of midscale material was added and cells were incubated for an additional 72 hours. Following this incubation, cells were treated with CyQuantNF reagent and allowed to incorporate dye into cellular DNA for 1 hour at 37 0 C. Total DNA was quantified by reading fluorescence at 485 nm excitation and 530 nm emission on a CytoFluor 4000 instrument (Applied Biosystems, Framingham, MA). Total time that cells were exposed to drug was 72 hours. Standard compounds were included in each experiment to verify assay performance and reproducibility. Linear regression analysis of the percent of inhibition by test compound was used to determine IC 50 values. 117 24039697_.DOC As demonstrated in Figure 7, in RH41 cells, His-tagged El-GS10-Il inhibited proliferation with comparable potency (IC 50 = 0.009 uM) to the IGFR binder, Il (IC 5 o = 0.028 uM). The EGFR binder, El, by itself had very little effect on the proliferation in this cell line (IC 50 > 12.5 uM). As demonstrated in Figure 8, in H292 cells, His-tagged E2-GS10-Il inhibited proliferation with greater potency (IC 5 0 = 0.329 uM) than the IGFR binder, Il, (IC 50 = 0.699 uM) or the EGFR binder, E2 (IC 5 0 = 0.553 uM). See Table 4 below for the IC50 values for the E and I monomers. Example 10: Competitive EGF ligand binding Assay The E/I binders El-GS1O-I1, Il-GS1O-El, E2-GS1O-Il and Il-GS1O-E2 (HTPP material) were tested in an EGF ligand binding cell-based competition assay in A431 cells and compared to EGFR 1 0 Fn3-based binders El and E2 (midscale material). A431 cells were plated at 15000 cells/well in 96-well plates in DMEM + 10% FBS and incubated 48 hours. Cells were washed with starvation media (DMEM + 0.1% BSA) and incubated in starvation media for 1 hour. Starvation media was removed and replaced with 1 Fn3-based binders that were diluted in starvation media and cells were pre-incubated for 30 minutes at 37 'C to allow proteins to bind to EGF receptors on cell surfaces. 10 nM final concentration of Europium (Eu)-labeled EGF (Perkin Elmer, Boston, MA) diluted in starvation media was added to pre-incubated cells and plates were incubated for 3 hours at 4 'C in the dark. Plates were washed twice with cold PBS and 50 ul/well of Enhancement solution (Perkin Elmer, Boston, MA) was added to plates and incubated 1 hour at 37 'C. Plates were read on the Flexstation II (Molecular Devices). The data was plotted with Softmax plus software and IC50 values, i.e., the concentration of 1 0 Fn3 based binders required to inhibit 50% of the Eu-EGF ligand from binding to the EGF receptor on the cell surfaces, were calculated. The results for E2 and El compared with E2-GS1O-I1, Il-GS1O-E2, El GS1O-Il and Il-GS1O-El are summarized in Table 3. This data indicates that the E/I I 0 Fn3-based binders compete with, and inhibit the binding of, EGF to the EGFR receptor on A431 cells with similar potency to the EGFR 1 0 Fn3-based binders. See Table 4 below for the IC50 values for the E and I monomers. 118 24039697_l.DOC Table 3: Summary of IC50 values for inhibition of EGF Binding to EGFR on A431 cell surfaces Protein IC50 (nM) E2 7 El 14 E2-GS10-11 1.8 11-GS10-E2 1.4 El-GS10-11 14.6 11-GS10-E1 7 Example 11: Activation and Signaling Activity in Cell-Based Assays Target effects of the various E/I 1 0 Fn3-based binders were evaluated in DiFi colon carcinoma cells by immunoblotting. Cells were seeded at 4 x 105 cells in each 25 cm2 flask and incubated overnight at 37 C in 5% CO 2 . The next day, treatments were initiated and cells were further incubated for various times from 1.5 to 120 hours. Cells were then lysed in HNTG (50 mM Hepes, 150 mM NaCl, 0.5% triton X-100, 8% glycerol, 2 mM Na 3

VO

4 , 1.5 mM MgCl 2 , 1 mlM EDTA containing the protease inhibitors AEBSF, aprotinin, leupeptin, bestatin, pepstatin-A and E64) and total protein was quantified with the BCA protein assay (Pierce, Waltham, MA). Levels of total EGFR, total IGF1R and the phosphorylation state of the EGFR, MAP kinase protein ERK1/2 isoforms, was detected by SDS-PAGE analysis of 20 micrograms of total protein followed by transfer of proteins to nitrocellulose and immunoblotting with specific antibodies. Blots were also probed with 3-actin to demonstrate equal loading of each sample. The pegylated E/I 1 0 Fn3-based binders El-GS10-I1 (SEQ ID NO: 55), E2 GS10-Il (SEQ ID NO: 56), and E3-GS1O-I1 (SEQ ID NO: 53), demonstrated the ability to degrade EGFR in this assay. In addition, for E3-GS10-I1 (SEQ ID NO: 53), degradation of IGF1R was also observed. The effect on EGFR degradation for the pegylated binder E2-GS10-Il is shown in Figure 10, as are other effects on signaling molecules. Additionally, the non-pegylated version of the binder E2 GS10-Il demonstrated similar EGFR degradation (data not shown). Figure 10 shows that for the pegylated binder Il-GS10-E2, there was no EGFR degradation. Table 4 below summarizes various properties of the E monomers. Table 4. Summary of properties of E monomers. 119 24039697_.DOC EGFR Monomer BlAcore Neutralizes Inhibition Inhibition Inhibition of KD EGF of pEGFR of pERK H292 IC50 Binding IC50 IC50 Proliferation IC50 IC50 El 14.6 nM 0.53 nM 18 nM 17 nM 18 nM E2 1.4 nM 1.46 nM 20 nM 40 nM 30 nM E3 0.72 nM 0.87 nM 11 nM 97 nM 26 nM Example 12: Evaluation of Certain E/I 10 Fn3-Based Binders on H292 Tumor Xenografts Grown In Nude Mice The pegylated E/I binders E2-GS1O-Il and E3-GS10-Il as well as the monoclonal antibody panitumumab were evaluated in an H292 tumor xenograft model. For in vivo models, panitumumab was obtained as the marketed drug and E/I binders were purified as described above. In vitro activity of all E/I binders was validated prior to administration in animals by testing functionality of each end in the EGF-stimulated pEGFR and the IGF1-stimulated pIGFR assay in H292 cells. E/I binders were diluted in phosphate buffered saline (PBS) at the beginning of the experiment and stored at 2-4 'C for the duration of each study. Both compounds were administered i.p. in a total volume of 500 pl/inj/mouse and were equilibrated to room temperature prior to administration. Mice and tumor propagation. Female athymic (nude) mice 5-6 weeks of age were obtained from Harlan Sprague-Dawley Co. (Indianapolis, IN). and were quarantined for approximately 3 weeks prior to their use for tumor propagation or drug efficacy testing. The animals were provided food and water ad libitum. Animal care was performed in keeping with AAALAC and Bristol-Myers Squibb guidelines. Tumors were propagated by subcutaneous (s.c.) implantation in nude mice. Tumor passages occurred approximately every two to four weeks. In vivo antitumor testing. Estimated tumor weight was calculated using the formula: Tumor weight (mg) = (w 2 * 1)/2; where w = width and 1= length in mm. Antitumor activity was evaluated in terms of % tumor growth inhibition (TGI) where a %TGI of >50% was considered active. Relative % tumor growth inhibition was calculated as %TGI=[(Ct-Tt)/(Ct-Co)] x 100 where Ct=median tumor weight of control mice at time t in days after tumor implant, T,=median tumor weight of treated mice at time t, Co= median tumor weight of control mice at time 0. %TGI 120 24039697_.DOC value was calculated at various time points beginning after 1.5 tumor volume doubling times and sustained over a time period of 3 tumor volume doubling times (TVDT) where possible. Where, TVDT = median time (days) for control tumors to reach target size - median time (days) for control tumors to reach half the target size. The definition of a cured mouse was one whose tumor was undetectable, or <35 mg, when assessed more than 10 TVDTs post-treatment. The dose of a compound which yielded the maximum therapeutic effect, was termed the optimal dose (OD). Treatment groups (typically 8 mice) with more than one death attributable to drug toxicity were considered to have had excessively toxic treatments and their data were not used in the evaluation of antitumor activity. The maximum tolerated dose (MTD) is defined as the dose level immediately below which excessive toxicity (i.e. more than one death) occurred. Treated mice dying prior to having their tumors reach target size were considered to have died from drug toxicity. Statistical evaluations of data were performed using Gehan's generalized Wilcoxon test (Gehan, EA, A Generalized Wilcoxon Test for Comparing Arbitrarily Slightly-Censored Samples, Biometrika 52:203-223, 1965). Measurement of pharmacodynamic endpoints in tumors. Tumors were harvested from untreated or drug treated mice and snap frozen in liquid nitrogen. Samples were weighed and homogenized in 10 pl of lysis buffer (50 mM Hepes, 150 mM NaCl, 0.5% triton-X-100, 8% glycerol, 2 mM Na 3

VO

4 , 1.5 mM MgCl 2 , 1mM EDTA containing one complete mini protease inhibitor tablet Sigma #S8820 per 15 ml buffer and phosphatase inhibitor cocktail Sigma #P5726) for each mg of tissue. Tissues were minced in a 100 mm petri dish with two scalpels, transferred to Falcon#2059 polypropylene round bottom tubes and macerated with a hand held homogenizer for 30 seconds. Homogenate was transferred to 1.5 ml eppendorf tubes and centrifuged at 15000 x g for 2 minutes in a microfuge. Clarified supernatant was transferred to a new tube and total protein concentration was determined with the Pierce BCA protein assay (Pierce Biotechnology). Samples were analyzed by immunoblotting or on a Meso scale MSD Sector Imager 6000 multi spot assay system as recommended by the manufacturer (Meso Scale Discovery, Gaithersburg, MD). 121 24039697_.DOC The pegylated E/I binders E2-GS10-Il and E3-GS10-I1 were tested in an H292 NSCLC in athymic mice. Tumors were implanted subcutaneously with 1 mm 3 H292 tumor fragments in the hind flank and allowed to establish to a size of 50-150 mg prior to initiation of treatment on Day 6 post-tumor implant. The pegylated E/I binders were administered i.p. at a dose of 100 mg/kg on a TIWX3 schedule to assess antitumor activity. Panitumumab was obtained as marketed drug and administered i.p. at its optimal dose of 1 mg/mouse and at a lower dose of 0.1 mg/mouse on a Q3DX5 schedule. Mean tumor sizes calculated from groups of 8 mice are shown in Figure 12A. The 1 mg/mouse and 0.1 mg/mouse doses of panitumumab were both active by %TGI with values of 101% and 100%, respectively and these values were significantly different from control animals (p=0.0002, Table 5). Pegylated E2-GS1O-I1 was also significantly active by %TGI with a value of 96% (p=O.0005). Pegylated E3-GS 10-Il was not active in this study with a %TGI value of 31% that was not statistically different from the control group (p=0.416). Post dosing analysis indicated that approximately two thirds of the pegylated E3-GS10-I1 was aggregated (66.64% aggregation/33.36% monomer for one batch and 72.53% aggregation/27.47% monomer for another batch) which could account for the poor activity of pegylated E3-GS 10-Il in this assay. In contrast, the pegylated E2-GS 10-Il showed only a small percentage of aggregation in post dosing studies (1.79% aggregation/98.21% monomer). All treatments were well tolerated with no treatment related deaths or excessive weight loss over the course of the study. Clinical observations revealed no evidence of toxicity and the average weight change over the course of therapy was within acceptable limits (Figure 12B). Table 5. Results of the H292 human tumor xenograft study AVE See Dp value Outcome Group Compound Schedule, Dose weight %TGI for by Route (mg/kg) chang TI %G e%TGI %TGI I Control----5.--10- 1 (untreated) 1.0 2 panitumumab q3dx5 2 pnu ma' lmg/mse 9.6 101 0.0002 A 3 panitumumab q3dx5; 0.mg/mse 6.3 100 0.0002 A 122 24039697_I.DOC S e Dp value Outcome Group Compound Schedule, Dose weight %TGI for by Route (mg/kg) chang TI %G e%TGI %TGI 6 ipa 4 2G0- TIWx3; 100 -0.1 94 0.0005 A 5 E3-GS10-I1 TIWx3; 100 9.5 28 0.416 I _____(w/ PEG) 6 pI I I aVehicle was phosphate buffered saline. Abbreviations used are as follows: ip, intraperitoneal route; %TGI, relative % tumor growth inhibition calculated as %TGI=[(Ct-Tt)/(Ct-C0)] x 100 where Ct-median tumor weight of control mice at time t in days after tumor implant, Tt=median tumor weight of treated mice at time t, CO= median tumor weight of control mice at time 0. %TGI value was calculated at two points as the average inhibition of Day 12 and Day20. Outcome, a treatment regimen was considered active if it produced a statistically significant %TGI value of >50%; q3dx5;6, compound was administered every three days for five doses starting on the sixth day after tumor implant; TIWx3;6, compound was administered three times a week for three weeks starting on the sixth day after tumor implant. p values were calculated on Day 20 relative to the control group in a two tailed paired analysis with 8 measurements per group. Outcome by %TGI, A = active and I = inactive. Pharmacodynamic endpoints from the H292 tumor study. Samples of tumors from untreated control, panitumumab and E/I binder treated groups were analyzed for levels of phosphorylated EGFR, ErbB2 and IGFR that would indicate target suppression. Tumors were also analyzed for levels of total EGFR to determine if EGF receptor degradation occurred. On day 20, a final treatment was administered and tumors were removed from 2 animals at 1 hour after dosing, 3 animals at 4 hours after dosing and 3 animals at 24 hours after dosing. All treatments showed marked suppression of phosphorylated EGFR and ErbB2 while the basal levels of phosphorylated IGFR were too low to discern a difference in this study (Figure 13). All treatments showed a reduction in the amount of total EGFR indicating degradation of the receptor had occurred. Example 13: Selection and Characterization of MCF7 Cells Resistant to IGF1R Inhibitor MCF7 cells (American Type Culture Collection, Cat No. HTB-22, Manassas, VA) were cultured in RPMI medium containing 10 mM hepes and 10% FBS at 37 'C in the presence of 5% CO 2 . The small molecule IGF1R inhibitor BMS-754807 was added to the culture medium and the concentration increased at 123 24039697_.DOC stepwise increments over a period of 10 months until the cells exhibited continued proliferation in the presence of 200 mM BMS-754807. The resistant cells were designated MCF7r and the IC50 for BMS-754807 was 1239 nM compared to 120 nM for the parental MCF7 cells as measured in a proliferation assay carried out as previously described (Carboni et al., Cancer Res. 69: 161-170 (2009)). The drug was then removed from the culture medium and the MCF7r cells were passaged in complete medium for an additional 20 or 60 days to remove all traces of residual BMS-754807. Analysis of the MCF7r cells by immunoblotting revealed that EGFR was significantly overexpressed in the resistant cells compared to the parental MCF7 cells (Figure 14). In addition, when MCF7 and MCF7r cells were serum starved and then stimulated with EGF for 7 minutes, phosphorylated EGFR could not be detected in the parental MCF7 cells (probably due to low levels of EGFR) but was strongly visible in MCF7r cells. In serum starved cells stimulated with IGF ligand, phosphorylated IGFR was seen in the parental MCF7 cells but despite the slightly higher levels of total IGFR present in the MCF7r cells almost no pIGFR was observed. This shows that the IGFR in the resistant MCF7r cells lost the ability to activate IGFR in response to IGF1 stimulation (Figure 14). Activation of the MAP kinase pathway in response to EGF stimulation was stronger in the MCF7r cells as measured by pERK activation. Example 14: Antitumor Studies in MCF7 and MCF7r Xenografts MCF7r cells were scaled up in T75 flasks and isolated by centrifugation. Viable cell numbers were measured by trypan blue exclusion with a Vi-CELL XR (Beckman Coulter, Fullerton, CA), resuspended in PBS to 5 x 106 viable cells/ml and implanted subcutaneously in the hind flank of athymic mice in a volume of 0.2 ml. For MCF7 and MCF7r tumor growth, all mice were supplemented with 0.25 mg 90 day release pellets of 17-f-estradiol (Innovative Research of America, Sarasota, FL, Cat. No. NE-121). Tumors were propagated until they reached a median size of 500-1000 mg when they were excised and 1 mm 3 fragments were reimplanted in the hind flank of new athymic mice. Tumors were adapted for solid tumor growth by serial trocar passage in mice through at least four rounds of growth during which tumor volume doubling time and take rate were monitored for each passage. 124 24039697_I.DOC Growth characteristics were observed to determine if the xenografts exhibited acceptable properties to serve as a reliable, reproducible model. The MCF7r tumor type demonstrated an acceptable take rate and doubling time and therefore satisfied the criteria for use as a xenograft model. The MCF7 parental tumor model had been previously established using the same techniques. For the MCF7 parental xenograft, 1 mm 3 tumor fragments were implanted subcutaneously in the hind flank and allowed to establish to a size of 50-150 mg prior to initiation of treatment on Day 13 post-tumor implant. Cetuximab was obtained as marketed drug and administered i.p. at its optimal dose of 1 mg/mouse and at a lower dose of 0.1 mg/mouse on a Q3DX5 schedule (doses administered on Day 13, 16, 19, 22, 25). Mean tumor sizes calculated from groups of 8 mice are shown in Figure 15A. In the MCF7 xenograft model, neither the 1 mg/mouse or the 0.1 mg/mouse dose of cetuximab was active by %TGI with values of -9% and 3.2%, respectively and the tumor sizes were not statistically different from the control group (Table 6). For the MCF7r resistant xenograft, 1 mm 3 tumor fragments were implanted subcutaneously in the hind flank and allowed to establish to a size of 50-150 mg prior to initiation of treatment on Day 6 post-tumor implant. Cetuximab was obtained as marketed drug and administered i.p. at its optimal dose of 1 mg/mouse and at a lower dose of 0.1 mg/mouse on a Q3DX5 schedule (doses administered on Day 6, 9, 12, 15, 18). Mean tumor sizes calculated from groups of 8 mice are shown in Figure 15B. In the MCF7r xenograft model, doses of cetuximab were active by %TGI with values of 105% and 75%, respectively. The high dose of cetuximab had a TGI value over 100% which indicates that it caused tumor regression below the starting size at the initiation of treatment. Both doses resulted in a statistically significant difference in tumor size compared to the control group (Table 7). Table 6. Results of the MCF7 human breast carcinoma tumor xenograft study. Schedule, Dose p value Outcome Group Compound Route (mg/mouse) %TGI for by %TGI %TGI 1 Control 1.0 (untreated) --- --- 1.0 - 2 cetuximab 131ip Ilmg/mse -9 0.223 I 125 24039697 1.DOC 3 cetuximab q3dx5; 0.1mg/mse 3.2 0.220 I 13 p aVehicle was phosphate buffered saline. Abbreviations used are as follows: ip, intraperitoneal route; %TGI, relative % tumor growth inhibition calculated as %TGI=[(Ct-Tt)/(Ct-C0)] x 100 where Ct=median tumor weight of control mice at time t in days after tumor implant, Tt=median tumor weight of treated mice at time t, CO= median tumor weight of control mice at time 0. %TGI value was calculated at three points as the average inhibition of Day 20, 24 and Day 27. Outcome, a treatment regimen was considered active if it produced a statistically significant %TGI value of >50%; q3dx5;13, compound was administered every three days for six doses starting on the thirteenth day after tumor implant. p values were calculated on Day 24 relative to the control group in a two tailed paired analysis with 8 measurements per group. Outcome by %TGI, A = active and I = inactive. Table 7. Results of the MCF7r human breast carcinoma tumor xenograft study. Grou Schedule, Dose p value Outcome p Compound Route (mg/kg) %TGI for by %TGI %TGI Control 1 (untreated)

--

_ -_-_1.0_ q3dx5; 2 cetuximab 6 ipa lmg/mse 105 0.001 A q3dx5 3 cetuximab ipa 0. 1mg/mse 75 0.024 A See footnotes to Table 6. p values were calculated on Day 19 relative to the control group in a two tailed paired analysis with 8 measurements per group. Example 15: Antitumor Studies in GEO Xenografts GEO tumors were established by implanting 1 mm 3 tumor fragments subcutaneously in the hind flank of athymic mice and allowing them to reach a size of 50-150 mg prior to initiation of treatment on Day 18 post-tumor implant. Cetuximab was administered ip at 0.25 mg/mouse on a Q3DX5 schedule (doses administered on Day 18, 21, 24, 27, 30). The IGFR kinase inhibitor BMS-754807 was administered at 25 mg/kg on a QDX21 schedule. Mean tumor sizes calculated from groups of 8 mice are shown in Figure 16. Cetuximab was active at 0.25 mg/mouse with a %TGI value of 67%. BMS-754807 was active with a %TGI of 80% and the combination of the two was considerably more active then either agent alone with a %TGI of 94% (Table 8). All treatment groups were statistically different from the control group on Day 26 (Table 8). Table 8. Results of the GEO human colon carcinoma tumor xenograft study. 126 24039697_.DOC Cetuximab BMS-754807 Out Schedule Dose Schedule, Dose come Group Route (mg/ Route (mg/kg) %TGI p value by Synergy mouse) %TG Control 1 (untreated) 0.25 2 q3dx5;6 ipa mg/ 80 A mse 3 --- qdx21;18 25 67 | A 0.25 4 q3dx5;6 ipa mg/ qdx21;18 25 94 A YES mse "Vehicle for cetuximab was phosphate buffered saline. Vehicle for BMS-754807 was 50% polyethylene glycol 400, 50% water. Abbreviations used are as described in Table 6 and synergy is defined as statistically significant activity that is better than either agent in the combination demonstrated on its own. Outcome by %TGI, A = active and I = inactive. Example 16: Antitumor studies in H292 xenografts H292 cells were implanted subcutaneously in the hind flank of athymic mice as 1 mm 3 fragments and allowed to establish to a size of 50-150 mg prior to initiation of treatment on Day 12 post-tumor implant. Cetuximab was administered ip at 0.1 mg/mouse on a Q3DX5 schedule. MAB391 is an antibody to IGF1R (R&D Systems, Minneapolis, MN, Cat. No. MAB391) and was administered at a dose of 40 mg/kg on a BIWX3 schedule. Mean tumor sizes calculated from groups of 8 mice are shown in Figure 17. Cetuximab was active at 0.1 mg/mouse with a %TGI value of 95.1% and MAB391 was inactive at 40 mg/kg with a %TGI value of 10.5% (Table 9). Mice dosed with the combination of cetuximab and MAB391 exhibited a %TGI value of 109.2% indicating tumor regression in the combination group (Table 9). After dosing ceased, tumors regrew in the cetuximab treated group more rapidly than in the group treated with the combination of cetuximab and MAB391 (Figure 17). 127 24039697_1.DOC Table 9. Results of the H292 human NSCLC tumor xenograft study. Cetuximab MAB391 Out Schedule, Dose Schedule, Dose p come Group Route Route (mg/kg) TGI value by Synergy mouse) %TG Control 1_____ (untreated) q3dx5;12 0.1 9. 2 q3 ;1 mg/ - 95.1 A mse 3 --- --- BIWx3;12a 40 10.5 1 q~dx5;12 0.1 4 3d;12 mg/ BIWx3;12a 40 109.2 A YES mse aVehicle for cetuximab and MAB391 was phosphate buffered saline. Abbreviations used are as described in Table 6 and 8. Example 17: Colony Formation Assay To determine the effects of test compounds on the ability to inhibit colony formation of H292 cells, 400 cells were seeded into 24-well plates (Becton Dickinson, Franklin Lakes, NJ, Cat. No. 351143) in complete medium and allowed to adhere overnight. The next day medium was removed and replaced with medium containing 2% FBS. Test compound was diluted into medium containing 2% FBS and added to cells in serial dilutions. Cells were incubated at 37 "C for 14 days. After 14 days, media was discarded and wells rinsed once with 2 ml PBS. Cells were stained with 0.5 ml Coomassie Stain Solution (Bio-Rad, Hercules, CA, Cat. No. 161-0436) for 20 min. The stain was aspirated and wells were washed quickly with IX Destain Solution Coomassie R-250 (Bio-Rad, Cat. No. 161-0438). A final rinse with 1 ml water per well was carried out and plates were inverted and allowed to dry. Colonies consisting of(at least) 50 cells or larger were counted by eye under low power magnification (10X-20X). All samples were tested in triplicate and IC50 values were calculated from linear regression of the percent inhibition of control. Representative results for a PEGylated E/I binder are shown in Figure 18 and IC50 values for various E/I 1 0 Fn3-based binders, monospecific IGFIR 1 0 Fn3-based binder, and EGFR antibody is shown in Table 10. 128 24039697_I.DOC Table 10. IC50 values of various E/I 1 0 Fn3-based binders, monospecific IGF1R 10Fn3-based binder, and EGFR antibody in the colony formation assay. SAMPLE C50 SAMPLE(nM) E4-GS10-Il (with Peg) 5 I1-GS10-E5 (with Peg) 1 I1-GS10-E4 6 E2-GS10-I1 (with Peg) 560 Il monomer (with 15,510 Peg) panitunumab 140 Example 18: Epitope mapping assay An epitope mapping assay was developed utilizing commercially available antibodies where the binding site on the EGFR extracellular domain is roughly known according to various literature reports. The antibodies used in this assay are listed in Table 11 and Figure 19A depicts how antibodies were localized to approximate binding domains on EGFR . The assay is a variation of the In Cell Western assay previously described and assesses the ability of EGFR 1 0 Fn3-based binders preincubated with A431 or other cells expressing EGFR to block binding of the detection antibodies from the panel listed in Table 11. The assay was carried out as follows: A431 cells in log phase growth were harvested by trypsinization and seeded in a 96 well plate at 24,000 cells/well in a total volume of 100 pl/well. The next day, media was dumped and the EGFR 1 0 Fn3-based binders diluted in cold DMEM base media were added to the plate and allowed to bind for 1 hour at 4 0 C to prevent internalization of EGFR. After binding, cells were washed with 0.2 ml PBS+0.1% Tween-20 and fixed for 20 minutes in PBS+3.7% formaldehyde at room temp. Cells were blocked in 0.2 ml of Odyssey blocking buffer for 1 hour at room temp. Next, primary antibodies were diluted in 50 pl of Odyssey blocker per well and incubated for 1-2 hours at room temp. Primary antibodies were dumped by inverting the plate, and each well washed 3X with 200[l of PBS+0.1% Tween-20. Secondary antibodies are the same ones used in the In Cell Western assay and were appropriate for the species of antibody being detected. These secondary antibodies were diluted (1:800) in Odyssey Blocker+0.2% Tween-20 and added in a volume of 50pl per well along with TOPRO3 (Invitrogen, Carlsbad, CA, cat#T3605) diluted at 129 24039697_.DOC (1:3000) to counterstain cells for normalization. Cells were incubated on bench for 1 hour at room temp. Secondary antibody was dumped out and each well washed 4X with 200[l of PBS+0.1% Tween-20 for 5 minutes at room temp. Plates were imaged on a Licor instrument at 160tm resolution, medium quality, focus offset of 3mm, intensity of 5. This assay was also carried out with the marketed drug antibodies cetuximab, panitumumab and nimotuzumab to determine if the

EGFR

1 4Fn3-based binders were interfering with their binding to EGFR on A431 cells. Representative results are shown in Figure 19B. Table 11. Commercially available antibodies to the extracellular domain of EGFR. Clone SUPPLIER SPECIES BINDS EPITOPE Binding __ ____ and cat# ____________________ motif 1 a8 Rab h Peptide AA 42-58 linear 2 E234 Abcam Peptide AA 40-80 linear ab32198 Rab h,mu,rat (No ICC) 3 N-20 CruSzant1155 Goat IgG h AA 110-160 linear Abcam ab231 AA 12 4

-

176 ' 4 ICR10 Santa Cruz Rat IgG2a h(HN5) .u.lc'" conf #57095 neutrahzmg Abcam ab30 AA 176-294, Chemicon nA 176-294, 5 EGFR MAB88910 Mu IgGI h(A431) ab3neutraig conf MS-311 @(1mg/ml) Labvision AA 124-176, non 6 199.12 MS-396-P Mu IgG2a h neutralizing conf 7 LA22 Upstate 05- Mu IgG2a h(A431) AA 351-364, near 104 neutralizing l Abcam Peptide AA376 8 ab15669 Rab Murat 394linear Sigma E2156 AA 294475, 9 225 Labvision Mu IgGI h(A431) neutralizing bc conf MS-269-P neutrlizin Abcam ab3103 Santa AA 294-475, 10 528 Cruz#120 Mu IgG2a h(A431) neutralizing c conf Labvision MS-268-P 11 B1D8 MS-66-n Mu IgG2a h(A431) AA 2 94

-

475 b conf 12 LA1 Upstate 05- Mu IgGI h neutralizing 101 Labvision AA 294-475, non 13 H1I MS-316-P Mu IgGI h neutralizing linear 14 111.6 Labvision Mu IgGI h AA 294-475, linear 130 24039697_.DOC Clone SUPPLIER SPECIES BINDS EPITOPE Binding ___and cat# ______ ____ ____ ______ motif MS-378-P neutralizing Imgenex IMG-80179 Sigma E2760 External 15 29.1 Abcam Mu IgG 1 h(A43 1) carbohydrate non ab10414 neutralizing Abbreviations: conf: epitope conformationally specific; linear: epitope independent of conformation. aJBC 264(1989)17469 Ala351-Asp364, bj Immunological Methods 287(2004)147, cMol Biol Medl(1983)51 1, dRaised against a peptide to mouse EGFR [FKGDSFTRTPPLDPRELEI (SEQ ID NO: 491)], "Int J Oncol 4(1994)277. [EEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLK TIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNY (SEQ ID NO: 492)], "Ile-Gln-Cys-Ala-His-Tyr-Ile-Asp-Gly-Pro-His-Cys (SEQ ID NO: 493) (amino acids 580-591). hCancer Cell 7(2005)301. Using various approaches, we have confirmed that the EGFR monomer E3 binds to domain I of EGFR. Since other E monomers have similar properties in various experiments, it is thought that the other E monomers also bind to domain I of EGFR. Example 19: Properties of I Monomers BIAcore analysis of the soluble fibronectin-based scaffold proteins The kinetics of I monomers binding to the target was measured using BlAcore 2000 or 3000 biosensors (Pharmacia Biosensor). A capture assay was developed utilizing an IGF-IR-Fc fusion. A similar reagent had been described by Forbes et al. (Forbes et al. 2002, European J. Biochemistry, 269, 961-968). The extracellular domain of human IGF-IR (aa 1-932) was cloned into a mammalian expression vector containing the hinge and constant regions of human IgG1. Transient transfection of the plasmid produced a fusion protein, IGF-IR-Fc which was subsequently purified by Protein A chromatography and captured on Protein A immobilized on Biasensor CM5 chips by amine coupling. The kinetic analysis involved the capture of IGF-IR-Fc on Protein A followed by injection of the fibronectin-based scaffold protein in solution and regeneration of the Protein A surface by glycine pH 2.0. Sensorgrams were obtained at each concentration and were evaluated using a program Biaevaluation, BIA Evaluation 2.0 (BlAcore), to determine the rate constants ka (ko,) and kd (korr) The dissociation constant, KD was calculated from the ratio of rate constants koff/ko. Typically, a concentration series 131 24039697_1.DOC (2 uM to 0 uM) of purified fibronectin-based scaffold protein was evaluated for binding to protein A captured human IGF-IR-Fc fusion protein. For experiments determining binding to human insulin receptor, recombinant human insulin receptor (IR) and recombinant human VEGF-R2-Fc were directly coupled to a CM5 Biasensor chip by amine group linkage following standard procedures recommended by Biacore (Uppsala, Sweden). In brief, 60 ug/mL of IR diluted in acetate 4.5 was coupled/immobilized to a level of 8300 RU and 11.9 ug/mL of VEGF-R2-Fc diluted in acetate 5.0 was immobilized to a level of 9700 RU on flow cells 2 and 3. A blank reference surface was prepared on FC 1. Specific binding to either IR or VEGF-R2-Fc was calculated by subtracting the binding observed to the blank reference flow cell 1. Fibronectin-based scaffold proteins were diluted to 10 uM in HBS-EP (10 mM Hepes, 150 mM NaCl, 3 mM EDTA, 0.05% Surfactant P20) and injected at 20 uL/min for 3 minutes over the flow cells at 25 'C and dissociation was observed over 10 mins. Cell-based Receptor Blocking Assay The human breast adenocarcinoma MCF-7 (ATCC, Manassas, VA) was plated in 24 well plates at a concentration of 50,000 cells per well in RPMI 1640 (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (Hyclone, Logan, UT). The following day, cells were washed in binding buffer consisting of RPMI 1640 containing 0.1% BSA (Sigma, St. Louis, MO), and then pre-incubated for 30 minutes on ice in 200 pL binding buffer containing IGF-IR competitor. After the pre-incubation period, 40 pM ['1]-IGF-I (Perkin Elmer, Wellesley, MA), equivalent to approximately 60000 counts per minute, was added to each well and allowed to incubate for an additional three hours on ice with gentle agitation. The wells were then washed with ice cold PBS containing 0.1% BSA. Cells were lysed with 500 pL buffer consisting of 0.1% SDS + 0.5 N NaOH. Radioactivity of the lysates was measured using a Wallac 1470 Gamma Counter (Perkin Elmer, Wellesley, MA), and the data were analyzed using SigmaPlot (Systat Software, Point Richmond, CA). pIGFR Assay Fibronectin-based scaffold proteins fused to Fc were evaluated for their ability to inhibit IGF-1R phosphorylation in Rh4l human rhabdomyosarcoma cells. 132 24039697_.DOC A Western Blot was employed to assess the ability of the I monomer to inhibit IGF IR phosphorylation in Rh41 human rhabdomyo sarcoma cells. Cells were stimulated with IGF-I, IGF-II, insulin ligands (50ng/ml), or no stimulation (NS) and then treated with various concentrations of the I monomer. Membranes were probed with phospho-specific antibodies. Cellular Proliferation in Rh4l (human Rhabdomyosarcoma and H929 human Multiple Myeloma) Proliferation was evaluated by incorporation of [ 3 H]-thymidine into DNA after a 72 hour exposure to reagents. Rh4l cells were plated at a density of 3500 cells/well in 96-well microtiter plates and 24 hours later they were exposed to a range of I monomer concentrations. After 72 hours incubation at 37'C, cells were pulsed with 4ptCi/ml [ 3 H] thymidine (Amersham Pharmacia Biotech, UK) for 3 hours, trypsinized, harvested onto UniFilter-96, GF/B plates (PerkinElmer, Boston, MA) and scintillation was measured on a TopCount NXT (Packard, CT). Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% to that of untreated control cells Data represents the average of triplicate wells with standard deviations shown. Results of the characterization of the I monomer are shown below in Table 12. Table 12. Properties of I monomers. IGFR Monomer BlAcore Neutralizes Inhibition of Inhibition of KD IGF Binding pIGFR RH41 IC50 IC50 IC50 Proliferation IC50 Il 0.11 nM 8 nM 0.2 nM 28 nM Example 20: Additional Characteristics of Monospecific and Bispecific EGFR and IGF-IR 1 0 Fn3-based binders 10 Fn3-based binders that bound either EGFR or IGF-IR were identified using the biochemical selection technique of mRNA display in which a protein is covalently attached to its coding nucleic acid sequences. 1 0 Fn3-based proteins mRNA fusion populations that bound either IGF-IR or EGFR when the receptors 133 24039697_.DOC were presented at concentrations from 1 to 10 nM were cloned into E. coli and expressed as ' 0 Fn3-based proteins. A subset of target binders that blocked EGFR or IGF-IR signaling and had suitable biophysical properties were identified (Table 13). These initial clones were optimized for target binding affinity and cellular potency with additional mRNA selection at increasingly lower target concentrations and selection for lower dissociation rate constants. IC 50 values obtained during the selection procedures ranged from 9 to 304 nM, illustrating the opportunity for choosing molecules from a wide range of potency values for the construction of bi specific 1 0 Fn3-based binders. EGFR 0 Fn3-based binders were tested by In-Cell Western screening assays for the blockade of phosphorylation of EGFR and ERK, a downstream signaling molecule of EGFR activation (methods similar to Example 1). Analogous studies were performed on optimized IGF-IR binders. Optimized EGFR binding clones (E3, El, and E2) inhibited EGFR phosphorylation on Y1068 and downstream phosphorylation of ERK on Y204 of p42/p44 in vitro with IC 50 values ranging from 9 to 40 nM, potencies that were more than 100-fold higher than the parental EGFR clone (Table 13, methods similar to Example 1). Il bound to IGF-IR with a KD value of 0.11 nM and inhibited IGF-I stimulated IGF-IR phosphorylation with an IC 50 of 0.2 nM (Table 13, methods similar to Example 6). The optimized IGF-IR and EGFR single-domain ' 0 Fn3-based binders were >95% monomeric based on size exclusion chromatography, had melting temperatures >56'C (Table 13, methods similar to Example 4), and exhibited minimal immunogenic potential as predicted from EpiMatrix (<7 for five out of six loops), a matrix-based algorithm for T-cell epitope mapping (De Groot AS, Moise L (2007) Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discovery Devel 10:332-340). The ' 0 Fn3-based binders El, E2, and E3 were selected for further development, and had EGFR binding constants in the range of 0.7 to 10 nM as determined from Biacore assay (Table 13, methods similar to Example 5). EGFR-binding of these 14Fn3-based binders was competitive for EGF binding to EGFR (Table 13) as measured by a displacement assay using Europium labeled EGF (methods similar to Example 10). Similarly, IGF-I binding to IGF-IR was inhibited by Il (Table 13, methods similar to Example19). 134 24039697_I.DOC Biophysical Characterization of Bi-Specific ' 0 Fn3-based binders. Tm values of selected E/I 1 0 Fn3-based binders ranged from 49-58'C and their SEC profiles indicated the protein was >90% monomer (Table 14, methods similar to Example 4). Monospecific 1 0 Fn3-based binders and E/I 10 Fn3-based binders showed comparable binding affinities, although Tm, values decreased slightly when the single domain

'

0 Fn3-based binders were linked together (Tables 13 and 14). To increase serum half life for in vivo applications, E/I I 0 Fn3-based binders were PEGylated with a 40 kDa branched PEG (methods similar to Example 3). PEGylation of E/I ' 0 Fn3-based binders resulted in a 10- to 20-fold reduction of binding affinity relative to the un PEGylated constructs due to decreased association rate constants but did not decrease Tm. Furthermore, PEGylation did not markedly reduce inhibition of EGFR/IGF-IR phosphorylation in cells. The PEGylated E-I orientation (wherein the EGFR binder is at the N terminus, and IGF1R is at the C terminus) exhibited slightly lower IC 50 values for the inhibition of EGFR and IGF-IR phosphorylation by ELISA compared to the I-E orientation. While minor differences in the KD values and biological activity were found between PEGylated E-I orientation, vs the I-E orientation, there were no consistent trends. Table 13. Properties of Monospecific 10 Fn3-based binders Relevant to the Construction of E/I ' 0 Fn3-based binders. A431 H292 H292 SEC EGF IGF- F A431 GF pIGF- Competition Name Tm Mono R KD IR R pERK R IR EGFR/IGF C mer nM KD IC 50 , IC 50 , IC 50 , IC 50 , IR % nM n' nM n' nM IC 50 , nM E-parent 56 ND 42.5 2580 2370 1148 ND 29 12.73 21 E3 60 >80 3.4 NA 15 8 11 ±7 22 1 >7000 4.75 ±1.77 El 64 >95 9.92 NA 24 ±7 13 ±3 9 2 >3400 15.9 ±2.97 E2 72 >95 0.7 NA 38+ 40 ±9 31 1 >3400 9.4± 3.68 15 I-parent ND ND NA 1.8 ND ND ND ND 13** Il 61.5 >95 >621 0.11 NA NA NA 0.2 8** 0 ND, not done; NA, not applicable; SEC, size exclusion chromatography. *IC 50 values for EGFR and 135 24039697_I.DOC ERK phosphorylation levies in A431 cells were determined by In-Cell Western assay (ICW). Phosphorylation levels of EGFR and IGF-IR in H292 cells were determined by Enzyme-linked immunosorbent assay (ELISA). ** Competition for IGF-IR binding. Standard deviations are from 3 - 6 experiments. Table 14. Properties of the E/I 1 0 Fn3-based binders. H292 H292 A431 A431 EGF T EGFR IGF-IR pEGF pIGF- pER pEGF EGFR Name KD nM KDnM R IR K R Competitio

IC

50 , IC 50

IC

50 , IC 50 , n nM nM nM nM IC 50 , nM E3-GS1O-Il 52 0.7 0.1 7 6 12 14 25 ± 6.5 E3-GS10- 52. 10.4 0.74 10 6 40 42 80.5 Il-PEG 5 12.02 El-GSIO-Il 48 3.8 0.8 30 1 51 36 51 El-GSIO- 49 57.9 2.4 123 4 295 297 396 223 Il-PEG E2-GSIO-I1 56 0.5 0.2 8 0.1 20 19 2.1 0.57 E2-GS10- 57. 10.1 1.17 32 0.3 78 77 56.5 24.5 Il-PEG 5 1-GS10- 60 3.6 0.46 47 0.8 118 97 128 4.95 E2-PEG Tm,, measurements are from thermal scanning flurometry. KD values are from Biacore binding assays using recombinant EGFR or IGF-IR domains adsorbed on the chip. In-Cell Western assays (ICW) were conducted to determine the ability of EI-Tandems to inhibit the phosphorylation of EGFR or ERK in A431 cells. Enzyme-linked immunosorbent assays (ELISA) were used to determine the phosphorylation of EGFR or IGF-IR in H292 cells. Example 21: Species Cross-Reactivity of E/I ' 0 Fn3-based binders Pegylated E/I ' 0 Fn3-based binders were analyzed for their binding affinities to EGFR from mouse, rat and monkey using surface plasmon resonance (BlAcore) analysis (methods identical to Example 5). Mouse EGFR was purchased from R&D systems (Minneapolis, MN), rat EGFR was produced in house, and monkey EGFR was purchased from KEMP (Frederick, MD) As shown in Table 15, all pegylated E/I ' 0 Fn3-based binders bound to mouse, rat and monkey EGFR with low nanomolar affinities indicating that all pegylated E/I binders are cross-reactive with human, mouse, rat and monkey EGFR. 136 24039697_.DOC Table 15 Analyte KID (nM) KD (nM) KD (nM) (mouse EGFR) (rat EGFR) (monkey EGFR) Il-GS10-E105 2.7 2.9 4.4 (pegylated) I1-GS10-E5 3.4 3.6 5.1 (pegylated) I1-GS10-E4 55 37 39 (pegylated) E4-GSI0-I1 6.9 5.6 5.7 (pegylated) E2-GS10-Il 9.6 9.6 18.0 (pegylated) I1-GS10-E85 13.9 10.7 7.0 (pegylated) Example 22: Characterization of Additional E/I 1 0 Fn3-based binders Figure 43 summarizes various characteristics of additional E/I ' 0 Fn3-based binders. The pegylated E/I I 0 Fn3-based binders were tested to determine inhibition of EGF induced EGFR and ERK phosphorylation in A431, using methods as previously described in Example 1. Results demonstrated that the pegylated E/I 1 0 Fn3-based binders inhibited EGF induced EGFR phosphorylation with IC50's ranging from 12 nM -297 nM and phosphorylation of ERK with IC50's ranging from 12 nM -295 nM (Figure 43, columns a and b). The ability of the pegylated E/I I 0 Fn3-based binders to inhibit IGFR and EGFR activity was also examined in H292 cells using methods previously described in Examples 6 and 7. Results indicated that the pegylated E/I 1 0 Fn3-based binders inhibited IGFR activity with IC50's ranging from 0.2 nM - 6 nM (Figure 43, column d) and inhibited EGFR activity with IC50's ranging from 1.3 nM - 123 nM (Figure 43, columns c). The pegylated E/I 1UFn3-based binders were tested to determine if they could induce degradation of EGFR and IGFR in Difi cells as shown in columns e and f of Table 16. Cells were treated with luM of pegylated E/I 1 0 Fn3-based binders and 137 24039697_1.DOC harvested at time points starting at 7 hrs and ending at 120 hrs and levels of EGFR and IGFIR were determine by Western blot analysis. The strength of degradation was scored as either (+) indicating the tandem degraded that receptor but the degrdation was not sustained and receptor expression reappeared during the time course or (++) which indicates the tandem degraded the receptor and sustained that degradation throughout the time course. Results (Figure 43, column e and f) demonstrated that the pegylated E/I ' 0 Fn3-based binders displayed various patterns of EGFR and IGF1R degradation; degradation of only IGFR, degradation of both EGFR and IGFR or no degradation of either receptor. No tandem tested displayed the ability to degrade only EGFR. The binding affinity of the pegylated E/I 1 0 Fn3-based binders for EGFR and IGF1R was assessed by surface Plasmon resonance (BIAcore) analysis as previously described in Example 5. Results demonstrated that the pegylated E/I ' 0 Fn3-based binders bound to EGFR with affinities ranging between 3.35 nM- 57.9 nM and bound to IGF1R with affinities ranging between 0.37 nM- 2.43 nM (Figure 43, columns g and h). The pegylated E/I ' 0 Fn3-based binders were tested to determine their potency for blocking EGF binding to EGFR on the surface of A431 cells using methods previously described in Example 10. The the pegylated E/I ' 0 Fn3-based binders blocked EGF binding to A431 cells with IC50's ranging from 19.5 nM to 238nM (Figure 43, column i). The pegylated E/I 1OFn3-based binders were assessed for their ability to inhibit colony formation of H292 cells using methods described in Example 17. As shown in Figure 43, column j, the pegylated E/I 1 0 Fn3-based binders inhibited colony formation with IC50 values ranging from 1 nM - 560 nM and three of the four pegylated E/I I 0 Fn3-based binders tested were 23-140 fold more potent than the anti-EGFR monoclonal antibody panitumumab. The fourth pegylated E/I ' 0 Fn3 based binders was 4 fold less potent than panitumuab. The pegylated Il monomer was only marginally active in inhibiting colony formation in H292 with an IC50 >15uM and this is expected since H292 cell growth is predominantly driven by EGFR signaling and not IGF1R signaling. 138 24039697_1.DOC The melting temperature was assessed for pegylated E/I 1 0 Fn3-based binders by DSC (as previously described in Example 4) or thermal dye melt methodology. For thermal dye melt assessment, the pegylated E/I 1 0 Fn3-based binders were diluted to 0.2 mg/mL in 50mM NaAc buffer pH 4.5. Each sample was spiked with luL of the 200x Sypro Orange in DMSO buffer for a final concentration of 0.5% dye. Each sample was loaded into the 96 well tray and coated with 5uL of silicone oil. The tray was spun down at 1,000 RPM and loaded onto the Bio-Rad CFX96 system and the following method was selected: 25'C for 10 minutes + Plate Read 25'C to 95'C @ 0.5 C increments for 15 minutes + Plate Read. Data analysis was performed for the inflection point with the CFX software. As shown in Figure 43, column k, all pegylated E/I 1 0 Fn3-based binders had similar Tm measurements, ranging from 49 62.5 degrees celsius. Tm measurements for the pegylated E/I ' 0 Fn3-based binders were independent of concentration and remained consistent at all concentrations tested. DSC analysis of an exemplary binder, Il-GS10-E5 pegylated, measured with a scan range of 15-95'C at lmg/ml protein concentration in PBS, resulted in a Tm measurement of 55.2'C as shown in Figure 20. Size exclusion chromatography (SEC) was performed on the pegylated E/I 1 0 Fn3-based binders as previously described in Example 4. SEC analysis revealed that all of the pegylated E/I 1 0 Fn3-based binders were >95% monomeric as shown in Figure 43 (column 1 of Table). Example 23: Biochemical and biophysical properties of E/I I 0 Fn3-based binder I1-GS1O-E5 pegylated with selected amino acid changes I1-GS1O-E5 pegylated was constructed without the 6HIS tag (SEQ ID NO: 487) and also with various alterations to the linker region. In addition, a global change was made to all the constructs wherein the C-terminal tail of the first monomer had a single point change of the aspartic acid to glutamic acid (D to an E). Several clones were made with selected serine residues mutated to cysteines (S to C) to provide for alternate PEGylation sites. The effect of these changes on biochemical and biophysical properties of the molecule were compared and are summarized in Table 17. Methods for measuring inhibition of pEGFR are described in Example 7, pIGFR in Example 6, pERK in Example 1, Tm in Example 4, EGFR 139 24039697 I.DOC and IGFR KD in Example 5. Detailed analysis of the binding kinetics were also carried out on these clones and are presented in Tables 18 and 19 (using methods similar to those described in Example 5). Table 17. pIGF pER pEGFR R K EGFR IGFR SEC IC50 IC50 IC50 Tm KD KD % CLONE NAME (nM) (nM) (nM) ("C) (nM) (nM) mono I1-GS1O-E5 pegylated 28 2.2 12 56 2.7 0.25 96 Il-GS10-E5 Sticky( pegylatedl) 30 1.2 11 56.8 0.23 94.1 Il-GSGCGS8-E5m) 19.8 1.4 8 54.8 4 0.29 95.2 Il-GS10-E5-GSGC( 4 ) 28.7 1.2 19 55 1.4 0.25 92.7 I (S62C)-GS10 ES5 21 1.9 10 55.5 8.7 0.7 97.45 I1-GS10-E5 (S62C) (6) 68.4 2.2 30 56 1.7 0.26 96.12 11 (S91C)-GS10 E5(7) 22.7 6.2 15 52 17 7.16 95.98 Il-GS10-E5(S91C)(') 22.6 2.1 29 50.5 17.9 0.28 93.39 (1) No His Tag was used for this construct. (2) a global change was made to all the alternative constructs of I1-GS1O-E5 pegylated, wherein the C-terminal tail of the first monomer had a single point change of aspartic acid to glutamic acid (D to an E). (3) The Il mononer linked with GSGC (SEQ ID NO: 489) plus GS8 (SEQ ID NO: 494), to E5. (4) 11 linked with GS10 to E5 with GSGC (SEQ ID NO: 489) at the tail of E5. (5) Il linked with GS10 to E5, wherein the Il has a single point change of serine to cysteine at position 62. (6) Il linked with GS10 to E5, wherein the E5 has a single point change of serine to cysteine at position 62. (7) Il linked with GS10 to E5, wherein the I has a single point change of serine to cysteine at position 91. (8) Il linked with GSIO to E5, wherein the E5 has a single point change of serine to cysteine at position 91. (9) This construct demonstrated non-specific binding to the flow cell so an accurate determination of affinity was not possible in this experiment. Table 18. Biacore binding of altered I1-GS10-E5 Pegylated clones to EGFR645-Fc. Description ka (1/Ms) kd (1/s) Kd (nm) (od (od (od 2.93 ±0.67 7.24 + 2.69 + Il-GS10-E5 Pegylated E04 3.14 2.53 I E-05I I Il-GS1O-E5 pegylated 2.27E+04 1.49E-04 6.6 0.8 0.5 0.4 Non-specific binding to reference cell surface at higher I1-GS10-E5 pegylated") analyte concentrations (600nM, 200nM prohibited kinetic value determination) ALTERNATIVE CLONES 4E I E 0 4 1 A l-GSGCGS8-E5 2.94E+04 1.E-04 4.0 1.0 10.6 1 0.7 140 24039697_1.DOC Il-GSl0-E5-GSGC( 4 ) 3.34E+04 4.52E-05 1.4 1.1 1.6 2.0 Il(S62C)-GS0-E5 5 ) 2.28E+04 1.99E-04 8.7 0.8 0.4 0.3 Il-GS10-E5(S62C) 1.78E+04 3.04E-05 1.7 0.6 2.4 1.6 Il(S9lC)-GS0-E5 7 ) 1.96E+04 3.34E-04 17.0 0.7 0.2 0.2 Il-GS10-E5(S91C)7 1.08E+04 1.93E-04 17.9 0.4 0.4 0.2 (1) No His Tag was used for this construct. (2) a global change was made to all the alternative constructs of Il-GS10-E5 pegylated, wherein the C-terminal tail of the first monomer had a single point change of aspartic acid to glutamic acid (D to an E). (3) The Il mononer linked with GSGC (SEQ ID NO: 489) plus GS8 (SEQ ID NO: 494), to E5. (4) 11 linked with GS10 to E5 with GSGC (SEQ ID NO: 489) at the tail of E5. (5) Il linked with GS10 to E5, wherein the I has a single point change of serine to cysteine at position 62. (6) Il linked with GS10 to E5, wherein the E5 has a single point change of serine to cysteine at position 62. (7) Il linked with GS10 to E5, wherein the II has a single point change of serine to cysteine at position 91. (8) Il linked with GS10 to E5, wherein the E5 has a single point change of serine to cysteine at position 91. Table 19. Biacore binding of altered I1-GS1O-E5 Pegylated clones to IGF1R-Fc. Description ka (1/Ms) kd (1/s) Kd (nm) (od (od (od Il-GSIO-E5 pegylated 1.04 0.04 2.62 ±0.21 0.25 ±0.01 - ___________________ E+06 E-04 Il-GS 10-E5 pegylated 1.1OE+06 2.78E-04 0.25 1.1 0.9 1.0 I1-GS1O-E5 pegylated(" E.28E+06, 2.88E-04 0.22, 0.23 1.2 0.9 1.1 1.2213±06 2.76E-04 ALTERNATIVE CLONES, 2 _ Il-GSGCGS8-E5") 8.52E+05 2.45E-04 0.29 0.8 1.1 0.9 I1-GS10-E5-GSGC( 4 ) 1.07E+06 2.65E-04 0.25 1.0 1.0 1.0 Il(S62C)-GS10-E57 3.34E+05 2.34E-04 0.70 0.3 1.1 0.4 I1-GS10-E5(S62C)(6> 1.07E+06 2.79E-04 0.26 1.0 0.9 1.0 Il(S9lC)-GS0-E5 7 ) 8.22E+04 5.89E-04 7.16 0.1 0.4 0.04 Il-GSl0-E5(S9C)7 8 - 9.86E+05 2.81E-04 0.28 0.9 0.9 0.9 (1) No His Tag was used for this construct. (2) a global change was made to all the alternative constructs of Il-GS1O-E5 pegylated, wherein the C-terminal tail of the first monomer had a single point change of aspartic acid to glutamic acid (D to an E). (3) The Il mononer linked with GSGC (SEQ ID NO: 489) plus GS8 (SEQ ID NO: 494), to E5. (4) Il linked with GS10 to E5 with GSGC (SEQ ID NO: 489) at the tail of E5. (5) Il linked with GS10 to E5, wherein the Il has a single point change of serine to cysteine at position 62. (6) Il linked with GS10 to E5, wherein the E5 has a single point change of serine to cysteine at position 62. (7) Il linked with GS10 to ES, wherein the Il has a single point change of serine to cysteine at position 91. (8) Il linked with GS10 to ES, wherein the E5 has a single point change of serine to cysteine at position 91. Example 24: Inhibition of shared downstream signaling pathways of EGFR and IGFR Inhibition of downstream signaling pathways were analyzed with a pAKT ELISA identical to those previously described in Example 8. Results of this study demonstrate that I1-GS1O-E5 pegylated is more potent than Il pegylated alone at 141 24039697_ .DOC blocking IGF1-stimulated AKT activation in H292 cells. E5 pegylated, the EGFR monospecific binder alone did not efficiently prevent activation of AKT by IGF1 stimulation (Figure 21). Example 25: Inhibition of cell proliferation by 1 Fn3-based binders and comparator antibody H292 and RH41 cell proliferation experiments were conducted as described in Example 9. The EGFR monospecific 1 0 Fn3-based binder E5-pegylated inhibited proliferation of H292 cells with an IC50 value of 0.016 pLM. The IGFR monospecific 1 0 Fn3-based binder Il-pegylated had an IC50 value of>8.4 ptM while the E/I 1 0 Fn3-based binder Il-GS 10-E5 pegylated was slightly more potent with an IC50 value of 0.006 ptM (Figure 22). The H292 cell line is of lung cancer origin and sensitive to inhibition of IGFR and EGFR ((Akashi Y, et al. (2008) Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br. J. Cancer 98:749-755; and Buck E, et al. (2008) Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 68:8322-8332.)) In contrast, only the Il-GS 10-E5 pegylated binder and the Il-pegylated binder inhibited the proliferation of RH41 cells (IC50 values were 0.0002 and 0.0004 pM, respectively, Figure 23). This was expected, since RH41 is a pediatric rhabdomyosarcoma cell line that is known to be driven predominantly by IGFR signaling ((Huang F, et al. (2009). The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 69:161-170)) and thus not sensitive to EGFR blockade. Example 26: Inhibition of receptor activation and downstream signaling in vitro by pegylated and non-pegylated 'Fn3-based binders In order to understand the dynamics of EGFR/IGFR signaling and its inhibition by I1-GS1O-E5 pegylated, DiFi, H292 or BxPC3 cells were serum starved, exposed to 1 pM or 0.1 pM E5 pegylated, Il pegylated, or Il-GS1O-E5 142 24039697 1.DOC pegylated, or vehicle control for 2 hours, then stimulated with either EGF, IGF-I, or EGF + IGF-I for 10 min. Cells were cultured in vitro, serum starved overnight and then exposed to 1 0 Fn3 based binders for 2 hours prior to stimulation with 1 OOng/ml of EGF or IGF. Cell lysates were prepared in lysis buffer (1% Triton X-100, 5% glycerol, 0.15 M NaCl, 20 mM Tris-HCl pH 7.6, Complete Protease Inhibitor Cocktail Tablets [Roche, Indianapolis, IN] and Phosphatase Inhibitor Cocktail 2 [Sigma-Aldrich Corp.]). Lysates (30 ptg) were resolved by SDS-PAGE, transferred to membranes, and immunoblotted with antibodies to phospho-EGFR and total EGFR (Santa Cruz Biotechnology, Carlsbad, CA), phospho-AKT (Ser 473), phospho-p44/42 MAPK (Thr202/Tyr2O4) (Cell Signaling Technology, Beverly, MA), or total actin (Chemicon International, Temecula, CA) in Odyssey Blocking Buffer with 0.1% Tween 20 (LI-COR Biosciences, Lincoln, NE). Membranes were incubated with the appropriate secondary antibodies. Protein visualization was performed using a LI COR Biosciences Odyssey infrared imaging system. As shown in Figure 24, the basal levels of phosphorylated EGFR, IGF-IR, and AKT were nearly undetectable after serum deprivation. In DiFi cells, neither II GS10-E5 pegylated or E5 pegylated (monospecific EGFR binder) are able to completely suppress EGF-stimulated EGFR phosphorylation. In H292 and BxPC3 cells there is strong inhibition of EGFR phosphorylation by both Il-GS10-E5 pegylated and E5 pegylated. In DiFi and BxPC3 cells, I1-GS1O-E5 pegylated blocks IGF-stimulated IGFR phosphorylation more than Il pegylated (monospeciific IGFR binder) by itself In H292 cells, IGF-stimulation cross activates the EGFR only when EGFR is blocked. I1-GS1O-E5 pegylated inhibited EGF-stimulated pAKT in DiFi; increased pAKT in EGF-stimulated H292 and in BxPC3 EGF did not activate pAKT. In DiFi, H292 and BxPC3 cells Il-GS10-E5 pegylated inhibited IGF-stimulated pIGFR more than the individual E5 pegylated and Il pegylated by themselves. Il-GS10-E5 pegylated had very little if any effect on EGF-stimulated pERK in DiFi, H292 or BxPC3. IGF-stimulation did not induce pERK in any cell line examined. In another experiment with unPEGylated_1 0 Fn3-based binders, H292 cells were serum-starved, exposed to 1 jM unPEGylated monospecific EGFR binder E2, 143 24039697_.DOC IGFR binder Il, or E2-GS 10-I1, or vehicle control for 1 hour, then stimulated with either EGF, IGF-I, or EGF + IGF-I for 10 min. The basal levels of phosphorylated EGFR, IGFR, and AKT were nearly undetectable after serum deprivation (Figure 25). Stimulation with EGF induced EGFR phosphorylation, but did not transactivate IGFR. EGFR phosphorylation was blocked by the E2, and E2-GS 10-I1, but not Il. Similarly, stimulation with IGF-I induced strong phosphorylation of IGFR that was blocked by Hand E2-GS10-I1, but not by E2. EGF stimulation only slightly increased AKT phosphorylation, but IGF-I or EGF + IGF-I strongly induced phosphorylation of AKT that was suppressed to basal levels by both Il and E2 GS 10-Il. The combination of IGF-I and EGF induced AKT phosphorylation more than either growth factor alone. E2 partially reduced pAKT induced by the combination of EGF and IGF-I. However, Il showed the most dramatic reduction in pAKT, suggesting that stimulation with EGF + IGF-I led to strong AKT phosphorylation through the IGFR pathway. Surprisingly, blockade of the EGFR pathway by E2 followed by stimulation with EGF ligand actually increased the phosphorylation of AKT, perhaps as a result of EGFR-independent activation of AKT ((Dobashi Y, et al. (2009) EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol (Epub Ahead of Print)). These results illustrate the complex cross-talk between the EGFR and IGFR pathways and feed-back mechanisms. Example 27: Competition binding studies with E/I Fn3-based binders For Biacore competition experiments, EGFR-Fc (3ptg/mL in Na-acetate pH 5.0) was immobilized on the Biacore CM5 chip surface using standard EDC/NHS amide coupling chemistry to a surface density of 300 RU. EGFR antibodies were obtained as a marketed drug and competition between monospecific EGFR binder E2 and antibodies for binding to EGFR-Fc was assessed by binding 450 nM E2 (30pLL/min, 200s contact time), immediately followed by 450 nM E2 alone, or a mixture of 450 nM E2 plus 450 nM cetuximab, panitumumab, or nimotuzumab (30pL/min, 200 sec contact time). The surface was successfully regenerated between cycles using two 10 sec pulses of 50 mM NaOH at a flow rate of 30gL/min. Initial injection of E2 shows binding to EGFR on the surface of the chip. A second 144 240396971.DOC injection of E2 mixed with an equal amount of cetuximab, panitumumab, or nimotuzumab shows no competition for binding of antibodies to EGFR by E2 (Figure 26A). Surface plasmon resonance (BlAcore) analysis was utilized to demonstrate simultaneous engagement of captured EGFR-Fc and solution phase IGF1R by E/I 1 0 Fn3-based binders. Recombinant human EGFR-Fc (aa 1-645 of the extracellular domain of human EGFR fused to human Fc) was purchased from R&D systems (Minneapolis, MN). Recombinant IGF1R (aa 1-932 of human IGFIR propeptide, proteolytically cleaved and disulfide linked) was purchased from R&D systems (Minneapolis, MN). To demonstrate simultaneous engagement, anti-human IgG was immobilized on flow cells 1 and 2 of a CM5 chip following the manufacturer's recommendations (GE Healthcare, Piscataway, NJ). EGFR-Fc (50 nM) was captured on flow cell 2 at 1OuL/min for 2 minutes. Binding of E/I I 0 Fn3-based binders to EGFR-Fc was achieved by injecting 10 Fn3-based protein samples (1 00nM) over both flow cells at 1 OuL/min for 2 minutes. Simultaneous engagement of EGFR-Fc and IGF1R was probed by subsequently injecting IGF1R (0,100lnM) over both flow cells at 30uL/min for 2 minutes. Dissociation of the complex was monitored for 300 seconds. Two 30 second injections of 3 M MgC 2 were used for regeneration of the bound complex from the anti-human IgG surface. Biacore T100 Evaluation Software, Version 2.0.1 (GE healthcare/Biacore) was utilized to overlay sensograms and remove airspikes. As shown in Figure 26B, both domains of the E/I

'

0 Fn3-based binder are functional and able to bind to EGFR-Fc and IGF1R simultaneously. Binding specificity of E2-GS10-Il pegylated to HER family receptors was assessed by Biacore as described in Example 5. HER-2-Fc, HER-3-Fc and HER-4 Fc (R&D Systems) was captured on the surface of the CM5 chip with anti-human IgG. E2-GS10-Il pegylated did not show any discernible binding to other HER family members under conditions where robust binding was seen for EGFR-Fc (HER-1) (Table 20). 145 24039697_1DOC Table 20. Binding affinity of E2-GS10-Il pegylated to extracellular domains of HER family of receptors. EGFR- HER- HER-

HER

Name Fe KD 2-Fc 3-Fc 4-Fc KD, KD, KD, rinrm nM nM E2-GS1O-I1 pegylated 10.1 >1000 >1000 >1000 Example 28: Measurement of plasma biomarkers Levels of soluble biomarkers TGFa and mIGF1 were measured in mouse plasma at the end of xenograft studies or in non tumor bearing mice at various times following treatment. Blood was obtained by terminal cardiac puncture into tubes containing EDTA as an anticoagulant. Plasma was prepared by centrifuging blood at 1300 xg for 10 minutes at 4 degrees C and removing the clarified supernatant to a separate tube. TGFa levels were measured in 0.1 ml of plasma, mIGF 1 levels were measured in 0.02 ml plasma with an ELISA assay as recommended by manufacturer (R&D Systems, Minneapolis, MN). Plasma levels of TGFa were increased in mice treated with Il -GS 10-E5 pegylated or the monospecific EGFR binder E5 pegylated but not cetuximab (Figure 27A-C). The TGFa could be secreted from the human tumor or may represent endogenous mouse TGFa. Due to the high homology between human and mouse TGFa (93% amino acid identity) the ELISA may cross react with mouse TGFa. Furthermore, human TGFa secreted by the implanted tumor can bind to the mouse EGFR. Because Il-GS10-E5 pegylated and E5 pegylated can bind both human and mouse EGFR, all host and tumor EGFR binding sites are blocked by these 10Fn3-based binders while cetuximab does not bind mouse EGFR. To determine if these 1 0 Fn3-based binders cause increases in endogenouse mouse TGFa and if the ELISA cross reacts with mouse TGFa, non tumor bearing nude mice were dosed with Il-GS10-E5 pegylated at 100mg/kg and plasma samples were taken at 4, 24, 48, 72 hours post dose. Increases in mouse TGFa were in fact observed that persisted out past 72 hours (Figure 28A). Plasma samples from non-tumored mice were also tested for nIGF1 with a mouse specific ELISA and increases in this ligand were also observed (Figure 28B). 146 24039697_1.DOC Example 29: Results of in vivo human tumor xenograft studies for various E/I 1 0 Fn3-based binders Several E/I 1 0 Fn3-based binders were evaluated in a head-to-head H292 NSCLC study (methods described in Example 12) at a lower dose than previously used so that differences in relative activity could be ascertained. Efficacy of the E/I ' 0 Fn3 based binders E2-GS10-I1 pegylated, E4-GS1O-I1 pegylated, I1-GS10-E5 pegylated, Il-GS10-E85 pegylated, Il-GS10-E4 pegylated, Il-GS10-E105 pegylated at a single dose of 0.625mg/mouse and panitumumab at two doses (1 mg/mouse and 0.1 mg/mouse) were compared. Both doses of panitumumab and all E/I 1 0 Fn3-based binders evaluated in this study were active by a tumor growth inhibition (TGI) endpoint. During the dosing phase, E4-GS1O-Il pegylated, I1-GS1O-E5 pegylated, Il-GS10-E4 pegylated and panitumumab all caused tumor regression (Table 21, TGI values greater than 100%) while E2-GS10-I1 pegylated, I1-GS10-E85 pegylated and I1-GS10-E105 pegylated caused tumor growth inhibition (Table 21, TGI values up to 100%). Differences in activity were statistically significant when compared to the control group. All treatments were well tolerated with no treatment related deaths or excessive weight loss over the course of the study. Comparison of the efficacy of the E/I ' 0 Fn3-based binders and panitumumab are presented in Table 21 below and in Figure 29. In Figure 29A, measurements out to day 43 shows the pattern of regrowth of the tumors after dosing ceased. Figure 29B shows measurements out to day 27 and the y-axis is expanded to illustrate the relative differences in activity among the treatment groups. Table 21. In vivo antitumor activity in the H292 NSCLC study AVE Oucm Group Compound Schedule, Dose weight %TGI value outcome Route (mg/kg) change (g) %TGI %TGI I Control --- 3.36 - 1.0 (untreated) 2 panitumumab q3dx5; 1mW 5.19 107 0.0023 A 6 ip' mse 3 panitumumab q3dx5; 0. 1mg/ 5.9 105 0.0029 A pantummab 6 jpa mse 147 24039697_.DOC 4 E2-GS10-I1 TIWX3; 0.625mg -1.4 93 0.0067 A pegylated 6 ipa /mse 5 E4-GS10-1l TIWX3; 0.625mg -0.23 105 0.0023 A pegylated 6 ipa /mse I1-GS1O-E5 TIWX3; 0.625mg A pegylated 6 ipa /mse 11-GS1O-E85 TIWX3; 0.625mg A 7 pegylated 6 ipa /mse 1.08 86 0.0114 pegylated 6 ipa /mse I1-GS10-E4 TIWX3; 0.625mg A 8 pegylated 6 ipa ' /mse -. 1 13 003 Il-GS10- A 9 E105 TIWX3; 0.625mg -1.54 95 0.0035 pegylated 6 1p /nse "Vehicle was phosphate buffered saline. Abbreviations used are as follows: ip, intraperitoneal route; %TGI, relative % tumor growth inhibition calculated as %TGI=[(Ct-Tt)/(CrCo)] x 100 where C =median tumor weight of control mice at time t in days after tumor implant, T,=median tumor weight of treated mice at time t, Co= median tumor weight of control mice at time 0. %TGI value was calculated at two points as the average inhibition of Day 20, Day 24 and Day 27. Outcome, a treatment regimen was considered active if it produced a statistically significant %TGI value of >50%; q3dx5;6, compound was administered every three days for six doses starting on the sixth day after tumor implant; 6 on/l off; 6, compound was administered once a day for 6 days then no treatment for 1 day and this regimen started on the sixth day after tumor implant. p values were calculated on Day 20 relative to the control group in a two tailed paired analysis with 8 measurements per group. Further in vivo studies were carried out with selected E/I 1 0 Fn3-based binders below, in various xenograft models using the methods described in Example 12. A description of the various xenograft models is as follows: H292 is a non-small cell lung carcinoma (NSCLC) and is described in more detail Example 12; MCF7r breast carcinoma is described in Example 14; and GEO colon carcinoma is described in Example 15. The DiFi human colon carcinoma expresses high levels of activated EGFR and also expresses IGFR; RH41 is a pediatric rhabdomyosarcoma cell line that is known to be driven predominantly by IGFR signaling (Huang F, et al. ((2009)) The mechanisms of differential sensitivity to an insulin-like growth factor-i receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 69:161-170) and thus is not sensitive to EGFR blockade; Cal27 is a human head and neck carcinoma expressing high levels of EGFR and moderate levels of IGFR; BxPC3 is a human pancreatic carcinoma; and H441 is a NSCLC. Comparison of the efficacy of selected E/I ' 0 Fn3-based binders are presented in Table 22. In these efficacy studies, all of the E/I 1 0 Fn3-based binders showed 148 24039697_.DOC equivalent activity to panitumumab and all treatments were able to regress H292 tumors below their starting size as indicated by %TGI values over 100%. In the DiFi study, panitumumab regressed tumors at the 1mg/mouse dose and was active at the 0.1mg/mouse dose while all of the E/I 1 0 Fn3-based binders were inactive although the I1-GS1O-E5 pegylated showed some inhibition of tumor growth (TGI = 43.8%). In the RH41 study, panitumumab was not active at either dose, the E2 pegylated construct was not active while the E/I ' 0 Fn3-based binders and the Il pegylated construct were all active. Figure 32 shows antitumor efficacy in the RH41 model for a representative construct E2-GS10-Il pegylated (data also shown in Table 23). In the Cal27 study panitumumab regressed tumors at the 1mg/mouse dose and was active at the 0. 1mg/mouse dose but among the E/I 1 UFn3-based binders only the Il-GS10-E5 pegylated E/I I 0 Fn3-construct was active. Results of human tumor xenograft studies with Il-GS10-E5 pegylated and individual Il and E5 components designed to assess synergy are presented in Table 23. These combination (synergy) studies were structured such that the individual pieces of the E/I 10 Fn3-based binders (ie., IGFR and EGFR monospecific pegylated versions) were included so antitumor effects beyond the contribution of isolated ends could be discerned. In the MCF7r study, I 1 pegylated was not active while the E5 pegylated, (E5 pegylated + Il pegylated) and the Il-GS10-E5 pegylated clones were all active and exhibited similar activity meaning that all of the antitumor activity likely comes from inhibition of EGFR and blocking the IGFR pathway did not provide any enhancement. Cetuximab regressed tumors at the 1mg/mouse dose and was not active at the 0.1mg/mouse dose. BMS-754807 was also not active showing that blocking the IGFR pathway with a small molecule inhibitor did not result in efficacy in this model. In the BxPC3 study, Il pegylated was not active while the E5 pegylated and (E5 pegylated + Il pegylated) clones were active (TGI = 61.2% and 68.8%, respectively). The I1-GS1O-E5 pegylated clone was more active (TGI = 78%) than the individual pieces it is made from and the difference was statistically significant by a two tailed paired t-test showing that it has synergistic activity in this model. Cetuximab was active at all doses studied but adding in IGFR inhibition by combining it with the Il -pegylated did not result in synergy. 149 24039697_.DOC In the GEO study, Il pegylated was not active while the E5 pegylated and (E5 pegylated + II pegylated) and Il-GS 10-E5 pegylated clones were active (TGI = 83.5%, 92.1 and 92.1%, respectively). While there may have been some enhancement provided by combining EGFR and IGFR inhibition together in this model, the difference was not significantly better than the E5 pegylated by itself Cetuximab was active at both doses studied but adding in IGFR inhibition by combining it with the Il -pegylated did not result in synergy. In the H441 study, Il pegylated and E5 pegylated were not active on their own but (E5 pegylated + Il pegylated) was active (TGI = 54.5%). The I1-GS10-E5 pegylated clone was more active (TGI = 69.2%) than the individual pieces it is made from but the differences were not statistically significant showing that it provides enhanced activity but not synergy in this model. Cetuximab was active at the 1mg/mouse dose and was not active at the 0.1mg/mouse dose. Adding in IGFR inhibition by combining it with the Il-pegylated did not result in any enhancement in this model. 150 24039697_ .DOC C:) CD6-) ) 00 0 00 -o NoL r ~ r4 rn CJ0 - 80 c-ci1i 'baa Con4 bn Wa to D 0 - - - - - - - - - - -, 03 N N- r- 00~ 4 C 0 00 ;o 1 E 6 ~o M C,3 CD oo -00 r' 2Z co C4CZ / C C C. U r) c)-' C:OC: C HE c _;._ - .p 0~~~ ~~CC cca m -z U)) >,H al~ cz2 0 C/ cl- COO u) n CZ~ COC ~~c Q') 0 Z)- C~ 0x 0 0 o3 co 4 ( 0 cz CZ C t U 42 cUC-S O~~~- "-C9~~$\~Q~C COz CCOC ,~4~~ Wur C 10k-) 0k 40 C/) 0 0. C, _- -o 6 C , N l 0Zt t__ q CCZ 44 -1 -1 M- 1 CD C) C) C 0)V tr) kn HHHYC. HHH& E C E 0) - -eC W) 0) c 4- 0) 7:; 0) -C 0Z - A-C bl) 0) O tn in 0) r +~r 0) CIA m tr D 0 _ n z o o ILI "D 00 r- a c C) cq C:)C 3 7 (=) C) >(Z) > C C- = C)0 C) C) C, 8i C:)'~ 8 ~~ ' 01)) -r 6 l 01) 01 -N 01 Ilel u 0 ~ S~ to -CD > J4 -- '.I ) C., -3 C -E ,fl l 0 z 0 -~~ L- ~ - clC (z -cCC cn - n fn0 3 -r - ~00~~0Ci~ci CP. a- 0~C o ~ -4"0 0 ~0 0 ~Wu -C13 0 C C C m C CzC, z C , c U. 0-Cl VD - 5C) 0 tn r - 'C -0 C Cj 00 ~ 0n V) \, - 0 > 04 Example 30: Pharmacokinetic profile of various E/I Fn3-based binders in mice The pharmacokinetic profiles of the pegylated E/I 1 0 Fn3-based binder, E2 GS10-I1, were assessed in mice via intraperitoneal injection. Three nude mice per dose group were dosed with E2-GS10-I1, formulated in PBS, at 10 and 100 mg/kg, ip and plasma samples were collected in citrate phosphate dextrose solution at pre dosing, 0.5, 2, 4, 8, 12, 24, 48, 72, 96, 144, and 168 hours post dosing. Plasma samples were assessed for pegylated E2-GS1O-I1 Fn3-based binder levels using a quantitative electrochemiluminescence (ECL) assay developed to detect and quantitate the pegylated E/I 10Fn3-based binder in plasma samples. In this assay, a mouse monoclonal antibody with specificity toward the EGFR binding region was adsorbed to Meso Scale Discovery plates overnight at 4 0 C to allow capture of the pegylated E/I 1UFn3-based binder in the plasma samples. The plasma samples were added to the plates and incubated at 22'C for 1 h. The captured pegylated E/I ' 0 Fn3 based binder was detected by a rabbit polyclonal antibody specific to the scaffold region of the E/I I 0 Fn3-based binder, mixed with a goat anti-rabbit antibody linked with a SULFO-TAG. Following a wash to remove unbound SULFO-TAG reagent, a read buffer was added and ECL detection was used. The level of pegylated E2 GS 10-Il in plasma samples was calculated based on comparison to a 4-parameter fit of a standard curve of the pegylated E2-GS 10-Il Fn3-based binder. Mice administered 10 or 100 mg/kg interperitoneally (ip) of pegylated E2 GS 10-Il resulted in peak levels of approximately 200 and 1700 ptg/mL, respectively, indicating dose-proportional pharmacokinetics (Figure 30). Pharmacokinetic parameters for Figure 30 were calculated in a similar fashion to those described in the paragraph below (note that "T 1/2" is interchangeable with "HLlambda z"and AUC is interchangeable with "AUCINFobs". The half-life of pegylated E2-GS1O-I1 in mice was 15.75 ± 1.52 h (Figure 30). Based on these pharmacokinetic parameters, administration of 100 mg/kg three times weekly (TIW) in human tumor xenograft studies was able to maintain drug levels 10- to 100-fold higher than the in vitro IC50 value. Additional pharmacokinetic experiments were conducted on several pegylated E/I ' 0 Fn3-based binders, where mice were administered 10 or 100 mg/kg 155 24039697_.DOC interperitoneally (ip) and, for the pegylated Il-GS10-E5, 10 or 64 mg/kg sub cutaneously (sc), plasma was collected and analyzed as described above to measure the levels of pegylated E/I 1 0 Fn3-based binders. The pharmacokinetic parameters of these various E/I 1 0 Fn3-based binders were obtained by non-compartmental analysis of plasma (serum) concentration vs. time data. WinNonlin software (version 5.1, Pharsight Corp. Mountain View CA) was used to calculate the terminal half-life (HL lambda z), maximum observed concentration (Cmax), the area under the curve from time zero extrapolated to infinity (AUCINFobs), clearance (CL F-obs), volume of distribution based on the terminal phase (Vz_F obs) and the mean residence time extrapolated to infinity (MRTINF-obs). Results showed that the half life for the pegylated E/I 1 0 Fn3-based binders were between 12.1-20.9 hours, as shown in Figure 44 and Figure 31. Example 31: Pharmacodynamics Samples were taken from the H292 and the DiFi xenograft models described in Table 22 at the end of the study and processed as outlined under Measurement of pharmacodynamic endpoints in tumors in Example 12 for analysis of total levels of EGFR and IGFR protein and phosphorylated EGFR and IGFR. Target effects of Il GS10-E5-pegylated and panitumumab were evaluated by immunoblotting as described in Example 11. In Figure 33A, levels of total EGFR, pEGFR and total IGFR were lower in Il-GS10-E5-pegylated treated tumors than in untreated tumors at the end of the DiFi xenograft model. In Figure 33B, levels of pEGFR were lower in tumors treated with panitumumab and Il-GS10-E5-pegylated. Levels of total EGFR were lower only in Il-GS10-E5-pegylated treated tumors but not in panitumumab treated tumors. Levels of total IGFR were lower in both I1-GS10-E5 pegylated treated tumors and in one panitumumab treated tumor but not the other. The amount of pIGFR in these models was too low to detect differences following treatment. Immunoblots were probed with GAPDH to demonstrate equal loading of protein. 156 24039697 I.DOC Example 32: EGFR 10 Fn3-based binders Optimization and Consensus Sequence Analysis The ' 0 Fn3-based binder 679F09 (as described in PCT WO 2009/102421) (Figure 34) was identified as a binder to EGFR ectodomain-Fc fusion protein (R&D Systems). Binding activity was selected using a bead coated with EGFR-Fc and

'

0 Fn3-based binders coupled to their nucleic acid coding sequence (see e.g., Xu et al., Directed Evolution of High-Affinity Antibody Mimics Using MRNA Display, Chem. Biol. 9: 933-942 (2002)). More potent variants of the parental EGFR binder 679F09 having alterations to the amino acid sequences in the BC, DE and FG loops were also identified. Sequence Analysis I: All ' 0 Fn3-based binders selected for high-affinity binding to EGFR In order to reveal sequence patterns that defined strong affinity for EGFR, all unique EGFR binding sequences (1044) were analyzed using several methods. First, the sequences were analyzed by the frequency of amino acids at each position in the loops (Figures 35-38). Only unique sequences for each loop were analyzed. From the above sequence analysis, the following broad sequence motif was defined: Sequence Motif #1 (a) BC loop: "YQ" in positions 7-8 (i.e., corresponding to positions 29 and 30 of SEQ ID NO: 1) (b) DE loop: aliphatic residue ("V/I/L/M/A") in position 3 (i.e., corresponding to position 54 of SEQ ID NO: 1) (c) FG loop: "D/N" in position 1 (i.e., corresponding to position 77 of SEQ ID NO: 1) All 1044 sequences analyzed, except one, follow the FG loop sequence pattern (c). Of all unique sequences analyzed, 90% follow pattern (a) for the BC loop, and 95% follow pattern (b) for the DE loop. All sequences analyzed, except four, follow at least two of the three patterns above. In addition, the 15-amino acid FG loop length is a noteworthy sequence feature. 157 24039697 I.DOC In addition to the broad Sequence Motif #1 defined above, the data in Figures 35-38 were used to define a second sequence motif based on the dominant residues at each position. Residues were included in this motif if the sum of the top 3 most frequent amino acids had a greater than 50% frequency. Sequence Motif #2 (a) BC loop: XXXXXXYQ (same as Motif #1), wherein X is any amino acid (b) DE loop: (G/Y/H)(D/M/G)(V/L/I)X, wherein X is any amino acid (c) FG loop, 10 amino acid length: (D/N)(Y/M)(Y/A/M)(Y/H/F)(K/Q/V)(E/P/R)(Y/T/K)X(E/Y/Q)(Y/G/H), wherein X is any amino acid (d) FG loop, 15 amino acid length: D(Y/F/W)(Y/F/K)(N/D/P)(P/H/L)(A/T/V)(T/D/S)(H/Y/G)(E/P/V)(Y/H)(T/K /I)(Y/F)(H/N/Q)(T/Q/E)(T/S/I) The analysis methods used to define Sequence Motifs #1 and #2 evaluate each residue position within a loop separately. To reveal any sequence motifs spanning multiple residues within a loop, the 1 0 Fn3-based binders were subjected to further analysis. In this analysis, the loop sequences were aligned using ClustalW (Thompson JD et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. Nucleic Acids Research 22: 4673 4680, 1994). From this alignment, families of sequences were grouped using manual inspection. For the BC and DE loops, sequence patterns similar to Sequence Motifs #1 and #2 were observed. However, additional sequence motifs could be defined for the 10 and 15 amino acid long FG loops. Sequence Motif #3 (a) FG loop, 10 amino acid length (1) DY(A/Y)GKPYXEY (SEQ ID NO: 473), wherein X is any amino acid (2) DY(A/Y)Y(K/R/Q/T)PYXEY (SEQ ID NO: 474), wherein X is any amino acid 158 24039697_.DOC (3) (D/N)Y(A/Y)(Y/F)(K/R/Q/T)EYXE(Y/H) (SEQ ID NO: 475), wherein X is any amino acid (4) DYY(H/Y)X(R/K)X(E/T)YX (SEQ ID NO: 476), wherein X is any amino acid (5) DYY(H/Y)(K/H/Q)(R/K)T(E/T)Y(G/P) (SEQ ID NO: 477) (6) (D/N)MMHV(E/D)YXEY (SEQ ID NO: 478), wherein X is any amino acid (7) DYMHXXYXEY (SEQ ID NO: 479) (like FG loop of 679F09), wherein X is any amino acid (8) D(M/Y)YHX(K/R)X(V/I/L/M)YG (SEQ ID NO: 480), wherein X is any amino acid (b) FG loop, 15 amino acid length (1) D(Y/F)(Y/F)NPXTHEYXYXXX (SEQ ID NO: 481), wherein X is any amino acid (2) D(Y/F)(Y/F)D(P/L)X(T/S)HXYXYXXX (SEQ ID NO: 482), wherein X is any amino acid (3) D(Y/F)(K/R)PHXDGPH(T/I)YXE(S/Y) (SEQ ID NO: 483), wherein X is any amino acid Sequence Analysis II: mFn3-based binders showing more potent inhibition of EGFR phosphorylation Another overall sequence analysis was performed on the subset of ' 0 Fn3 based binders that showed the most potent activity in a cell-based assay (as opposed to Sequence Analysis I, which was performed on all binders selected for high affinity binding to EGFR through Profusion). Because many of the binders were only run through single-point cell-based assays, binders that showed greater than 75% inhibition of EGFR phosphorylation at a fixed concentration of 100 nM were included in this analysis. The percent inhibition at a given concentration is related to the IC50 by: % inhibition = 100 x concentration/(concentration + IC50). Normally, an IC50 is calculated by fitting the data for % inhibition at various concentrations. However, given that only a single data point is available for each binder, it is inappropriate to use this single data point to calculate an IC50. 159 24039697_I.DOC Therefore, the percent inhibition of EGFR signaling at a single concentration point was used as an approximation of the potency of the binder. Although a binder may show 75% inhibition at a concentration of 100 nM, increasing the concentration will allow the clone to show 100% inhibition at a higher concentration. The % inhibition is inversely related to the IC50; i.e., the higher the % inhibition, the lower the IC50 and the more potent the binder. If a binder showed 75% inhibition at a concentration of 100 nM, we considered this to be a "potent" binder for the purposes of Sequence Analysis II. However, the binders which showed less than 75% inhibition at 100 nM concentration for the most part still bind to EGFR and still have an effect on EGFR signaling. For instance, the anti-EGFR monoclonal antibody Nimotuzumab (Friedlander E et al. ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol Lett 116: 126 140, 2008) is currently under development as a therapeutic, but it shows <5% inhibition at a 100 nM concentration in the EGFR phosphorylation assay (data not shown). The sequences of all "potent" binders assayed and their % inhibition of EGFR phosphorylation at 100 nM concentration is shown in Figure 45. The total number of unique ' 0 Fn3-based binders that showed >75% inhibition at 100 nM concentration was 111. As before, the sequences first were analyzed by the frequency of amino acids at each position in the loops (Figures 39 42). Since these binders are a subset of all the binders selected for high affinity binding to EGFR during Profusion, they also follow Sequence Motif #1 (see above). All "potent" sequences analyzed follow the FG loop sequence pattern ("D/N" in position 1). Of all unique "potent" sequences analyzed, 93% follow the pattern for the BC loop ("YQ" in positions 7-8), and 98% follow the pattern for the DE loop (aliphatic residue ("V/I/L/M/A") in position 3). All "potent" sequences analyzed follow at least two of the three patterns of Sequence Motif #1. Of note, the 15-amino acid FG loop length also appears to be highly represented in the most "potent" binders. While 15-amino acid long FG loops represent only 55% of all binders selected for high affinity binding to EGFR (Sequence Analysis I), 15-amino acid FG loops represent 86% of the binders with >50% inhibition of EGFR phosphorylation at 100 nM concentration, and 91% of the binders with >75% inhibition ("potent" binders in Sequence Analysis II). Therefore, 160 24039697_.DOC the longer 15-amino acid FG loop appears to be a sequence pattern associated with greater potency. Of the 111 "potent" sequences analyzed, only 10 contain 1 0-amino acid long FG loops, and 6 of those are unique. Therefore, a single sequence motif can encompass every "potent" 10-amino acid FG loop sequence. Sequence Motif #4 was defined based on these 6 sequences. Sequence Motif #4 FG loop, 10-amino acid length, "potent" binders (D/N)(M/Y)(M/A/W)(H/F/Y)(V/K)EY(A/Q/R/S/T)E(Y/H/D) The sequence analysis of the "potent" binders with 15-amino acid FG loops also further illuminated which residue positions were most conserved, allowing Sequence Motif #5 to be defined. An "X" in this sequence motif denotes positions where there are no three dominant amino acids. Sequence Motif #5 FG loop, 15-amino acid length, "potent" binders D(Y/F/W)(Y/F/K)(N/P/D)(P/H/L)X(T/D/S)(H/G/Y)(E/P/Y)(Y/H)XYXXX, wherein X is any amino acid All of the EGFR binders that were analyzed are progeny of the parent 679F09 and constitute a sequence "family," i.e. they are all related in sequence according to the aforementioned sequence motifs. Various members of the 679F09 family of binders can tolerate a T511 scaffold mutation and retain binding activity. Therefore, a T511 scaffold mutation could be combined with any of the aforementioned sequence motifs to also yield a binder with high affinity binding to EGFR. Finally, it should be noted that amino acids with similar properties can often be substituted into protein sequences with little or no effect on structure or function. This indeed is the case for 1 0 Fn3-based binders as well, where conservative amino acid substitutions in either the loop or scaffold regions can still lead to binders which 161 24039697 1.DOC bind to EGFR. For instance, substituting "Y" for "H" in the second position of the FG loop of binder E98 yields binder E99, and both binders show similar potency in inhibiting EGFR phosphorylation (Figure 45). The term "comprising" as used in this specification and claims means "consisting at least in part of'. When interpreting statements in this specification and claims which include "comprising", other features besides the features prefaced by this term in each statement can also be present. Related terms such as "comprise" and "comprised" are to be interpreted in a similar manner. 162 24039697_ 1.DOC

Claims (2)

1. An antibody-like protein dimer comprising a) a tenth fibronectin type III domain (1"Fn3) that binds IGF-IR with a KD of less than 500 nM covalently or non covalently linked to b) a 1 0 Fn3 that binds EGFR with a KD of less than 500 nM; wherein the IGF-IR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 3, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 3, and an FG loop having the amino acid sequence set forth in amino acids 76-83 of SEQ ID NO: 3, and wherein the EGFR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 112, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 112, and an FG loop having the amino acid sequence set forth in amino acids 76-92 of SEQ ID NO:

112. 2. An antibody-like protein dimer comprising a tenth fibronectin type III domain (14Fn3) that binds IGF-IR with a KD of less than 500 nM covalently or non covalently linked to a ' 0 Fn3 that binds EGFR with a KD of less than 500 nM; wherein the IGFIR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); wherein the EGFR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence XgWAPVDRYQXh (SEQ ID NO: 137), a DE loop having the amino acid sequence XIRDVYXj (SEQ ID NO: 138), and an FG loop having the amino acid sequence XkDYKPHADGPHTYHESXI (SEQ ID NO: 139); and wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k, and 1 are integers independently selected from 0 to 5. 3. The antibody-like protein dimer of claim 2, 163 24039697_.DOC wherein the IGF-IR binding ' 0 Fn3 comprises a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); and an EGFR binding ' 0 Fn3 comprising a BC loop having the amino acid sequence SWWAPVDRYQ (SEQ ID NO: 115), a DE loop having the amino acid sequence PRDVYT (SEQ ID NO: 116), and an FG loop having the amino acid sequence TDYKPHADGPHTYHESP (SEQ ID NO: 117). 4. The antibody-like protein dimer of anyone of claims 1-3, wherein the IGF-IR binding 1 Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 3 and the EGFR binding ' 0 Fn3 scaffold has an amino acid sequence at least 90% identical to SEQ ID NO: 112. 5. The antibody-like protein dimer of anyone of claims 1-4, wherein the IGF-IR binding 1 0 Fn3 is covalently linked to the EGFR binding ' 0 Fn3 via a polypeptide linker or a polyethylene glycol moiety. 6. The antibody-like protein dimer of claim 5 comprising an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 126-132. 7. An antibody-like protein comprising a tenth fibronectin type III domain (1 0 Fn3) that binds EGFR with a KD of less than 500 nM, wherein the EGFR binding 1aFn3 comprises a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 112, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 112, and an FG loop having the amino acid sequence set forth in amino acids 76-92 of SEQ ID NO: 112. 8. An antibody-like protein comprising a tenth fibronectin type III domain (1 0 Fn3) that binds EGFR with a KD of less than 500 nM, wherein the EGFR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence XgWAPVDRYQXh (SEQ ID NO: 137), a DE loop having the amino acid sequence XiRDVYXj (SEQ ID 164 24039697_1.DOC NO: 138), and an FG loop having the amino acid sequence XkDYKPHADGPHTYHESXI (SEQ ID NO: 139); and wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k, and 1 are integers independently selected from 0 to 5. 9. The antibody-like protein of claim 8, wherein the EGFR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence SWWAPVDRYQ (SEQ ID NO: 115), a DE loop having the amino acid sequence PRDVYT (SEQ ID NO: 116), and an FG loop having the amino acid sequence TDYKPHADGPHTYHESP (SEQ ID NO: 117). 10. The antibody-like protein of anyone of claims 7-9, further comprising a second tenth fibronectin type III domain (' 0 Fn3). 11. The antibody-like protein of claim 10, wherein the second 1 0 Fn3 binds to IGF-IR. 12. The antibody-like protein of claims 10 or 11, wherein the second 1 4Fn3 is covalently linked to the EGFR binding 10Fn3 via a polypeptide linker or a polyethylene glycol moiety. 13. An antibody-like protein dimer comprising a tenth fibronectin type III domain (10Fn3) that binds IGF-IR with a KD of less than 500 nM covalently or non covalently linked to a ' 0 Fn3 that binds EGFR with a KD of less than 500 nM; wherein the IGFIR binding 10Fn3 comprises a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XeKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); wherein the EGFR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence XgDSGRGSYQXh (SEQ ID NO: 40), a DE loop having the amino acid sequence XiGPVHXj (SEQ ID NO: 42), and an FG loop having the amino acid sequence XkDHKPHADGPHTYHEX (SEQ ID NO: 44); and 165 24039697 1.DOC wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k, and 1 are integers independently selected from 0 to 5. 14. The antibody-like protein dimer of claim 13, wherein the IGF-IR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); and an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWDSGRGSYQ (SEQ ID NO: 39), a DE loop having the amino acid sequence PGPVHT (SEQ ID NO: 41), and an FG loop having the amino acid sequence TDHKPHADGPHTYHESP (SEQ ID NO: 43). 15. The antibody-like protein dimer of claims 13 or 14, wherein the IGF-IR binding ' 0 Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 3 and the EGFR binding 1 0 Fn3 scaffold has an amino acid sequence at least 90% identical to SEQ ID NO: 5. 16. The antibody-like protein dimer of any one of claims 13-15, wherein the IGF-IR binding 14Fn3 is covalently linked to the EGFR binding 1 0 Fn3 via a polypeptide linker or a polyethylene glycol moiety. 17. The antibody-like protein dimer of claim 16, comprising an amino acid sequence at least 90% identical to SEQ ID NOs: 20, 21, 23, or 24. 18. An antibody-like protein dimer comprising a tenth fibronectin type III domain (10Fn3) that binds IGF-IR with a KD of less than 500 nM covalently or non covalently linked to a 1 0 Fn3 that binds EGFR with a KD of less than 500 nM; wherein the IGFIR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); 166 24039697_.DOC wherein the EGFR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence XmVAGAEDYQX, (SEQ ID NO: 34), a DE loop having the amino acid sequence XoHDLVXp (SEQ ID NO: 36), and an FG loop having the amino acid sequence XqDMMHVEYTEHX, (SEQ ID NO: 38); and wherein X is any amino acid and a, b, c, d, e, f, m, n, o, p, q, and r are integers independently selected from 0 to 5. 19. The antibody-like protein dimer of claim 18, wherein the IGF-IR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 10Fn3 comprising a BC loop having the amino acid sequence SWVAGAEDYQ (SEQ ID NO: 33), a DE loop having the amino acid sequence PHDLVT (SEQ ID NO: 35), and an FG loop having the amino acid sequence TDMMHVEYTEHP (SEQ ID NO: 37). 20. The antibody-like protein dimer of claims 18 or 19, wherein the IGF-IR binding ' 0 Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 3 and the EGFR binding ' 0 Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 7. 21. The antibody-like protein dimer of any one of claims 18-20, wherein the IGF-IR binding 10Fn3 scaffold is covalently linked to the EGFR binding " 0 Fn3 scaffold via a polypeptide linker or a polyethylene glycol moiety. 22. The antibody-like protein dimer of claim 21, comprising an amino acid sequence at least 90% identical to SEQ ID NOs: 26, 27, 29, or 30. 23. An antibody-like protein dimer comprising a tenth fibronectin type III domain ( Fn3) that binds IGF-IR with a KD of less than 500 nM covalently or non covalently linked to a 1 0 Fn3 that binds EGFR with a KD of less than 500 nM; 167 24039697_.DOC wherein the IGFIR binding ' 0 Fn3 comprises a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); wherein the EGFR binding ' 0 Fn3 comprises a BC loop having the amino acid sequence XSLPGKLRYQXt (SEQ ID NO: 60), a DE loop having the amino acid sequence XuHDLRX (SEQ ID NO: 62), and an FG loop having the amino acid sequence XYNMMHVEYSEYXz (SEQ ID NO: 64); and wherein X is any amino acid and a, b, c, d, e, f, s, t, u, w, y and z are integers independently selected from 0 to 5. 24. The antibody-like protein dimer of claim 23, wherein the IGF-IR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 1 Fn3 comprising a BC loop having the amino acid sequence LPGKLRYQ (residues 3-13 of SEQ ID NO: 59), a DE loop having the amino acid sequence PHDLR (residues 1-5 of SEQ ID NO: 61), and an FG loop having the amino acid sequence TNMMHVEYSEY (residues 1-11 of SEQ ID NO: 63). 25. The antibody-like protein dimer of claims 23 or 24, wherein the IGF-IR binding ' 0 Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 3 and the EGFR binding 10Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 82. 26. The antibody-like protein dimer of any one of claims 23-25, wherein the IGF-IR binding ' 0 Fn3 scaffold is covalently linked to the EGFR binding ' 0 Fn3 scaffold via a polypeptide linker or a polyethylene glycol moiety. 168 24039697 I.DOC 27. The antibody-like protein dimer of claim 26, comprising an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 53, 54, 87, 88, 98, 99, 104 or 105. 28. An antibody-like protein dimer comprising a tenth fibronectin type III domain (' 0 Fn3) that binds IGF-IR with a KD of less than 500 nM covalently or non covalently linked to a ' 0 Fn3 that binds EGFR with a KD of less than 500 nM; wherein the IGFIR binding 1 0 Fn3 comprises a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50); wherein the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XgHERDGSRQXh (SEQ ID NO: 134), a DE loop having the amino acid sequence XiGGVRXj (SEQ ID NO: 135), and an FG loop having the amino acid sequence XkDYFNPTTHEYIYQTTX (SEQ ID NO: 136); and wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k and 1 are integers independently selected from 0 to 5. 29. The antibody-like protein dimer of claim 28, wherein the IGF-IR binding ' 0 Fn3 comprises a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 1 0 Fn3 comprising a BC loop having the amino acid sequence SWHERDGSRQ (SEQ ID NO: 109), a DE loop having the amino acid sequence PGGVRT (SEQ ID NO: 110), and an FG loop having the amino acid sequence TDYFNPTTHEYIYQTTP (SEQ ID NO: 111). 30. The antibody-like protein dimer of claims 28 or 29, wherein the IGF-IR binding 1 0 Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 3 and the EGFR binding ' 0 Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 107. 169 24039697_.DOC 31. The antibody-like protein dimer of any one of claims 28-30, wherein the IGF-IR binding 10Fn3 scaffold is covalently linked to the EGFR binding 1 0 Fn3 scaffold via a polypeptide linker or a polyethylene glycol moiety. 32. The antibody-like protein dimer of claim 31, comprising an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 118-125. 33. A pharmaceutically acceptable composition comprising the antibody-like protein dimer or antibody-like protein of any one of claims 1-32, wherein the composition is essentially pyrogen free. 34. A method for treating a hyperproliferative disorder in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 33. 35. An antibody-like protein comprising a tenth fibronectin type III domain ( 10 Fn3) that binds EGFR with a KD of less than 500 nM, wherein the EGFR binding 1aFn3 comprises a BC loop comprising the amino acid sequence XXXXXXYQ, a DE loop comprising the amino acid sequence XX(V/I/L/M/A)X, and an FG loop comprising the amino acid sequence (D/N)Xn, wherein X is any amino acid and n is 9-14 amino acids. 36. The antibody-like protein of claim 35, wherein n is 14. 37. The antibody-like protein of claims 35 or 36, further comprising a second tenth fibronectin type III domain (1 0 Fn3). 38. The antibody-like protein of claim 37, wherein the second 10 Fn3 binds to IGF-IR. 170 24039697_.DOC 39. The antibody-like protein of claim 37 or 38, wherein the second 1 0 Fn3 is covalently linked to the EGFR binding 10Fn3 via a polypeptide linker or a polyethylene glycol moiety. 40. A pharmaceutically acceptable composition comprising the antibody-like protein of any one of claims 35-39, wherein the composition is essentially pyrogen free. 41. A method for treating a hyperproliferative disorder in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 40. 171 24039697_.DOC